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ABSTRACT  
Background 
Vaccination against rotavirus, the leading cause of diarrhoea in children under 5 years of age, 
has the potential to reduce diarrhoeal morbidity and mortality. Lower vaccine efficacy and 
immunogenicity were observed in clinical studies of oral rotavirus vaccines in low- and middle-
income countries in Africa compared to high-income countries. The impact of routine vaccine 
use in African countries, where almost half of the global rotavirus deaths occur, is yet to be 
established. In addition, factors affecting immune responses to the rotavirus vaccine warrant 
further investigation. 
 
Objectives 
To assess the effectiveness and public health impact of introduction of the monovalent oral 
rotavirus vaccine into the national immunisation programme in South Africa, a setting with a 
high prevalence of human immunodeficiency virus infection; and to determine the effect of 
maternal rotavirus-specific antibodies and abstention from breastfeeding at the time of rotavirus 
vaccination on immune responses to the rotavirus vaccine. 
 
Methods 
A case-control study was used to estimate vaccine effectiveness in children under 2 years of age, 
with comparison of rotavirus vaccination status among rotavirus-positive diarrhoeal cases to 
rotavirus-negative and respiratory controls, respectively. The impact of routine rotavirus 
vaccination on all-cause diarrhoeal hospitalisations was assessed by comparing the incidence 
before and after vaccine introduction among HIV-infected and HIV-uninfected children under 5 
years of age. HIV-uninfected mother-infant pairs were randomised to either abstention from 
breastfeeding or unrestricted breastfeeding at the time of rotavirus vaccination to assess the 
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effect of breast milk on the immune response to the vaccine; in addition maternal rotavirus 
serum antibodies were measured. 
 
Results 
Two doses of rotavirus vaccine provided protection of 57% (95% CI 40–68) against 
hospitalisation for acute rotavirus diarrhoea. Protection extended through the first 2 years of life 
and the vaccine protected against different rotavirus strains. Routine vaccine introduction was 
temporally associated with a 34% to 57% decrease in the overall incidence of all-cause 
diarrhoeal hospitalisations in children under 5 years of age during 2010–2014 compared to pre-
vaccination years (p<0.001).The greatest reductions were observed in children under 12 months 
of age. Reductions were maintained for 5 years post-vaccine introduction. Abstention from 
breastfeeding for 60 minutes before and after each rotavirus vaccine dose showed no significant 
improvement in infant immune responses to the vaccine. However, mothers of infants who 
seroconverted after the first vaccine dose had significantly lower anti-rotavirus immunoglobulin 
G titres at baseline than those whose infants did not seroconvert. 
 
Conclusion 
Rotavirus vaccination was an effective intervention against severe diarrhoea in South African 
children, preventing hospitalisations due to rotavirus while also reducing diarrhoeal 
hospitalisations for diarrhoea of any cause. These studies add to the growing body of evidence 
showing that rotavirus vaccines are reducing diarrhoeal disease in low- and middle-income 
countries and should form part of comprehensive diarrhoeal disease control and prevention. A 
change in breastfeeding practice at the time of rotavirus vaccination did not improve immune 
responses to the vaccine, yet maternal antibodies may play an important role. Continued research 
is needed to optimise the protection afforded by currently licenced vaccines and to develop novel 
rotavirus vaccines. 
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PREFACE  
Ten years ago I joined the Respiratory and Meningeal Pathogens Research Unit (RMPRU) 
based at the Chris Hani Baragwanath Academic Hospital in Soweto and embarked on my 
research career. Soon after joining the unit, as a medical officer, I was involved in the Phase 
III clinical trial investigating the efficacy of Rotarix®, never envisioning that I would one day 
contribute to assessing the impact of introduction of this life-saving vaccine into the national 
immunization programme in my home country, South Africa.  
Immersed in the research-rich environment of the RMPRU, I have grown as a researcher 
under the mentorship and guidance of our unit director Shabir Madhi. My work on rotavirus 
vaccines has given me the opportunity to interact with the global rotavirus community which 
has enriched my knowledge and provided me with endless support. One such opportunity was 
sharing thoughts and ideas with giants in the field, Umesh Parashar, Roger Glass and Duncan 
Steele, against the backdrop of the spectacular Victoria Falls. I have been privileged to 
present my work at conferences in the United States, India and here on the African continent.  
Being part of the University of the Witwatersrand’s School of Public Health Interdisciplinary 
PhD programme, under the leadership of Kathleen Kahn, provided me with broad exposure to 
many areas of public health. The interaction with fellow students and staff members during 
the past four years has made this PhD journey a fulfilling and memorable experience. 
I look forward to continuing my rotavirus work, establishing new collaborations both on the 
African continent and further afield, as well as broadening my horizons and embracing new 
opportunities and challenges. To quote one of my favourite authors, Jon Krakauer, “The joy 
of life comes from our encounters with new experiences, and hence there is no greater joy 
than to have an endlessly changing horizon, for each day to have a new and different sun.”  
Michelle Groome 2016
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BACKGROUND 
INTRODUCTION 
With the discovery of rotavirus in 1973, the arduous journey began to find an effective 
rotavirus vaccine that would prevent diarrhoeal disease due to rotavirus infection and lead to 
decreased morbidity and mortality in young children (1). Though not without 
disappointments along the way, such as the withdrawal of the first licenced rotavirus vaccine, 
Rotashield due to concerns of its association with intussusception, vaccine initiatives 
culminated in the global licensure of two oral rotavirus vaccines (2). It is an exciting time for 
rotavirus vaccines as, following World Health Organization (WHO) recommendations, an 
increasing number of countries have introduced this life-saving vaccine into their national 
immunisation programmes (3). Eighty countries have introduced the rotavirus vaccine 
worldwide, as of 1 January 2016, including 32 African countries either with (26 countries) or 
without (6 countries) support from the GAVI Alliance (4). 
 
BURDEN OF ROTAVIRUS DISEASE 
Diarrhoeal disease has long been recognised as a major contributor to the global public health 
burden, with descriptions of diarrhoea dating back to ancient Greek civilisations and 
featuring prominently during the modern centuries (5). Children are particularly susceptible 
to diarrhoeal disease, which remains an leading cause of morbidity and mortality in children 
<5 years of age worldwide, accounting for approximately 9% of the 6.3 million deaths in this 
age group in 2013 (6). The burden of diarrhoeal disease is greatest in low- and middle-
income countries with the highest incidence rates found among children <12 months of age 
(7). In South Africa, diarrhoea has been identified as one of the leading causes of death in 
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children and accounted for 18% of all deaths in those aged <5 years in 2009 according to 
official statistics, but the true burden of disease is not accurately defined (8).  
Diarrhoea can be caused by a number of viral, bacterial and parasitic enteropathogens but 
rotavirus remains the most important cause of severe diarrhoea in infants and young children 
globally (9, 10). Global surveillance among children hospitalised for severe diarrhoea in 
2001−2008, prior to the introduction of universal rotavirus vaccination programmes, showed 
that 39% (range 20%−73%) tested positive for rotavirus (11). In 2008, rotavirus-diarrhoea 
resulted in an estimated 453 000 deaths annually – 37% of all diarrhoeal deaths in children 
<5 years of age worldwide, with the greatest burden of disease in Africa and Asia (12). The 
incidence of rotavirus disease was shown to be similar in children in low- and high-income 
countries. However, children from less-developed countries were more likely to die due to 
poorer access to health care and comorbidities like malnutrition (10, 12-14). 
The rotavirus, a genus of the Reoviridae family, comprises an 11-segment double-stranded 
RNA genome surrounded by an outer capsid, an inner capsid and an internal core. Based on 
the inner capsid protein (VP6), rotaviruses are classified into seven groups A‒G, three of 
which occur in humans. Group A rotaviruses are responsible for almost all of the disease in 
humans and are very important from a public health point of view (15, 16). Two structural 
proteins in the outer capsid, VP7 (a glycosylated protein) and VP4 (a protease-cleaved 
protein) have been characterised and define the G and P serotypes of the virus, respectively. 
These differ geographically as well from one season to the next, and in South Africa regional 
differences in rotavirus strains were observed with the most commonly detected strains being 
the VP7 serotype G1 rotaviruses, followed by G4 and G2 strains, and the VP4 genotypes 
P[8], P[4] and P[6] (17). Rotaviruses are classified according to the G-P protein combination, 
for example G1P[8].  
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In South Africa, prior to rotavirus vaccine introduction, rotavirus was associated with 
approximately 25% of diarrhoeal hospitalisations, with the greatest burden of disease (75%) 
in children <12 months of age (17). The annual incidence of severe rotavirus diarrhoea in 
children <2 years of age was estimated to be 874−1076 per 100 000 and incidence was 
highest in children aged 3−11 months (18). Rotavirus infection occurred year round but had a 
clear peak in the cooler, drier autumn-winter months (17, 18). Multiple infections, with 
detection of rotavirus and at least one other enteropathogen, were also common (39%) (17).  
 
PREVENTION OF ROTAVIRUS DISEASE 
Interventions which have been successful against bacterial and parasitic enteropathogens 
causing diarrhoeal disease, for example administration of oral rehydration therapy, 
improvements in management of diarrhoea cases and zinc supplementation, have not had a 
significant impact on rotavirus disease (19). Transmission of rotavirus occurs through person-
to-person contact, thus improvements in sanitation and hygiene have also had limited impact 
on its prevention, with similar incidence of rotavirus infection, albeit differing severity, 
reported in children from high-income and lower income countries (10, 14, 20). Vaccination 
is one of the most cost-effective health interventions available (21). Rotavirus vaccines have 
the potential to substantially reduce the burden of diarrhoeal disease in young children and in 
so doing have a tremendous public health impact on children’s health, especially in Africa 
and Asia.  
Natural infection with rotavirus was shown to offer protection against subsequent severe 
acute and recurrent rotavirus diarrhoea, as well as cross protection against multiple 
circulating strains, and this observation led to development of the currently licenced live-
attenuated vaccines, in order to mimic natural infection and develop broad heterotypic (i.e. 
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against many strains) protective immunity (22, 23). Two oral rotavirus vaccines, Rotarix® − a 
monovalent human-derived vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium)  and 
RotaTeq® − a pentavalent bovine-derived vaccine (Merck Vaccines, Whitehouse Station, NJ), 
are currently licenced in many countries worldwide and recommended for global use in 
children by the WHO (3). Pre-licensure clinical studies of these vaccines demonstrated very 
good protective efficacy (85-98%) against severe rotavirus disease in middle- and high-
income countries in Latin America, Europe and the United States (24-26). Lower efficacy 
and immunogenicity have, however, been observed in clinical studies of rotavirus vaccines in 
low- and middle-income countries in Africa and Asia, including South Africa (27-29). These 
countries tend to have poorer socioeconomic conditions, high mortality from diarrhoeal 
disease, high rates of malnutrition, high maternal human immunodeficiency virus (HIV) 
prevalence and vaccine schedules with co-administration of oral polio vaccine (OPV) and 
rotavirus vaccine.  
 
ROTAVIRUS VACCINES IN AFRICA AND ASIA 
The African study of either two doses (given at 10 and 14 weeks of age) or three doses of the 
monovalent rotavirus vaccine, Rotarix® (given at 6, 10 and 14 weeks of age) reported vaccine 
efficacy against severe rotavirus gastroenteritis of 77% (95% confidence interval (CI) 56−88) 
in South Africa and 49% (95% CI 19−68) in Malawi during the first year of life (27). The 
pentavalent rotavirus vaccine (RotaTeq®) was evaluated in Ghana, Mali and Kenya, 
demonstrating a vaccine efficacy of 64% (95% CI 40−79) against severe rotavirus diarrhoea 
in the first year of life (28), and also in Bangladesh and Vietnam with vaccine efficacy of 
51% (95% CI 13−73) (29). This is in keeping with the poorer performance observed in 
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lower-income countries of other live oral vaccines such as those targeting poliomyelitis, 
typhoid and cholera, as well as previous rotavirus vaccine candidates (30, 31). 
However, vaccine efficacy does not always accurately reflect a vaccine’s public health value 
as it does not account for background disease incidence (32). Although vaccine efficacy was 
lower in these countries compared to higher income countries, the high incidence of severe 
rotavirus disease resulted in a considerable vaccine-attributable decrease in severe rotavirus 
diarrhoea i.e. the number of episodes of severe diarrhoea prevented by rotavirus vaccination 
was greater (27). Regional differences in immunogenicity to rotavirus vaccine have also been 
observed, with infants in low-income countries found to have significantly lower rotavirus-
specific immunoglobulin A (IgA) titres and rates of seroconversion compared to infants in 
high-income countries (33).  
Locally manufactured oral rotavirus vaccines are available in China (Lanzou lamb rotavirus 
vaccine; Lanzou Institute of Biological Products), Vietnam (Rotavin-M1; POLYVAC) and 
India (Rotavac; Bharat Biotech International, Ltd) but the vaccines are only licenced for use 
within these countries and there are limited efficacy data (34-36).  
 
FACTORS AFFECTING VACCINE EFFICACY IN LOW- AND MIDDLE-INCOME COUNTRIES 
Differences in the behaviour of live oral vaccines in the digestive tracts of infants in lower 
income settings may have an impact on their efficacy. Immune response and efficacy of oral 
rotavirus vaccine are dose dependent and factors decreasing the dose of the vaccine may 
impact its immunogenicity and efficacy (33). Rotavirus immunity is not completely 
understood and there is not an established correlate of protection, but a strong correlation was 
found between serum rotavirus IgA titres and efficacy after rotavirus vaccination (37). This 
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suggests that serum rotavirus IgA titres are an important measurable predictor of protection, 
albeit not the only immunonological determinant of the defense mechanism protecting infants 
from rotavirus-associated diarrhea.  
Immune responses in the infant may be decreased by conditions that lower the effective titre 
of vaccine delivered to the intestine such as the amount of gastric acid present in the infant’s 
gut, and interference by high levels of rotavirus antibodies acquired transplacentally from the 
mother during pregnancy or during breastfeeding. Micronutrient deficiency (zinc, vitamin A), 
malnutrition, interfering microbiota present in the gut, enteric viral and bacterial co-infections 
and concomitant disease in the infant such as diarrhoea, tuberculosis, malaria or HIV 
infection as well as co-administration with OPV may also contribute to sub-optimal immune 
responses among infants in lower-income settings (30, 33). Rotavirus vaccine tends to be 
administered at a younger age in many lower income countries, where the rotavirus disease 
burden is high and infection at a young age is more common than higher income countries. 
The earlier administration of the vaccine is advised to prevent early rotavirus infection but the 
ability to induce neutralising antibodies against rotavirus is dependent on age, and 
immunogenicity might be reduced when vaccination occurs at a very young age (38).  
 
Breastmilk and immune responses to rotavirus vaccines 
Studies investigating the effects of breast milk on immunogencity and seroconversion to 
previous rotavirus vaccine candidates suggested a trend toward lower immunogenicity among 
breastfed infants compared to non-breastfed infants after a single vaccine dose, but this was 
overcome by increasing the dose and number of doses administered (39-43). Results from the 
clinical trials of the two currently licenced oral rotavirus vaccines have not shown reduced 
vaccine efficacy in breastfed infants. The human rotavirus vaccine trial showed a small 
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difference in immunogenicity but vaccine efficacy was equally high in breastfed and formula-
fed infants in the first rotavirus season (44). Similarly, the pentavalent vaccine showed 
similar vaccine efficacy in infants never breastfed, sometimes breastfed and exclusively 
breastfed (45). However, these studies did not investigate the interval between breastfeeding 
and administration of the vaccine. There are no published data on rotavirus vaccine efficacy 
and breastfeeding from Africa or Asia. 
In-vitro studies have been conducted to investigate the role of rotavirus antibodies and 
neutralising activity in breast milk. Breast milk with low neutralising titres did not 
significantly reduce the titre of vaccine virus. However, high titres of neutralising activity in 
breast milk resulted in a reduction of vaccine virus titres. The magnitude of the reduction was 
dependent on the level of neutralising activity in the breast milk (46). Theoretically, rotavirus 
antibodies could neutralise virus vaccine if there was breast milk in the stomach of the infant 
at the time of vaccination. This could decrease the effective titre of vaccine virus reaching the 
gut thus rendering the vaccine less immunogenic.  
Rotavirus-specific IgA titres, lactoferrin levels, lactadherin and neutralising activity in breast 
milk vary by setting with higher titres found among Indian and South African women 
compared to those in the United States (47). Both breast milk rotavirus-specific antibodies 
and neutralising activity are highly prevalent in lower income country settings, where 
mothers have greater natural exposure to rotavirus infection (48, 49). These high titres 
present in breast milk consumed at the time of vaccination could explain, in part, the reduced 
vaccine efficacy in infants in these countries compared to higher income countries. Using this 
rationale, abstention from breastfeeding near the time of administration of an oral vaccine 
could theoretically improve the immunogenicity of the oral rotavirus vaccine.  
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Maternal antibodies and immune responses to rotavirus vaccines   
The inhibitory effects of high levels of maternal antibodies on infant immune responses have 
been reported for live vaccines such as influenza, measles and OPV as well as non-replicating 
vaccines (50-53). Animal studies demonstrated that high titres of maternal antibodies have 
substantial effects on immune responses to rotavirus vaccines (54). Earlier studies using 
reassortant rotavirus vaccine candidates observed that pre-vaccination neutralising antibody 
titres to different rotavirus strains were negatively correlated with seroconversion, suggesting 
that maternal immunoglobulin G (IgG) may interfere with immune responses following 
vaccination (55).  
Rotavirus-specific IgG crosses the placenta and a strong correlation between maternal serum 
and cord serum rotavirus-specific IgG titres has been demonstrated (48, 56). High titres of 
pre-vaccination IgG decreased the immune response and seroconversion of infants to the oral 
RV vaccine candidate ORV-116E. However, this effect was overcome by using a higher dose 
and increased number of doses. Infants with the lowest IgG titres had a more rigorous 
immune response (57).  
There are limited data on the comparisons of maternal serum rotavirus antibody titres 
between low and high-income countries, with most studies limited to quantification of 
antibodies in breast milk. Frequent rotavirus re-infection as a result of higher viral loads in 
the community and greater serotype diversity in lower income countries most likely leads to 
the higher maternal antibody titres in women from these countries, which results in higher 
rotavirus-specific IgG titres in their infants. These higher titres could interfere with infant 
immune responses to the vaccine, especially if the vaccine is administered at a young age e.g. 
6 weeks, and this could partially explain the reduced vaccine efficacy in lower income 
countries. However, the ways by which maternal antibodies impact infant immune responses 
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are complex and their influence depends on the prevalence of maternal antibodies in a 
specific population at a specific time as well as the vaccine schedule, number of vaccine 
doses administered and type, route of administration and antigenicity of the vaccine (54, 58).  
 
HIV exposure and diarrhoeal disease  
Although diarrhoeal disease was more common among HIV-infected children than HIV-
uninfected children, rotavirus did not cause more frequent or more severe disease in HIV-
infected children (59-62). HIV-exposed-uninfected children have been identified as having an 
increased risk of morbidity and mortality from diarrhoeal disease but there are limited data on 
rotavirus-specific diarrhoea in these children (63, 64). Rotarix® was safe, well tolerated and 
immunogenic in a group of HIV-positive South African infants, with no effect on their 
immunological condition (65). Similarly, a study in Kenya showed Rotateq® to be safe when 
used in HIV-infected and HIV-exposed infants (66). These studies were not powered to 
evaluate vaccine efficacy specifically in HIV-infected and HIV-exposed-uninfected infants.  
 
Enteric co-infections  
Concurrent infection with enteropathogens at the time of rotavirus vaccination may lead to an 
impaired immunological response, as was recently described in a systematic review on OPV 
in which concurrent diarrhoea at the time of vaccination was associated with decreased  
seroconversion (67, 68). Environmental enteropathy, where there is chronic exposure to 
enteric pathogens, leads to inflammation and structural changes in the small bowel potentially 
resulting in functional changes (69). This may influence the immune response to oral 
vaccines, but has not been specifically evaluated yet in any studies. Prenatal Vitamin A 
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deficiency may impair responses and decrease efficacy to rotavirus vaccine yet oral 
supplementation of Vitamin A together with rotavirus vaccine did not increase vaccine 
efficacy in piglets (70, 71). Colonisation by probiotics affects neonatal immune responses to 
oral rotavirus vaccine and addition of probiotics to infant formula may act to enhance the 
efficacy of rotavirus vaccines (72, 73).  
Both OPV and rotavirus vaccines are administered orally and replicate in the gut, so the 
possibility of interference between these two vaccines exist. Co-administration of rotavirus 
vaccine with OPV did not affect immune responses to OPV but immune responses to 
rotavirus vaccine were generally lower when the two vaccines were co-administered (74). A 
reduced immune response was demonstrated following the first dose of the monovalent 
rotavirus vaccine in those infants who received a concomitant dose of OPV compared to 
those that did not. However, this effect was overcome with administration of the second 
rotavirus vaccine dose (75). Concomitant use of OPV and the pentavalent rotavirus vaccine 
showed some reduction in immune responses to the rotavirus vaccine, but the seroresponse 
rate was non-inferior compared to that in the group where OPV was not co-administered  
(76). A recent study from Bangladesh showed decreased immune responses to the 
monovalent rotavirus vaccine, with no significant difference between the OPV formulation 
used i.e. children co-administered monovalent, bivalent or trivalent OPV had similar immune 
responses to the rotavirus vaccine (77). Despite the lower immunogenicity, concomitant 
administration of rotavirus vaccine and OPV did not seem to affect vaccine efficacy in Latin 
America, but further data is needed from Africa and Asia to fully evaluate the impact of OPV 
on rotavirus vaccines (74, 78).  
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Epidemiology of rotavirus 
Differences in the epidemiology of rotavirus and circulating serotypes of rotavirus between 
low- and high-income settings could lead to differences in vaccine efficacy. Rotavirus tends 
to occur at a younger age among children in lower income countries compared to high 
income countries, and up to 80% of children in poorer countries have rotavirus antibodies by 
12 months of age (79). In South Africa, rotavirus shedding was detected in over 75% of 
infants <12 months of age hospitalised with diarrhoeal illness and 95% of hospitalised 
rotavirus cases occurred in children <18 months old (17). This has implications for the 
schedule of rotavirus vaccine administration as the vaccine needs to be given at a younger 
age in order to confer protection to young infants. However, immune responses and 
seroconversion rates were found to be lower when administered at a younger age (75).  
Lower income countries with a tropical climate tend to have year round disease, some having 
no clear seasonal variation whereas others may have peaks in the cooler, drier months. In 
South Africa rotavirus infection occurred throughout the year but with increased detection 
during the autumn-winter months of April through September (17, 18). There is some 
evidence to suggest that the timing of the infant birth, and thus vaccine administration, in 
relation to the rotavirus season may impact vaccine efficacy. Bovine rotavirus vaccine was 
found to be more efficacious when administered immediately before the rotavirus season 
(80).  
Strain type does not seem to determine severity of infection but the diversity of rotavirus 
strains requires rotavirus vaccines to provide good protection across a variety of strains in 
order to be maximally effective in preventing rotavirus disease. This includes protection 
against the strain(s) contained in the vaccine (homotypic strains) as well as cross-protection 
against strains not contained in the vaccine (heterotypic strains) (16, 81). There was greater 
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rotavirus strain diversity, with an increased number of unusual strains and mixed infections 
identified in countries in Africa and Asia which may have implications for vaccine efficacy in 
these countries (79, 82-84). Cross protection has, however, been observed against the 
common circulating stains in African infants. Vaccine  efficacy against severe gastroenteritis 
caused by diverse circulating rotavirus stains was demonstrated in South Africa and Malawi, 
providing support for heterotypic protection provided by rotavirus vaccines even in lower 
income countries (85). Concerns remain regarding the degree of protection against fully 
heterotypic strains such as G2P[4], as well as duration of protection and potential waning of 
immunity (86, 87).  
 
THE IMPACT AND EFFECTIVENESS OF ROTAVIRUS VACCINES POST-LICENSURE 
Following the introduction of vaccines into routine immunisation programmes, it is important 
to monitor their impact on rotavirus-associated diarrhoeal morbidity and mortality in order to 
demonstrate their public health benefits. Partial vaccination, delays in vaccination, use of 
differing vaccine schedules, co-administration with other routine infant vaccines, cold chain 
disruption, changes in rotavirus epidemiology, circulation of differing rotavirus strains, 
waning immunity and indirect benefits may all impact on the effectiveness of rotavirus 
vaccine under field conditions once introduced into a national immunisation programme (88). 
The WHO has emphasised the need for post-licensure monitoring of the impact of rotavirus 
vaccine on diarrhoeal morbidity and mortality, as well as effectiveness in the setting of 
routine use which may differ from controlled clinical trial settings (89). This can be achieved 
by use of a case-control design to assess effectiveness, or by monitoring trends in diarrhoea 
and rotavirus disease burden through active surveillance systems or use of administrative data 
sources such as hospital discharge and mortality data (90). 
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Australia and countries in Europe and the Americas were among the first to introduce 
rotavirus vaccines into their national immunisation programmes and this has led to substantial 
decreases in diarrhoea-related hospitalisations (17-50%), diarrhoeal deaths (22-50%) and 
rotavirus-specific hospitalisations (49-91%) among children <5 years of age in these 
countries (91-102). Case-control studies have demonstrated good vaccine effectiveness in 
preventing rotavirus hospitalisations, with high-income countries in Europe and the United 
States reporting vaccine effectiveness similar to the efficacy observed in the clinical trials 
(103-106). Lower income countries such as Bolivia, El Salvador and Nicaragua showed good 
vaccine effectiveness estimates, albeit slightly lower than higher income countries (107-109). 
A recent meta-analysis, assessing the strain-specific vaccine effectiveness of the monovalent 
and pentavalent rotavirus vaccines, found that both vaccines provide similar effectiveness 
against homotypic and heterotypic rotavirus strains (110). There are limited data from Africa 
on the impact of rotavirus vaccine, although many countries are presently conducting 
effectiveness studies. South Africa and Ghana have shown reductions in diarrhoea 
hospitalisations in children <5 years of age after introduction of rotavirus vaccine but these 
studies were limited to the first two years post-introduction and did not specifically assess 
reductions in diarrhoea hospitalisations in HIV-infected children (111, 112).  
Vaccine introduction against pathogens such as Streptococcus pneumoniae and Haemophilus 
influenzae type b have demonstrated the prevention of disease due to these pathogens in 
unvaccinated, susceptible children and adults due to vaccine-induced immunity in the 
population, suggesting indirect protection by vaccines (113, 114). Vaccination of a proportion 
of the childhood population could lead to an overall decrease in transmission of the targeted 
pathogen in the community, and thus a decrease in disease risk among unvaccinated 
individuals. This has also been shown for rotavirus vaccines and many of the early 
introducing countries have observed indirect benefits for unvaccinated individuals, such as 
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older children and adults, with decreases in both diarrhoeal and rotavirus hospitalisations 
observed after rotavirus vaccine introduction (96, 115-117).  
 
DURATION OF PROTECTION 
Efficacy trials of the monovalent rotavirus vaccine in Europe and Latin America showed 
sustained protection through two years of life (26, 118). The South African efficacy trial, 
while not powered to assess protection against severe rotavirus diarrhoea in the second year 
of life, showed a lower point-estimate over two consecutive rotavirus seasons compared to 
during the first rotavirus season, which was particularly evident in children who had received 
two rather than three doses of vaccine (119). This was also shown in the clinical trials 
conducted in Malawi, Ghana, Mali and Kenya (28, 120). Rotavirus effectiveness studies in 
some low-income settings have found protection to be lower among children ≥12 months of 
age, suggesting the possibility of waning immunity, whereas another showed no difference in 
effectiveness of rotavirus vaccine between the two age groups (107, 108, 121).  
 
SAFETY OF ROTAVIRUS VACCINES 
Intussusception, the telescoping of one segment of the bowel into a more distal bowel 
segment, is a cause of acute intestinal obstruction in young children and is potentially life-
threatening. Intussusception is uncommon and incidence rates vary by age, region, ethnicity, 
socioeconomic characteristics and feeding patterns (122, 123). The underlying cause of 
intussusception is unknown in most cases, but there has been suggestion of an association 
between infectious pathogens, for example adenovirus, and the development of 
intussusception in young children (124-126). A rhesus-human reassortant oral rotavirus 
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vaccine (Rotashield, Wyeth Lederle Vaccines, Philadelphia) was licenced and introduced in 
the United States for routine immunisation in 1998, but withdrawn nine months after its 
introduction as a result of its association with intussusception (127).  
Currently licenced oral rotavirus vaccines were found to be safe with regards to 
intussusception and other severe adverse events (24, 25). Post-marketing surveillance in 
Mexico detected a small yet significant increase in the risk of intussusception among infants 
in the first week following administration of the first dose of rotavirus vaccine (Rotateq®), 
while no significant risk was found after the first dose among infants in Brazil. A small 
increased risk was seen after the second dose in these infants (128). In Australia, both 
Rotarix® and Rotateq® were associated with an increased risk of intussusception following 
the first and second doses of vaccine (129). Recent studies conducted in the United States 
similarly showed a small increased risk of intussusception after the first dose of vaccine for 
both the monovalent and pentavalent rotavirus vaccines (130, 131).  
Global data thus suggests that both rotavirus vaccines are associated with a small risk of 
intussusception (estimated 0.8−7 cases per 100 000), though of a magnitude substantially less 
than that associated with Rotashield (10−20 cases per 100 000) (132). However, the benefits 
of reductions in hospitalisations and death far outweigh the relatively few excess cases of 
intussusception associated with rotavirus vaccines (128, 129) and thus national immunisation 
remains a valuable public health intervention, especially in high burden countries in Africa 
and Asia. There is limited data on rates of intussusception in low and middle-income 
countries and no studies have yet been completed assessing the intussusception risk following 
routine introduction of rotavirus vaccine. 
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JUSTIFICATION AND OBJECTIVES 
An increasing number of African countries have introduced or are planning to introduce 
rotavirus vaccination into their national immunisation programmes and impact data from 
early adopter countries are pivotal to inform public health decisions and to provide evidence 
for sustaining policies for vaccine use and investments from governments or donors. As one 
of the first African countries to introduce rotavirus vaccine into the national immunisation 
programme, we were able to evaluate effectiveness and impact of this vaccine under routine 
use in South Africa. In particular, vaccine effectiveness needed evaluation in lower income 
settings with high HIV prevalence, concurrent OPV use, high rates of malnutrition and 
enteric co-infections, as well as with schedules different from those used in the efficacy trials. 
The immunogenicity and efficacy of a two-dose schedule of Rotarix® at 6 and 14 weeks of 
age had not been previously studied. Persistence of protection against rotavirus diarrhoea 
during the second year of life may be suboptimal due to waning immunity and must be 
assessed post-licensure. The effect of maternal rotavirus antibodies and breastfeeding on 
immune responses elicited by the rotavirus vaccine in infants may account for differences in 
efficacy between lower and higher income countries and needed to be better understood. 
Even small improvements in rotavirus vaccine efficacy could lead to an increase in the 
number of deaths and hospitalisations prevented by the vaccine. 
The overall purpose of this thesis was to assess the effectiveness and public health impact of 
rotavirus vaccine introduction into the Expanded Programme on Immunisation (EPI) in South 
Africa and determine the effect of abstention from breastfeeding near the time of rotavirus 
vaccination on immune responses to the vaccine. 
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The primary objectives were: 
 
1. To assess the effectiveness of two doses of rotavirus vaccine against severe rotavirus 
gastroenteritis that required hospitalisation among South African children <2 years of age 
after its introduction into the EPI (Paper I).  
2. To determine the impact of introduction of rotavirus vaccine into the EPI on all-cause 
diarrhoea hospitalisations in children <5 years of age in Soweto, stratified by age group 
and HIV infection status (Paper II). 
3. To determine whether abstention from breastfeeding for at least 60 minutes pre- and post-
rotavirus vaccination affected the serum rotavirus IgA immune response induced by 
rotavirus vaccine in the infants (Paper III). 
4. To examine the association between rotavirus-specific antibodies in maternal sera and 
breast milk and the serum rotavirus IgA immune response induced by rotavirus vaccine in 
the infants (Paper IV). 
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METHODS 
SETTING 
South Africa is located on the southernmost tip of the African continent, with a population of 
approximately 54 million people in 2014. The annual birth cohort is about 1.2 million with an 
estimated 5.7 million children <5 years of age and an under-5 mortality rate of 41 per 1000 in 
2014 (133). The national prevalence of HIV infection among pregnant women aged 15–49 
years attending antenatal clinics has remained steady at 29−30% since 2004 (134). Among 
children <5 years estimated national HIV prevalence has decreased over time from 4.4% in 
2006 to 3.5% by 2013 due to improvement in the prevention of  mother-to-child transmission 
of HIV – the estimated HIV transmission rate decreased from 9.6% in 2008 to 2.8% in 2011 
(135, 136). Access to antiretroviral therapy (ART) has gradually improved since its 
introduction in the public sector in South Africa in 2004, and the overall estimated coverage 
in HIV-infected children requiring treatment was 63% in 2012 (137, 138). Although 
categorised as an upper middle-income country, it is ranked by the World Bank to be the 
country with the highest income inequality (GINI co-efficient 0.63 in 2011) (139). Certain 
areas within South Africa may thus be more similar to low- and low-middle income settings. 
South Africa introduced the monovalent oral rotavirus vaccine into the EPI on 1 August 
2009. Two doses of Rotarix® are recommended at 6 and 14 weeks of age together with other 
EPI vaccines, including co-administration with trivalent oral polio vaccine (OPV-Merieux; 
Sanofi Pasteur, Lyon, France) at the 6-week immunisation visit and inactivated poliovirus 
vaccine (IPV) at the 14-week immunisation visit. The vaccine schedule adopted in the EPI in 
2009 (6 and 14 weeks of age) was different to that used in the South African vaccine efficacy 
trial, i.e. two doses at 10 and 14 weeks or three doses at 6, 10 and 14 weeks and different to 
that recommended by the WHO (two doses at 6 and 10 weeks of age) (27). Estimates of 
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coverage rates for the second dose of rotavirus vaccine in South Africa, as per the District 
Health Information Systems, increased from 67% in 2010 to 96% in 2011, which are higher 
than the WHO-UNICEF estimates for vaccination coverage for the last dose of rotavirus 
(66% in 2010; 72% in 2011) (140, 141).  
 
STUDY DESIGN 
Randomised controlled trials (RCTs) are regarded as the gold standard for assessing the 
effect of an intervention (142). Pre-licensure clinical trials of the oral rotavirus vaccines used 
this study design with infants randomised to receive the rotavirus vaccine or a placebo. Once 
a vaccine has been introduced into the national immunisation program of a country it is 
usually considered unethical, except in a few situations, to conduct placebo-controlled trials 
and other study designs are needed to assess the effect of the vaccine on the disease it 
prevents (143, 144). Several study methodologies were utilised in order to address the 
objectives of this thesis. The choice of study design was influenced by the nature of the 
research question, as well as feasibility of the study, taking into account the advantages and 
disadvantages of each method. Descriptions of the study methods are discussed in detail 
within the methods sections of each paper but specific considerations are elaborated on 
below. 
 
Case-control study 
The observational case-control study design has been used successfully to evaluate the 
protection conferred by the rotavirus vaccine under routine use after introduction in low-
middle income settings (108, 109, 145). Vaccine effectiveness is estimated by comparing the 
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vaccination status among cases that have rotavirus diarrhoea with the vaccination status 
among controls (those without disease). Case-control studies do not need established 
surveillance prior to vaccine introduction and are cheaper and quicker to conduct than cohort 
studies. They are, however, subject to several potential biases and need to be done before 
vaccine coverage becomes too high. Case-control studies necessitate the controls to represent 
the source population from which the cases are drawn, and inappropriate selection of controls 
may introduce bias. The choice of a suitable control group is thus pivotal to the validity of the 
study results. A number of different control groups have been previously used in rotavirus 
vaccine effectiveness studies including case-negative controls, community or neighbourhood 
controls, hospital controls and respiratory controls (86, 103, 105, 107-109, 146, 147).   
A case-control study, to estimate the effectiveness of the monovalent rotavirus vaccine 
against hospitalisation for rotavirus gastroenteritis in children <2 years of age, was conducted 
at seven hospitals in South Africa from April 2010 to October 2012. The hospitals selected 
for the study encompassed both urban and rural settings as well as differing HIV infection 
prevalence. Our primary control group consisted of children hospitalised with acute diarrhoea 
who tested rotavirus-negative. Three of the hospitals were recruiting children for a concurrent 
study investigating the effectiveness of the pneumococcal conjugate vaccine (PCV-7) and 
provided a convenient respiratory control group − children hospitalised with lower 
respiratory tract infection presumed not to be bacterial pneumonia. All control groups have 
some advantages and disadvantages so in order to strengthen the reliability our findings we 
included this second non-diarrhoea control group.  
Matching may be utilised to control for known confounders, for example matching on age or 
HIV status (148). Rotavirus test results were not available immediately and case-control 
assignment could not occur at the time of enrolment, thus it was more practical to use an 
unmatched study design i.e. controls were not matched to cases. The unmatched test-negative 
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design has been used to assess the effectiveness of the influenza vaccine and, more recently, 
effectiveness of the rotavirus vaccine (149, 150).  
Although vaccine effectiveness is a useful determinant of impact, it does not measure impact 
in absolute terms, only in relative terms. In a case-control study both cases and controls will 
be protected indirectly and herd (indirect) protection or decreased circulation of disease 
cannot be assessed (144). It is thus important to assess the change in the absolute amount of 
disease in the community rather than just comparing the prevalence of vaccination in cases 
versus controls. This can be done by assessing trends in disease incidence before and after 
vaccine introduction.  
 
Monitoring trends in diarrheal hospitalisations 
Sentinel surveillance for diarrhoeal hospitalisations, including rotavirus-associated 
hospitalisations, started in South Africa in May 2009, a few months before vaccination 
introduction in August of that year. We were thus unable to measure absolute reductions in 
rotavirus-specific diarrhoeal hospitalisations in the post-vaccine period compared to the pre-
vaccine period as there were limited data collected prior to vaccine introduction. There was 
an attempt to assess rotavirus vaccine impact using the rotavirus surveillance data by 
comparing the number of rotavirus and non-rotavirus diarrhoea hospitalisations from May‒
December 2010 and 2011 with those from May‒December 2009 but there are limitations in 
this approach (111). Most importantly, rotavirus disease tends to have year-on-year natural 
seasonal variation with some years having larger seasons than others or different strain 
circulation, and the WHO recommends 3‒5 years of pre-vaccine data collected year round to 
establish baseline rates (151). Multiple rotavirus seasons prior to vaccine introduction are 
needed to give a comprehensive overview of the natural variability of rotavirus seasons so 
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that comparisons of the post-vaccine period to this pre-vaccine period will be accurate. 
Baseline risk of the disease may differ pre- and post-vaccination and these potential 
differences should be assessed on a sufficient number of pre-vaccine years (144). For 
example, the United States’ National Respiratory and Enteric Virus Surveillance System has 
monitored laboratory-confirmed rotavirus diarrhoea over a 15 year period, including multiple 
pre-vaccine introduction years (2000‒2006), and was able to show sustained reductions in 
rotavirus diarrhoea in the post-vaccine years 2007‒2014 (152). This highlights the 
importance of establishing surveillance systems for a disease several years prior to vaccine 
implementation.  
In the absence of long-term rotavirus surveillance in Soweto, we used all-cause diarrhoeal 
hospitalisations as a proxy for rotavirus diarrhoeal hospitalisations at the Chris Hani 
Baragwanath Academic Hospital (CHBAH) and compared incidence rates before and after 
rotavirus vaccine introduction. This approach has been used in other studies to estimate the 
impact of rotavirus vaccines on diarrhoeal hospitalisations (92, 95, 112, 153). Rotavirus 
caused approximately 25‒30% of diarrhoeal hospitalisations prior to vaccine introduction and 
so the impact of vaccination should be observed for rotavirus-specific diarrhoeal 
hospitalisations as well as all-cause diarrhoeal hospitalisations (17). Previous South African 
studies have shown that rotavirus disease occurred early in life with 90‒95% of children 
hospitalised for severe rotavirus diarrhoea being <18 months of age and we would expect that 
the major impact of vaccination would be in children <2 years of age (17, 18).  
 
Randomised, longitudinal cohort study  
To investigate the effect of abstention from breastfeeding (intervention) at the time of 
rotavirus vaccination on the immune response to Rotarix®, we conducted a prospective, 
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randomised, longitudinal cohort study of healthy, HIV-uninfected, mother-infant pairs. 
Mothers and their infants were enrolled when they presented for their 6 week immunisation 
visit at a primary health clinic in Soweto. All vaccines were given according to the EPI 
schedule, with two doses of Rotarix® given at 6 and 14 weeks of age.  
Infants were randomised to one of two groups: 1) infants were not breastfed for 60 minutes 
before and 60 minutes after the administration of each dose of rotavirus vaccine 2) 
unrestricted breastfeeding in the infants. RCTs such as this have been used to compare 
immune responses to rotavirus candidates between breastfed and nonbreastfed children (43).  
Only HIV-uninfected mothers-infant pairs were eligible for enrolment as maternal HIV 
infection could reduce transplacental antibody transfer which could affect the immune 
responses, regardless of the child’s HIV status (154, 155). Inclusion of HIV-infected mothers 
into the study would make the analysis more difficult as one would need to control for 
differential pre-existing rotavirus immunity in the mothers and infants.  
Rotavirus-specific IgA in breast-milk and serum samples and IgG in serum samples were 
determined by enzyme-linked immunosorbent assays and rotavirus-specific neutralizing 
activity in breast-milk was measured by a microneutralization assay, as described (46). 
Despite the lack of an established correlate of protection, serum rotavirus IgA titres are 
regarded as an important measurable predictor of protection (37).  
The study was powered to detect at least a 20% higher frequency of seroconversion among 
infants abstaining from breastfeeding than infants being breastfed at the time of rotavirus 
vaccine administration. When formulating a hypothesis it is advisable to be aware of practical 
and policy issues as well as the scientific basis for potential interventions. For example, 
although a larger sample size could have detected a smaller difference in seroconversion, 
from a policy point of view it would be difficult to support a change in breastfeeding 
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practices based on minimal benefit for the infant in terms of improved immune response. It is 
also important not to give a negative impression of breastfeeding among mothers, which 
could potentially impact on the acceptability of breastfeeding in the community. Similarly, 
we only assessed abstention of breastfeeding for 60 minutes before and 60 minutes after 
vaccine administration. It is possible that a longer period of abstention may in fact lead to 
better immune responses in these infants but, on a practical level a longer abstention from 
breastfeeding in a 6 week old infant is not advisable for physiological reasons and it would be 
difficult for mothers to accept.  
 
STATISTICAL CONSIDERATIONS 
The choice of statistical analysis was influenced by the study design utilised in each paper. 
Specific statistical considerations are elaborated on below, with full details of the analyses 
available in the attached papers. 
In the case-control study, controls were not matched to cases which was problematic in that 
hospitalisation for rotavirus disease is associated with the age of the child as well as the 
season of hospitalisation (17). Vaccination status is also influenced by the age of the child. 
As a result we decided, a priori, to adjust for timing of birth (birth month and year) and 
hospitalisation (admission quarter and year), and only included children whose vaccine status 
was unlikely to change i.e. aged ≥18 weeks, which gave children an additional four weeks for 
vaccination with the second dose. The unmatched design of the case-control study dictated 
the use of unconditional logistic regression to estimate adjusted odds ratios (aORs) with 
associated 95% CIs. We adjusted for site a priori as protection offered by the vaccine can 
vary based on geographical location (27). Additional potential confounders were assessed in 
the unconditional logistic regression models and included in the final models if their 
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inclusion changed the OR associated with vaccination by >5 percentage points. Interactions 
between covariates were assessed and interaction terms were included in the finals models if 
appropriate. Adjusted vaccine effectiveness against hospitalisation for acute rotavirus 
diarrhoea was calculated as (1−aOR) x 100%. The primary analysis utilised the rotavirus-
negative control group, with secondary analyses limited to respiratory controls at the three 
hospitals where this second control group was available. 
For the trend analysis of diarrhoeal hospitalisations in Soweto we estimated the annual 
incidence of all-cause diarrhoeal hospitalisations (per 1000 population) using the number of 
children hospitalised for diarrhoea at the CHBAH per year in the numerator and the mid-year 
population estimates in relevant age categories for Soweto in the denominator (133). HIV 
prevalence for Soweto was estimated from projections of the Actuarial Society of South 
Africa’s 2008 AIDS and Demographical model (135). Hospitalisation incidence rates were 
stratified by age group 0−11, 12−23 and 24−59 months, and by HIV infection status. Median 
annual incidence rates during the pre-vaccine years 2006-2008 were compared to those in the 
vaccine-era (2010‒2014). To determine whether there were any changes in hospital 
admission practices during the study period we also assessed the incidence of hospitalisation 
for bronchiolitis, for which there were no preventative intervention strategies implemented 
over the same period. Mathematical modelling and complex statistical time series analyses 
have been used in other studies (94, 156). However, the absence of annual Soweto-specific 
rotavirus vaccine coverage data, ART coverage data and measures of improvement in access 
to tapped water and improved sanitation limited our ability to attempt more complex analyses 
to adjust for these potential confounders.  
Randomisation is used to ensure similarity between groups with respect to all measured and 
unmeasured characteristics except the intervention, in this case timing of breastfeeding in 
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relation to rotavirus vaccination, allowing any difference between the groups to be attributed 
to the intervention without influence from unmeasured confounders. Mother-infant pairs were 
randomised to one of two groups (abstention from breastfeeding or unrestricted 
breastfeeding) in order to assess the effect of breastfeeding on the immune responses to 
rotavirus vaccine while maintaining a balance of potential confounders between groups. Pre-
vaccination (baseline) characteristics and rotavirus-specific titres were compared between 
groups to ensure that the randomisation had achieved similarity between groups. 
Seroconversion was defined as ≥ fourfold increase in titres compared to baseline titres prior 
to the first vaccine dose. The frequency of seroconversion between the two groups was 
compared one month after the first and second doses of rotavirus vaccine. A significantly 
higher seroconversion rate in the abstention from breastfeeding group would support the 
hypothesis that abstention from breastfeeding near the time of administration could improve 
the immunogenicity of the oral rotavirus vaccine.  
Associations between pre-existing maternal and infant rotavirus-specific antibodies and 
seroconversion following administration of one or two doses of Rotarix® were also examined, 
using univariate and multivariable logistic regression. The randomisation of mother-infant 
pairs to one of the two breastfeeding groups allowed us to assess the influence of abstention 
from breastfeeding on seroconversion without adjusting for confounders (both measured and 
unmeasured). The additional analyses included the cohort irrespective of breastfeeding group 
assignment, and thus covariates had to be assessed for confounding and adjusted for in the 
multivariate models as necessary. Antibody titres are generally not normally distributed and 
so rotavirus-specific titres of IgA, IgG and neutralising activity were log-transformed in the 
analyses to give a better approximation to a normal distribution. A P-value of <0.05 was 
considered statistically significant for all analyses. 
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RESULTS AND DISCUSSION 
 
South Africa has played an instrumental role in influencing policy recommendations for 
rotavirus vaccine introduction in low- and middle-income countries by conducting pivotal 
clinical trials which assessed the monovalent oral rotavirus vaccine. Early immunogenicity 
studies paved the way for a Phase III efficacy study which informed the WHO’s global 
recommendation for use of the vaccine in 2010 (27, 157). As the first African country to 
introduce the rotavirus vaccine into its national immunisation programme, we explored many 
of the key issues regarding post-licensure effectiveness and impact of the rotavirus vaccine. 
The monovalent oral rotavirus vaccine given at 6 and 14 weeks of age was shown to be 
effective under conditions of routine use and was temporally associated with a decrease in 
all-cause diarrhoeal hospitalisation rates in HIV-infected and HIV-uninfected children after 
its introduction into South Africa’s EPI. A change in breastfeeding practice at the time of 
vaccination did not improve immune responses to the rotavirus vaccine in infants. However, 
high levels of maternal rotavirus antibodies may inhibit responses to a vaccine dose given at 
an early age.  
 
EFFECTIVENESS AND PUBLIC HEALTH IMPACT OF ROTAVIRUS INTRODUCTION  
Our multi-centre case-control study, primarily using rotavirus-negative controls, showed that 
two doses of rotavirus vaccine provided protection of 57% (95% CI: 40−68) against 
hospitalisation for acute rotavirus diarrhoea in children <2 years of age. Adjusted vaccine 
effectiveness was estimated to be 54% (95% CI: 32−68) in children 18 weeks to 11 months 
of age and similar protection was maintained through the second year of life (61%; 95% CI: 
35−77). The trend analysis conducted over the period 2006-2014 showed that the 
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introduction of the rotavirus vaccine was temporally associated  with a 34 to 57% decrease in 
the overall incidence of all-cause diarrhoeal hospitalisations in children <5 years of age in the 
urban setting of Soweto, Johannesburg. Reductions were greatest in children <12 months of 
age and were maintained over a 5-year period post-vaccine introduction in this age group. 
The hospitalisation incidence decreased from 54 per 1000 pre-vaccination to 30 per 1000 in 
the first year post-vaccine introduction (incidence reduction of 24 per 1000; percent decrease 
of 45%; p<0.001). Further reductions of 57 to 65% (incidence reduction of 31 to 36 per 1000; 
p<0.001) were maintained through the following four years. Among children in the second 
year of life, reductions of 40 to 49% (6 to 7 per 1000, p<0.001) were observed from the 
second year post-vaccine introduction compared to pre-vaccination years, and were 
maintained over time. Among children aged ≥24 months the incidence of all-cause diarrhoeal 
hospitalisations in the post-vaccine years remained relatively unchanged compared to pre-
vaccination years. The reductions thus occurred specifically in the age groups that received 
rotavirus vaccination and were consistent with increasing vaccine coverage over the study 
period i.e. reductions observed in children <12 months during the first year and increasing in 
the second year after vaccine introduction; reductions in the 12−23 month olds from the 
second year post introduction.  
There was a change in the epidemiology of diarrhoeal disease after rotavirus vaccine 
introduction, with diminished peaks in all-cause diarrhoea hospitalisations during 2010 and 
near loss of the peaks during 2011−2014, where a bimodal pattern was observed each year. 
Prior to vaccine introduction diarrhoeal hospitalisations were characterised by peaks during 
the autumn-winter months of March to May, consistent with published observations of 
rotavirus seasonality before routine vaccine use (17).  
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Comparison with results of the Phase III efficacy study in South Africa 
It is important to compare the vaccine effectiveness and impact estimates post-vaccine 
implementation with those obtained from the pre-licensure efficacy study conducted in the 
same setting. Although unmeasured confounding may affect the results of a case-control 
study, a comparison of RCTs and observational studies showed that in the majority of cases 
the estimate of treatment effects from observational studies and RCTs were similar (158). 
Our point estimate for vaccine effectiveness in the first year of life was lower than the 
vaccine efficacy observed for the two-dose schedule at 10 and 14 weeks of age in the clinical 
efficacy trial (54% versus 72% respectively); yet it lay within the 95% confidence interval 
estimate (40–88%) (24). We showed sustained protection in the second year of life, whereas 
the Phase III study estimated the vaccine efficacy over two consecutive seasons to be 32% 
(95% CI -71‒75) for the two-dose group. These were, however, exploratory analyses as the 
study was not powered to assess efficacy of the vaccine in the second year of life (119).  
Comparisons between the efficacy trial (a RCT) and our observational study must, however, 
be made cautiously. Differences in study methodology, such as the definition of the outcome 
(severe rotavirus diarrhoea as measured by the Vesikari score versus hospitalisation for 
rotavirus diarrhoea), may have contributed to slightly different point estimates of protection 
of the rotavirus vaccine in the two studies. There were also differences in enrolment 
strategies with infants in the efficacy study being vaccinated immediately prior to the onset of 
the rotavirus season, whilst infants in the case control study were vaccinated throughout the 
year. 
There was a 57 to 65% reduction in all-cause diarrhoeal hospitalisations in children <12 
months of age after rotavirus vaccine introduction, which was higher than the vaccine 
efficacy of 44% (95% CI 19-61) against all-cause severe gastroenteritis demonstrated in this 
31 
 
age group in the clinical trial, although with overlapping confidence intervals. A decrease in 
transmission due to an overall decrease in circulation of rotavirus in the population could not 
be accounted for in the efficacy study design, and may account for the greater reductions 
which we observed.  
The overall frequency of seroconversion for rotavirus-specific serum IgA one month after the 
second rotavirus vaccine dose was 61% (95% CI: 54−68) among the cohort of HIV-
uninfected infants enrolled into a longitudinal study assessing immune responses to the 
rotavirus vaccine,  which was similar to that obtained in clinical trial for the two-dose group 
(57%, 95% CI 45‒69). Different assays were, however, used for the immunogenicity 
assessments in the two studies and direct comparisons should once again be made with 
caution. 
 
FACTORS AFFECTING IMMUNOGENICITY OF THE ORAL ROTAVIRUS VACCINE  
Understanding the reasons behind the lower vaccine efficacy in low- to middle-income 
countries is critical as even small improvements in efficacy could lead to significant 
decreases in the number of deaths and hospitalisations caused by rotavirus in countries where 
disease burden is high (159). 
 
Breast milk antibodies and a change in breastfeeding practice at the time of vaccination 
High levels of rotavirus-specific antibodies and other neutralizing factors found in breast-
milk from women in lower-income countries, including South Africa, could diminish infant 
immune responses to the vaccine by lowering the effective titre of vaccine delivered to the 
intestine. A short abstention from breastfeeding around the time of vaccination may, 
32 
 
therefore, improve immunogenicity (46, 47). We tested this hypothesis by randomising a 
cohort of infants to either abstention from breastfeeding or unrestricted feeding at the time of 
rotavirus vaccination and assessed immune responses to the vaccine. Among this cohort of 
infants, serum anti-rotavirus IgA geometric mean titres (GMTs) increased significantly 
following administration of two rotavirus vaccine doses, compared to pre-vaccination titres, 
in both the abstention from breastfeeding group and those with unrestricted breastfeeding. 
There were no significant differences in seroconversion or serum rotavirus-specific IgA 
GMTs measured after the first or second doses of Rotarix® between the two groups. The 
frequency of seroconversion after the second dose was 63% in the abstention from 
breastfeeding group and 59% in the unrestricted breastfeeding group (p=0.485). Reverse 
cumulative frequencies of infant serum rotavirus-specific IgA titres in Group-1 (abstention) 
and Group-2 (unrestricted) are shown below in Figure 1. 
 
Figure 1: Reverse cumulative frequency profiles of infant rotavirus-specific IgA titres, by group 
(Group-1: abstention; Group-2: unrestricted), pre-vaccination, after the first dose and after the 
second dose of rotavirus vaccine. 
33 
 
These results are consistent with a study investigating the effect of breastfeeding on antibody 
response to OPV in infants, in which no difference in seroconversion rates were observed 
among infants on unrestricted breastfeeds and those abstaining from breastfeeding (160). In 
addition, studies assessing the impact of breastfeeding on the immunogenicity of rotavirus 
vaccines in infants have now also been conducted in other settings and support the findings 
from our study. In India, withholding breastfeeding for 30 minutes before and after each 
rotavirus vaccine dose (Rotarix®), despite being an acceptable intervention among mothers, 
similarly showed no improvement in the infant immune response. The frequency of 
seroconversion was lower than observed in our study but there were no significant 
differences between the infants in which breastfeeding was withheld and those with 
unrestricted feeding (26% versus 27% respectively) (161, 162). A study in Pakistan, which 
assessed withholding breastfeeding for an hour before and after each dose of Rotarix®, also 
showed no improvement in infant immune responses after three vaccine doses. On the 
contrary, IgA seroconversion in the group in which breastfeeding was encouraged tended to 
be higher than in the abstention from breastfeeding group (163). Withholding of 
breastfeeding for 90 minutes before and 60 min after the first dose of Rotateq® in Nicaraguan 
infants similarly did not show any significant benefit of withholding breastfeeding (164). 
There were no significant differences in baseline maternal rotavirus-specific IgA or 
neutralising antibodies in breast milk between infants in our cohort who seroconverted and 
those that did not seroconvert after either the first or second dose, which was supported by 
similar findings among the Nicaraguan infant cohort (164). There was also no relationship 
observed between innate immune factors (lactoferrin, lactadherin, and Tenascin-C) in breast 
milk and immune responses to the rotavirus vaccine in these Nicaraguan infants (165). There 
is thus overwhelming evidence to suggest that this hypothesis does not hold true in vivo and 
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that withholding breastfeeding at the time of rotavirus vaccination shows no benefit for the 
infant in terms of improved rotavirus immune responses to the vaccine. 
 
Pre-existing maternal and infant rotavirus antibody levels  
It has also been hypothesised that high levels of maternal rotavirus antibodies found in lower 
income countries are transferred to their infants during pregnancy and breastfeeding, resulting 
in an inhibitory effect on immune responses to rotavirus vaccines in the infants. Additional 
analyses of matched serum samples from the mother-infant pairs in our cohort showed that 
mothers of infants who seroconverted after the first dose had significantly lower rotavirus-
specific IgG titres at baseline than those whose infants did not seroconvert (median 5120 vs. 
10 240 respectively, p=0.031). A significant difference in maternal IgG rotavirus titres 
between those who seroconverted and those that did not was no longer observed following 
the second dose of vaccine, suggesting that the inhibitory effect of maternal rotavirus 
antibodies may be overcome by administration of the second dose at 14 weeks of age when 
maternal antibody levels are lower. This is consistent with the current understanding of the 
mechanisms of maternal antibody inhibition, whereby the influence of maternal antibodies 
depends on the ratio of maternal antibody to vaccine antigen at the time of vaccination. The 
second dose of vaccine could induce an infant response because the maternal antibody levels 
declined beyond a certain threshold, decreasing the inhibitory effect and enabling a better 
immune response to the second dose (58). Infants who seroconverted after the second dose 
had lower rotavirus IgA titres at baseline compared to those who did not seroconvert, which 
suggests that pre-existing infant rotavirus antibodies, most likely from exposure to natural 
rotavirus infection prior to vaccination, may also have an inhibitory effect on the immune 
response to the vaccine.  
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Our findings are consistent with those from Nicaragua, where infants who seroconverted after 
the first Rotateq® dose had mothers with significantly lower baseline serum rotavirus-specific 
IgG titres compared with infants who did not seroconvert. In addition, infant baseline IgA 
titres were significantly lower in the seroconverted compared with non-seroconverted infants 
(164). These associations were, however, not assessed after subsequent doses of Rotateq®, so 
the effects of further doses could not be evaluated. In contrast, in the Indian study lower odds 
of seroconversion after the second Rotarix® dose were observed with increasing titres of 
baseline maternal serum rotavirus-specific IgG, similar to what was observed with the Indian 
rotavirus vaccine ORV 116E vaccine (57, 161). 
Further investigation of rotavirus exposure in infants prior to vaccination as well as the 
impact of maternal rotavirus antibodies on the immune response is needed. The above-
mentioned studies all measured maternal antibody titres at the time of infant vaccination, not 
at birth. We showed moderate correlation (r=0.56) between maternal and infant rotavirus-
specific IgG titres at baseline i.e. infant aged 6 weeks, similar to that in the Nicaraguan study 
(r=0.57) (164). This is likely due to decreasing levels of transplacentally-derived rotavirus-
specific IgG in infant serum which occurred since birth. Studies assessing rotavirus antibody 
levels in maternal serum and infant cord blood may be useful to tease out the relative effects 
of transplacental transfer of antibodies from the mother versus rotavirus exposure in the 
infant.  
The influence of maternal antibody titres on infant immune responses depends on the 
distribution of the titres in a specific population at a specific time point (58). The introduction 
of a rotavirus vaccine could itself influence levels of pre-existing rotavirus-specific 
antibodies in infants at the time of vaccination. As a vaccine program matures, diminished 
circulation of rotavirus in the community may lead to lower rotavirus antibody titres in 
women of child-bearing age, resulting in lower transplacental transfer from mothers to their 
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infants. Infants would also be less likely to be exposed to natural rotavirus infection in the 
first 6 weeks of life, further lowering pre-existing rotavirus antibodies and leading to an 
overall improvement in the immune response following the first rotavirus vaccine dose.  
We observed an increase in maternal rotavirus-specific IgA GMTs following the first dose of 
rotavirus vaccine in their infants. This was not shown in any of the other studies as maternal 
serum samples were only obtained at baseline and not after vaccination in the infant as in our 
study. The majority of the maternal samples were obtained prior to the classic peak rotavirus 
season, indicating possible boosting in the mother through acquiring rotavirus vaccine from 
the shedding in their infants. We do not, however, know how this increase in maternal titres 
following infant vaccination compares to natural boosting of maternal antibody titres and 
further evaluation is necessary to determine whether this might affect infant immune 
responses.  
 
HIV infection 
Exposure to HIV infection in-utero remains an important consideration among South African 
children. The phase III clinical trial included HIV-infected children, but was not powered to 
specifically address the question of efficacy in this sub-group children and data are limited to 
safety and immunogenicity of the rotavirus vaccine among HIV-infected children (27, 65). 
While our case-control study did not enrol sufficient HIV-infected children to assess rotavirus 
vaccine effectiveness in this group, the adjusted two-dose vaccine effectiveness was similar 
in HIV-exposed-uninfected and HIV-unexposed-uninfected children (64%; 95% CI: 34−80 
and 54%; 31−69 respectively). With just under a third of infants born to HIV-infected 
mothers, it is reassuring that rotavirus vaccine was equally effective in the HIV-exposed 
infants. The hospitalisation incidence among HIV-infected children aged <12 months 
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decreased from 133 per 1000 in pre-vaccination years to 104, 58, 39, 50 and 31 per 1000 
during 2010−2014 respectively (incidence decrease of 29 to 102 per 1000, percent decrease 
of 22 to 78%, p<0.05 for all comparisons). Percent reductions in incidence in the post-
vaccine years 2011‒2014 compared to pre-vaccine years among those aged 12-23 months 
ranged from 45 to 65% (incidence decrease of 17 to 24 per 1000, p<0.05 for all 
comparisons). There were significant reductions in hospitalisation incidence in older HIV-
infected children aged 24‒59 months in most post-vaccine years compared to pre-vaccine 
years, in contrast to the relatively unchanged hospitalisation incidence among older HIV-
uninfected children.  
It is more difficult to attribute reductions in the HIV-infected children to the rotavirus 
vaccine. Firstly, although rotavirus was shown to be the most common organism causing 
diarrhoea among HIV-infected children <5 years of age in this setting, the prevalence of 
rotavirus detection among HIV-infected children hospitalised with diarrhoea was lower than 
that among HIV-uninfected children hospitalised for diarrhoea (34.7% versus 14.8% 
respectively) (166). Reductions in diarrhoea attributable to rotavirus may thus be diluted, as 
rotavirus is responsible for proportionally less diarrhoea hospitalisations among these 
children. Secondly, the upscaling of ART has led to a decrease in HIV-related 
hospitalisations and overall mortality at CHBAH with HIV prevalence among paediatric 
admission peaking at 31.7% in 2005 and decreasing to 19.3% by 2010/2011 (167). ART may 
thus account for some of the reductions in all-cause diarrhoea hospitalisations which we 
observed. In the absence of accurate ART coverage data among children in the age groups 
that were assessed, it is difficult to quantify the reduction due to ART and that due to 
rotavirus introduction. ART coverage data stratified by year and age group would allow 
statistical modelling to be performed which could provide estimates of the individual effects 
of interventions. 
38 
 
We were unable to assess the immune response to the two dose rotavirus vaccine schedule 
among HIV-exposed infants, as only HIV-unexposed infants were enrolled into the 
longitudinal cohort. In the case-control study, point estimates for adjusted vaccine 
effectiveness after one dose were higher in HIV-exposed uninfected children than HIV-
unexposed children (61% (95% CI 22−81) versus 24% (95% CI -17−51) respectively), albeit 
with overlapping confidence intervals. This may suggest lower transplacental transfer of 
rotavirus-specific antibodies from HIV-infected mothers to their infants, with a more robust 
immune response after the first dose in HIV-exposed infants. South African HIV-exposed 
uninfected infants were shown to have lower antibody levels to pertussis and pneumococcus 
at birth than unexposed infants, with higher antibody responses to pertussis and 
pneumococcal vaccination (155). Further investigation is needed to see whether this holds 
true for rotavirus antibodies. The similar vaccine effectiveness point estimates between HIV-
exposed and HIV-unexposed uninfected children after two doses suggest that any differences 
in pre-existing rotavirus-specific antibodies are overcome after the second dose is given at 14 
weeks when maternal ant-rotavirus antibody levels are lower. 
 
CONSIDERATIONS WHEN ASSESSING VALIDITY OF RESULTS  
The limitations of the individual studies have been highlighted within the papers but a 
summary of limitations and their potential threat to the validity of the conclusions are 
discussed below. 
Methodological  
An ecological study is limited in its ability to attribute causality. We used all-cause diarrhoeal 
hospitalisations as a proxy for rotavirus hospitalisations, in the absence of long-term 
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pathogen-specific diarrhoea surveillance, and it is thus difficult to definitively conclude that a 
causal relationship exists between rotavirus vaccine introduction and reductions in diarrhoeal 
hospitalisations. There may be secular trends in diarrhoeal hospitalisation incidence unrelated 
to the vaccine, including introduction of non-vaccine prevention measures, such as 
improvement in access to fresh water, sanitation and refuse removal in the population, which 
may contribute to the observed decline in diarrhoeal hospitalisations in the post-vaccine 
period. Optimally one would require accurate annual data on improvements in access to clean 
water, sanitation and other socio-economic indicators but in Soweto these data are limited to 
that obtained from 5-yearly census data. Although sub-district level information is lacking, 
there were some improvements in these indicators over the study period in the Johannesburg 
region (168). These changes would, however, have been more consistent over time and 
unlikely to account for the dramatic decline observed in the vaccine-era years. Changes in 
hospital referral practices could also account for changes in hospitalisation rates but the 
incidence of bronchiolitis hospitalisations were relatively unchanged during 2006-2014, 
giving reassurance that this was unlikely to account for the reductions we observed in 
diarrheal hospitalisations.  
Reliance on census data to obtain annual population estimates for Soweto and extrapolation 
of provincial model projections to obtain HIV prevalence estimates for Soweto are limitations 
and may have influenced the validity of our diarrhoeal hospitalisation incidence estimates. 
However, the population in Soweto had been relatively stable over the years included in the 
study and the method used for producing the population estimates has been consistent over 
time, so the decreases in incidence of diarrhoeal hospitalisation observed post-vaccine 
introduction, compared to pre-vaccine introduction, should be valid. Children who were not 
tested for HIV infection were considered to be HIV-uninfected, assuming that physicians 
were less inclined to test for HIV in the absence of clinical stigmata. This may have 
40 
 
underestimated the disease burden among HIV-infected children. However, an HIV-infected 
child would have had several hospitalisations, prompting HIV testing and thus our 
assumption most likely approximates the true prevalence of HIV-infection among children 
hospitalised for diarrhoea. 
The choice of the control group in a case-control study may influence the validity of the 
results obtained. We used rotavirus-negative diarrhoea controls as the primary control group 
and performed secondary analyses using respiratory controls enrolled from a subset of the 
study hospitals. These analyses gave similar estimates of protection of the vaccine against 
hospitalisation for rotavirus diarrhoea, which gave us some reassurance that the effectiveness 
estimates we obtained were valid.  
We were reliant on the results of a commercially available enzyme immunoassay (EIA; 
ProSpecT ELISA, Oxoid, UK) to define rotavirus-positive cases and rotavirus-negative 
controls which, when compared to reverse-transcriptase-PCR as the gold standard, had a 
sensitivity of 75% and specificity of 100% (169). There was thus potential for 
misclassification of the case status as children with a false negative EIA test would have been 
defined as a control rather than a case. We also assumed that rotavirus was the cause of the 
hospitalisation if it was detected in the stool, which may not necessarily have been the case, 
and we may have falsely attributed disease to rotavirus instead of a co-infecting viral or 
bacterial pathogen. These misclassifications would likely have biased estimates toward the 
null.  
Vaccine uptake increased quickly in South Africa reaching a high, steady rate soon after 
introduction as has been seen in settings where vaccination programmes are well-established , 
for example in the Americas (170). Estimates of coverage rates for the second dose of 
rotavirus vaccine in South Africa increased from 67% in 2010, the first year after vaccine 
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introduction, to 96% in 2011 (140). High coverage can be problematic when using a case-
control design as the sample size is dependent on the vaccine coverage and once it reaches 
beyond 80% the required the sample size can become prohibitively high (151). We enrolled a 
sufficient number of cases when coverage rates were <80% and were adequately powered for 
the analyses we conducted. In contrast, high coverage is preferable when looking at the 
impact of an intervention on disease incidence. If rotavirus vaccination coverage had 
remained low, it would have been difficult to observe reductions in a non-specific outcome 
such as all-cause diarrhoeal hospitalisations. 
We excluded HIV-infected mothers in the breastfeeding study so we could not assess 
maternal rotavirus-specific antibody titres in HIV-infected mothers and compare these titres 
to those measured in HIV-uninfected women.  
 
Generalisability of results 
The public health impact of rotavirus vaccines may differ between countries as well as 
between regions in the same country but we were not powered to assess site-specific vaccine 
effectiveness in the case-control study. The trend analysis was restricted to one low-income, 
urban community in South Africa and may not be generalisable to all areas of the country. A 
similar analysis of all-cause hospitalisation trends should be replicated in other hospitals in 
South Africa, which would strengthen the evidence supporting vaccine introduction in 
geographical and socially diverse settings.  
Vaccine effectiveness estimates from Malawi, a very low-income African country, have 
recently been published with a similar vaccine effectiveness estimate (64%; 95% CI 24‒83) 
observed against rotavirus gastroenteritis for two doses of Rotarix® as observed in our study. 
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The vaccine schedule introduced, a two-dose schedule given at 6 and 10 weeks of age, as 
well as the study methodology was slightly different and age-specific estimates were not 
provided (150). Case-control studies are underway in several other African countries and as 
additional post-implementation data become available, the body of evidence supporting 
rotavirus vaccine introduction in the African region will grow.  
 
OTHER CONSIDERATIONS FOR THE USE OF ROTAVIRUS VACCINES 
Optimising the dosing schedule of oral rotavirus vaccines 
Alternative dosing schedules of the vaccine should also be explored in view of the potential 
inhibition by maternal rotavirus antibodies with an early vaccine dose. There does not appear 
to be any benefit from addition of a third dose of Rotarix® as a study in Pakistan recently 
showed that immunogenicity did not improve significantly with three doses administered at 
6, 10 and 14 weeks compared to two doses given at 6 and 10 weeks. In addition, a delayed 
two-dose schedule (10 and 14 weeks) did not result in improved seroconversion compared to 
two doses given at 6 and 10 weeks (171). This supports data from the clinical efficacy trial in 
South Africa which showed no significant difference in immunogenicity or efficacy against 
severe rotavirus diarrhoea between the two and three-dose arms in the first year of life, 
although the study was not powered to detect a difference between these two arms (27). We 
also observed similar immunogenicity of the 6 and 14 week schedule compared to that of the 
6 and 10 week schedule in the clinical trial (27).  
Due to initial concerns about the age-specific risk of intussusception associated with use of 
rotavirus viruses, WHO initially recommended that the last dose of vaccine be administered 
by 32 weeks of age, but subsequently these recommendations have been revised and the age 
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restrictions removed (3, 172). A study in Bangladesh investigated the administration of a 
booster dose of Rotarix® at 9 months of age, following two primary doses at 6 and 10 weeks 
of age. Concomitant administration of measles-rubella vaccine and rotavirus vaccine was safe 
with no negative effect of the rotavirus vaccine on measles and rubella immunity. Serum 
rotavirus-specific IgA and IgG GMTs measured two months following the booster dose 
increased significantly from pre-vaccination levels measured at 9 months of age. Increases 
were mainly observed among infants with low pre-vaccination titres, suggesting that this 
additional dose at the 9 month routine immunisation visit could have public health benefit 
(173).  
Rotavirus infection occurs at an early age in lower income countries and some infants may be 
exposed to natural rotavirus and acquire disease prior to their first vaccination, even with a 
dose given as early as 6 weeks of age. One alternative approach is to use a birth dose of 
rotavirus vaccine. This would enable completion of three doses prior to 3 months of age i.e. 
0, 6 and 10 weeks and in addition minimise any potential risk of intussusception associated 
with the first dose as intussusception risk is low in the neonatal period. The neonatal vaccine 
candidate RV3-BB was found to be immunogenic and well-tolerated in Phase I and II trials 
and this birth-dose strategy potentially provides a way to improve the safety and effectiveness 
of rotavirus vaccines in lower income countries (174, 175).  
 
Season of birth and vaccination 
Seasonal factors may influence rotavirus vaccine performance as evidenced by a recent 
pooled analysis of results from case-control studies performed in the Americas which found 
that vaccine effectiveness was significantly reduced among children aged <12 months born 
during the rotavirus season compared to those born outside of these months (176). Infections 
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with other enteric pathogens at the time of vaccination may vary by season, for example 
bacterial diarrhoeal infections are generally more common in the warmer summer months 
outside of the peak rotavirus season, and may affect the immune response in infants 
differently depending on when they are born (177). Maternal rotavirus-specific antibody titres 
are likely to be higher during the rotavirus season resulting in higher levels of transplacental 
transfer of antibodies to their infants, with greater potential to inhibit the immune response to 
the vaccine (48). In addition, children born in the rotavirus season are likely to be vaccinated 
just after the rotavirus season with several months delay until their first exposure to natural 
rotavirus infection in the following rotavirus season, which may also result in waning of 
immunity.  
We did not assess vaccine effectiveness by season of birth or season of vaccine 
administration, but additional analyses of the case-control data are underway. An additional 
year of enrolment was conducted at all seven sites and while the coverage may be too high to 
allow additional sub-analyses of vaccine effectiveness against hospitalisation for rotavirus 
diarrhoea, a closer look at factors associated with vaccine failure (i.e. rotavirus diarrhoea in 
children who had received two doses of rotavirus vaccine) are warranted. New methods such 
as the propensity score design and analysis could also be utilised in further analysis of the 
data, where traditional analysis methods are not appropriate (178). 
 
Waning of immunity and indirect protection 
We did not observe any waning of vaccine effectiveness and similar estimates were observed 
in children <12 months as children aged 12-23 months. In addition, there was no shift 
towards increased incidence of diarrhoeal hospitalisation in this age group, which is 
encouraging. Some reduction in all-cause diarrhoeal hospitalisations was observed in the first 
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post-vaccination year with greater reductions observed from the second year of vaccine 
introduction. Reductions were maintained in all four subsequent years, suggesting that the 
vaccine affords protection through the second year of life. We did not see any clear evidence 
of indirect protection i.e. protection in older unvaccinated children, as has been observed in 
some high-income settings (96, 115). In our setting very little rotavirus-associated 
hospitalisation occurs in children >2 years of age, so any indirect protection in this age group 
would be minimal.  
 
Impact on mortality 
Trends in all-cause diarrhoea deaths should also be assessed post-vaccine introduction, 
especially in countries where diarrhoeal mortality rates are high, as many policy makers and 
national health departments have prioritised decreasing overall mortality in their countries. 
Although the number of children hospitalised, together with the diagnoses, were consistently 
recorded at CHBAH during the study period, data on the outcome of the hospitalisation were 
less accurately recorded with many of hospitalised children missing outcome data. We were 
thus unable to assess trends in all-cause diarrhoeal deaths in addition to the hospitalisation 
trends. In addition, diarrhoeal mortality rates are much lower than hospitalisation rates 
making it difficult to interpret when numbers are small. Plans are underway to analyse vital 
registration data in South Africa to measure the impact of rotavirus vaccine introduction on 
all-cause diarrhoeal mortality at a national level. This may, however, be difficult to interpret 
in the context of reduction in under-5 childhood mortality specifically related to declines in 
death due to HIV/AIDS.  
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Strain replacement 
There is a concern that selective pressure from strain-specific rotavirus vaccines may impact 
strain circulation after vaccine introduction and that rotavirus vaccines may not provide 
protection against emergent strains. Our case-control study showed effectiveness of the 
rotavirus vaccine against homotypic, partly heterotypic and fully heterotypic strains but was 
not powered to assess protection against specific strains, except for G12P[8], the dominant 
strain during the study period. An integrated analysis of all the clinical trials using the 
monovalent rotavirus vaccine showed comparable clinical protection against severe rotavirus 
diarrhoea caused by multiple rotavirus strains (179). A recent systematic review found that 
both the monovalent and pentavalent rotavirus vaccines had similar effectiveness against 
homotypic and heterotypic strains and that predominance of specific strains was not observed 
after routine vaccine introduction (110). In particular, initial concern over the predominance 
of genotype G2P[4] after introduction of the monovalent vaccine was shown to disappear 
over time (180). Continued diarrhoeal surveillance and monitoring of rotavirus strains is 
warranted in South Africa to detect the emergence of new and unusual genotypes, especially 
with the high genetic strain diversity observed in Africa, as well as to monitor the potential 
for replacement by other viruses, for example norovirus (82). 
 
Safety considerations 
The overwhelming benefit of rotavirus vaccination compared to the low intussusception risk, 
has allowed policy makers and global health authorities, for example WHO, to support 
routine vaccination of infants with rotavirus vaccine, albeit with recommendations for 
continued safety monitoring (132, 181). While we have demonstrated significant benefits of 
rotavirus vaccine introduction in South Africa, it is important to monitor vaccine safety 
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following rotavirus vaccine introduction in order to better evaluate the risk-benefit ratio 
specifically in African countries.  
Once again South Africa is in a prime position to provide post-implementation safety data 
from Africa, and active prospective surveillance for intussusception was implemented at 8 
hospitals, which include the majority of the larger paediatric surgical departments, in South 
Africa since October 2013 (principal investigators M.J. Groome, S.A. Madhi). This 
surveillance will use a case-series as well as a case-control methodology and generate data on 
the risk of intussusception following rotavirus vaccination, other potential risk factors for 
intussusception, and explore the mechanisms of disease. These methods have both been 
successfully used to assess intussusception risk, with consistency of estimates observed in 
studies using both methodologies (128, 129). Serum, stool and tissue samples will be 
collected on both cases and control to investigate possible aetiological agents and the role of 
C-reactive protein in the pathogenesis of intussusception in children (124).  
 
The future of rotavirus vaccines 
Despite the success of the currently licenced rotavirus vaccines, continued research and 
development of new live-attenuated rotavirus vaccines is warranted to ensure a sustainable 
and uninterrupted vaccine supply as the demand for rotavirus vaccines increase. Issues 
associated with the live-attenuated oral vaccines may be circumvented by the development of 
“new generation” inactivated rotavirus vaccines, which are administered parenterally and 
may have superior efficacy, have less safety risks, be less expensive to produce and could be 
added to existing EPI vaccines, thereby facilitating delivery (182).  
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Vaccine candidates include protein subunit vaccines, inactivated virus and virus-like particle 
vaccines. There is a rich rotavirus vaccine pipeline with several vaccine candidates under 
development, and one such vaccine candidate is currently in Phase1/II human trials in 
Soweto, South Africa (principal investigator M.J. Groome; ClinicalTrials.gov number, 
NCT02109484). This monovalent P2-VP8 subunit vaccine was shown to be well tolerated 
and immunogenic in healthy adults in the US (183). Preliminary results from the current 
clinical trial in South African toddlers and infants showed that the vaccine was well-tolerated 
in the target population, and, pending favourable immunogenicity results, a Phase I/II trial of 
the trivalent P2-VP8 subunit vaccine will commence at three sites in South Africa in 2016 
(184).  
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CONCLUSION 
Through the work undertaken in this doctoral thesis, the monovalent oral rotavirus vaccine 
was shown to be an effective intervention against hospitalisation for rotavirus diarrhoea in 
children <2 years of age in a middle-income setting with a high prevalence of HIV infection 
among pregnant women, high rates of malnutrition and enteric co-infections, as well as with a 
schedule different to that used in the efficacy trials of rotavirus vaccine. Despite lower 
rotavirus vaccine efficacy and effectiveness estimates observed in South Africa, compared to 
higher income countries, there was a significant impact of the vaccine on all-cause diarrhoeal 
hospitalisations in both HIV-infected and HIV-uninfected children <5 years of age which was 
maintained for five years after vaccine introduction. As an increasing number of African 
countries introduce or plan introduction of this life saving vaccine into their national 
immunisation programmes, our data are pivotal to inform public health decisions and to 
provide evidence for sustained vaccine use and continued investment from governments and 
donors.  
Although abstention from breastfeeding at the time of vaccination has been conclusively 
shown not to improve the immune response to the rotavirus vaccine, several key factors 
surrounding optimal use of the oral rotavirus vaccines still need further evaluation. Further 
studies are needed to better define the role of maternal rotavirus antibodies as well as the 
impact of enteric co-infections, concurrent medical conditions, zinc supplementation and 
probiotic administration with the vaccine. Economic impact assessments, such as cost 
effectiveness studies, are essential to inform decisions in countries yet to introduce the 
rotavirus vaccine and support decisions made in countries already using the vaccine. 
Furthermore, success of the currently licenced vaccines should not deter future vaccine 
research or comprehensive strategies to control diarrhoeal disease including promotion of 
oral rehydration and improvements in water and sanitation. 
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Eﬀ ectiveness of monovalent human rotavirus vaccine 
against admission to hospital for acute rotavirus diarrhoea 
in South African children: a case-control study
Michelle J Groome, Nicola Page, Margaret M Cortese, Jocelyn Moyes, Heather J Zar, Constant N Kapongo, Christine Mulligan, Ralph Diedericks, 
Cheryl Cohen, Jessica A Fleming, Mapaseka Seheri, Jeﬀ rey Mphahlele, Sibongile Walaza, Kathleen Kahn, Meera Chhagan, A Duncan Steele, 
Umesh D Parashar, Elizabeth R Zell, Shabir A Madhi
Summary
Background The eﬀ ectiveness of the rotavirus vaccine under conditions of routine use in an African setting with a 
high prevalence of HIV infection needs to be established. We assessed the vaccine eﬀ ectiveness of monovalent 
human rotavirus vaccine in preventing admission to hospital for acute rotavirus diarrhoea, after its introduction at 
age 6 and 14 weeks into South Africa’s national immunisation programme.
Methods This case-control study was done at seven hospitals in South Africa between April 19, 2010, and Oct 31, 2012. 
The hospitals were located in a range of urban, peri-urban, and rural settings, with varying rates of population HIV 
infection. Cases were children aged from 18 weeks to 23 months who were age-eligible to have received at least one dose 
of the human rotavirus vaccine (ie, those born after June 14, 2009) admitted to hospital with laboratory-conﬁ rmed acute 
rotavirus diarrhoea, and the primary control group was children admitted to hospital with diarrhoea testing negative for 
rotavirus. A second control group comprised children admitted to a subset of three of the seven hospitals with respiratory 
illness. The primary endpoint was adjusted vaccine eﬀ ectiveness (1 − adjusted odds ratio × 100%) in children aged from 
18 weeks to 23 months and was calculated by unconditional logistic regression. This study is registered on the South 
African National Clinical Trial Register, number DOH-27-0512-3247.
Findings Of 540 rotavirus-positive cases, 278 children (52%) received two doses, 126 (23%) one dose, and 136 (25%) no 
doses of human rotavirus vaccine, compared with 1434 rotavirus-negative controls of whom 856 (60%) received two 
doses, 334 (23%) one dose, and 244 (17%) no doses. Adjusted vaccine eﬀ ectiveness using rotavirus-negative controls 
was 57% (95% CI 40–68) for two doses and 40% (16–57) for one dose; estimates were similar when respiratory 
controls were used as the control group. Adjusted vaccine eﬀ ectiveness for two doses was similar between age groups 
18 weeks–11 months (54%, 95% CI 32–68) and 12–23 months (61%, 35–77), and was similar in HIV-exposed-
uninfected (64%, 95% CI 34–80) and HIV-unexposed-uninfected children (54%, 31–69).
Interpretation Human rotavirus vaccine provided sustained protection against admission to hospital for acute 
rotavirus diarrhoea during the ﬁ rst and second years of life. This ﬁ nding is encouraging and establishes the public 
health value of rotavirus vaccine in an African setting, especially as rotavirus vaccines are introduced into an increasing 
number of African countries.
Funding GAVI Alliance (with support from PATH).
Introduction
Rotavirus is the leading cause of diarrhoeal morbidity 
and mortality in children younger than 5 years, 
accounting for an estimated 453 000 global deaths in 
2008, with more than 90% of deaths occurring in low-
income countries in Africa and Asia.1,2 In 2009, 
diarrhoea was a leading cause of death in South African 
children younger than 5 years,3 and rotavirus was 
detected in about 25% of children admitted to hospital 
for diarrhoea before the rotavirus vaccine was 
introduced in August, 2009.4
Two oral rotavirus vaccines—a monovalent human 
rotavirus vaccine (Rotarix, GlaxoSmithKline Biologicals, 
Rixensart, Belgium) and a pentavalent bovine–human 
reassortant rotavirus vaccine (RotaTeq, Merck Vaccines, 
Whitehouse Station, NJ, USA)—are recommended for 
global use by WHO.5 Both vaccines showed high eﬃ  cacy 
against severe rotavirus diarrhoea in trials undertaken in 
middle-income and high-income countries in Europe 
and Latin America.6,7 However, lower immunogenicity 
and vaccine eﬃ  cacy were shown in subsequent trials in 
low-income and middle-income countries in Asia and 
Africa.8–10
Eﬃ  cacy trials of the monovalent human rotavirus 
vaccine showed sustained protection through 2 years,11,12 
but some post-licensure studies in low-income and 
middle-income countries have recorded lower degrees of 
protection in children aged 12 months and older, 
suggesting the possibility of waning immunity.13,14 In a 
trial of the human rotavirus vaccine in South Africa, 
vaccine eﬃ  cacy against severe rotavirus diarrhoea in the 
composite group of vaccinees who received either two 
Lancet Infect Dis 2014; 
14: 1096–104 
Published Online
October 8, 2014
http://dx.doi.org/10.1016/
S1473-3099(14)70940-5
This online publication has 
been corrected. 
The corrected version ﬁ rst 
appeared at thelancet.com/
infection on October 20, 2014
See Comment page 1031
Department of Science and 
Technology/National Research 
Foundation: Vaccine 
Preventable Diseases 
(M J Groome MBBCh, 
Prof S A Madhi PhD), Medical 
Research Council: Respiratory 
and Meningeal Pathogens 
Research Unit (M J Groome, 
Prof S A Madhi), School of Public 
Health, Faculty of Health 
Sciences (J Moyes MBBCh, 
C Cohen MBBCh), and MRC/Wits 
Rural Public Health and Health 
Transitions Research Unit 
(Agincourt), School of Public 
Health, Faculty of Health 
Sciences (K Kahn PhD), 
University of the 
Witwatersrand, Johannesburg, 
South Africa; National Institute 
for Communicable Diseases: a 
Division of National Health 
Laboratory Service, 
Sandringham, South Africa 
(N Page PhD, J Moyes, C Cohen, 
S Walaza MBBCh, Prof S A Madhi); 
Division of Viral Diseases, 
Centers for Disease Control and 
Prevention, Atlanta, GA, USA 
(M M Cortese MD, 
U D Parashar MBBS); Department 
of Paediatrics and Child Health, 
Red Cross War Memorial 
Children’s Hospital, University 
of Cape Town, Cape Town, 
South Africa (Prof H J Zar PhD, 
C Mulligan MBChB, 
R Diedericks FCP[Paed]); 
Department of Paediatrics, 
Ngwelezane Hospital, 
Empangeni, South Africa 
(C N Kapongo FCPaeds[SA]); 
PATH, Seattle, WA, USA
Articles
www.thelancet.com/infection   Vol 14   November 2014 1097
(J A Fleming PhD, A D Steele PhD); 
MRC/Diarrhoeal Pathogens 
Research Unit, Department of 
Virology, Medunsa Campus, 
University of Limpopo/National 
Health Laboratory Service, 
Pretoria, South Africa 
(M Seheri PhD, 
Prof J Mphahlele PhD, A D Steele); 
Centre for Global Health 
Research, Umeå 
University, Umeå, Sweden 
(K Kahn); INDEPTH Network, 
Accra, Ghana (K Kahn); 
Department of Paediatrics and 
Child Health, University of 
KwaZulu-Natal, South Africa 
(M Chhagan*); Bill & Melinda 
Gates Foundation, Seattle, 
Washington, USA (A D Steele†); 
and Stat-Epi Associates Inc, FL, 
USA (E R Zell MStat)
*Dr Chhagan died in August, 2014 
†Denotes current aﬃ  liation
Correspondence to:
Dr Michelle J Groome, 
New Nurses Residence, 
11th Floor West Wing, 
Chris Hani Baragwanath 
Academic Hospital, 
Chris Hani Road, Soweto, 2013, 
South Africa
groomem@rmpru.co.za
doses (at 10 and 14 weeks of age) or three doses (at 6, 10, 
and 14 weeks of age) of human rotavirus vaccine was 77% 
(95% CI 56–88) during the ﬁ rst year of life and 59% 
(1–83) during two consecutive rotavirus seasons.8,15 
However, the study was not powered to speciﬁ cally assess 
eﬃ  cacy in the second year of life.
The performance of rotavirus vaccines post-licensure 
has been assessed in countries in the Americas, Australia, 
and Europe,16 but no published data assessing the 
eﬀ ectiveness of these vaccines are yet available from 
Africa. It is important to establish the eﬀ ectiveness of 
rotavirus vaccination in an African setting, under 
conditions of routine use, including durability of 
protection in the second year of life for the two-dose 
series of the monovalent human rotavirus vaccine.
South Africa was the ﬁ rst African country to introduce 
rotavirus vaccine into its national immunisation pro-
gramme, starting in August, 2009, with vaccination 
recommended at 6 and 14 weeks of age. Children receive 
trivalent oral polio vaccine (Merieux; Sanoﬁ  Pasteur, 
Lyon, France) concurrent with human rotavirus vaccine 
at the 6-week immunisation visit.17 District Health 
Information Systems estimates of coverage rates for the 
second dose of rotavirus vaccine increased from 67% in 
2010 to 96% in 2011.18 In the same year, the estimated 
national HIV prevalence was 30% in pregnant women 
aged 15–49 years.19 
We did a case-control study to assess the vaccine 
eﬀ ectiveness of human rotavirus vaccine in preventing 
admission to hospital for acute rotavirus diarrhoea in 
children younger than 2 years in a setting with a high 
prevalence of HIV exposure in infants.
Methods
Study design and participants
The study was done between April 19, 2010, and Oct 31, 
2012, at seven hospitals in South Africa, including urban, 
peri-urban, and rural settings, with varying rates of 
population HIV infection. The hospitals were: Chris 
Hani Baragwanath Academic Hospital, Mapulaneng 
Hospital, Matikwane Hospital, Dr George Mukhari 
Academic Hospital, Edendale Hospital, Ngwelezane 
Hospital, and Red Cross War Memorial Children’s 
Hospital (ﬁ gure 1 and appendix pp 1–3). All hospitals 
have inpatient and outpatient facilities and care is 
provided free of charge. Children with diarrhoea present 
either to community clinics, where hospital referral is 
based on health-care worker assessment, or directly to 
the hospital. All decisions regarding admission, 
investigations, and treatment were made by the attending 
physician, independent of study staﬀ .
Children admitted to hospital overnight with physician-
diagnosed acute diarrhoea who were age-eligible to have 
received at least one dose of human rotavirus vaccine (ie, 
those born after June 14, 2009) were invited to participate. 
Written consent was obtained from a parent or guardian. 
A stool specimen was collected within 48 h of admission 
and was stored at 2–8°C before transfer to the National 
Institute for Communicable Diseases (Sandringham, 
South Africa) or MRC Diarrhoeal Pathogens Research 
Unit (Pretoria, South Africa), where rotavirus testing was 
done by a commercially available enzyme immunoassay 
(ProSpecT; ELISA, Oxford, UK). Rotavirus-positive 
samples were genotyped with standardised methods.20 
Stool samples from all hospitals except for Dr George 
Mukhari Academic Hospital were also tested for the 
presence of adenovirus, norovirus genogroup I and II, 
astrovirus, and sapovirus by real-time PCR detection 
assays (in accordance with published methods; see 
appendix p 4).
Children fulﬁ lling the case deﬁ nition for acute 
diarrhoea (≤7 days duration at admission and three or 
more loose stools in a 24-h period) and EIA-conﬁ rmed 
rotavirus infection were classiﬁ ed as cases. Children with 
acute diarrhoea testing rotavirus negative by EIA served 
as the primary control group. A second control group was 
selected from children enrolled into a concurrent study 
investigating the eﬀ ectiveness of a pneumococcal 
conjugate vaccine at three of the hospitals (Chris Hani 
Baragwanath Academic, Ngwelezane, and Red Cross War 
Memorial Children’s hospitals). Age-eligible children 
admitted to hospital with physician-diagnosed lower 
respiratory tract infection were assessed with C-reactive 
protein and chest radiograph.21 Children who were 
presumed not to have bacterial pneumonia (ie, those with 
C-reactive protein <381 nmol/L [<40 mg/L] and without 
radiologically conﬁ rmed pneumonia) were eligible for 
inclusion into the respiratory control group, since they 
could be judged unlikely to have a vaccine-preventable 
Limpopo
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Figure 1: Location of study hospitals in South Africa
Antenatal HIV prevalence in each province in 2011: Gauteng 29% (95% CI 
27–30); Mpumalanga 37% (34–39), KwaZulu-Natal 37% (36–39), Western Cape 
18% (14–23).19
See Online for appendix
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disease. At the time of study initiation, few published 
studies were available that used rotavirus-negative 
children with diarrhoea as controls in assessments of 
rotavirus vaccine eﬀ ectiveness. Because of the importance 
of studying eﬀ ectiveness in an African setting and the fact 
that every control group has some advantages and 
disadvantages for its use, we felt it prudent to include a 
second non-diarrhoea control group because overall 
consistency in results would strengthen our ﬁ ndings.
We obtained ethical approvals from the ethics com-
mittees of the University of the Witwatersrand, University 
of KwaZulu-Natal, University of Cape Town, and 
University of Limpopo, and from PATH’s Research 
Ethics Committee. Respiratory controls consented as 
part of the pneumococcal conjugate vaccine eﬀ ectiveness 
study with separate ethical approval. This study is 
registered on the South African National Clinical Trial 
Register, number DOH-27-0512-3247.
Procedures
Demographic characteristics, medical history, clinical 
presentation, and outcome were obtained by interview 
with each child’s parent or guardian and by hospital 
record review. Vaccination history was ascertained by 
review of the vaccination card, a photocopy of which was 
obtained when possible, before determination of case or 
control status. If the vaccination card was unavailable but 
the parent reported that the child had not received any 
vaccines other than those given at birth, the child was 
included and judged not to have received any doses of 
human rotavirus vaccine. When a photocopy of the 
vaccination card was available, discrepancies between the 
photocopy and transcribed vaccination data were 
reviewed, after which a ﬁ nal vaccination status was 
assigned.
HIV testing included HIV ELISA testing for children 
aged 18 months or older and those born to women not 
infected with HIV; or HIV PCR testing in children 
younger than 18 months born to women known to be 
infected with HIV or if maternal HIV status was 
unknown. HIV PCR testing was done for children who 
tested HIV positive on ELISA. An HIV-uninfected child 
was judged to be HIV-exposed if the mother gave a 
history of testing HIV positive during pregnancy, or HIV-
unexposed if the mother had a history of negative HIV 
tests during pregnancy.
Statistical analysis
In the primary analysis, we assessed the primary 
endpoint of adjusted vaccine eﬀ ectiveness of two 
human rotavirus vaccine doses compared with no 
vaccination in the prevention of admission to hospital 
for acute rotavirus diarrhoea in children aged from 
18 weeks to 23 months, irrespective of their HIV 
infection status, with use of rotavirus-negative controls. 
We excluded children without an adequate stool sample 
or available vaccination history. We counted a dose of 
human rotavirus vaccine if it was given 14 days or more 
before admission to hospital. Our secondary analyses 
were limited to children from the three hospitals where 
respiratory controls were enrolled.
We calculated that a minimum sample size of 148 cases 
with rotavirus diarrhoea was needed for the primary 
analysis, based on an estimated two-dose vaccine 
eﬀ ectiveness of 60%,8,15 with a control-to-case ratio of 2:1, 
and two-dose estimated vaccine coverage in controls of 
80%. We enrolled additional cases to enable the stratiﬁ ed 
analyses speciﬁ ed in the secondary objectives.
We used unconditional logistic regression to estimate 
adjusted odds ratios (aOR) with associated 95% CIs, and 
we calculated adjusted vaccine eﬀ ectiveness as 
(1 – aOR) × 100%. We included hospital, birth month, birth 
year, month by year of birth (interaction term), quarter of 
hospital admission, year of hospital admission, and 
quarter by year of hospital admission (interaction term) in 
the models a priori. We included other covariates in the 
models if their inclusion changed the OR associated with 
vaccination by more than 5%. We did stratiﬁ ed analyses to 
assess adjusted vaccine eﬀ ectiveness by age 
(18 weeks–11 months and 12–23 months) and by HIV 
exposure status in HIV-uninfected children. We included 
interaction terms for age or HIV exposure and vaccination 
status in the model for these analyses. All reported 
adjusted vaccination eﬀ ective ness estimates were against 
admission to hospital for acute rotavirus diarrhoea. We 
used STATA version 12.1 for all analyses.
2295 children fulﬁlled case deﬁnition of acute diarrhoea
196 excluded because no stool 
         sample available or 
         sample insuﬃcient
1522 rotavirus-negative
           controls
88 excluded
         3 previously a 
             case/control†
      85 no vaccination 
             history available*
577 rotavirus-positive cases
37 excluded because no 
      vaccination history 
       available*
540 rotavirus-positive
         cases
1434 rotavirus-negative 
            controls
Figure 2: Enrolment of children aged from 18 weeks to 23 months with acute 
diarrhoea, and age-eligible to have received rotavirus vaccine (ie, born after 
June 14, 2009) at seven hospitals in South Africa
Enrolled children age-eligible to receive rotavirus vaccine and aged <18 weeks 
and ≥24 months are not included in the enrolment ﬁ gure. *539 of 540 rotavirus-
positive cases and 1427 of 1434 rotavirus-negative controls had a vaccination 
card available for review. †A child enrolled more than once into the study for 
acute diarrhoea with any stool testing positive for rotavirus was deﬁ ned as a case 
and any other admissions for that child were excluded from the analysis. If all 
stool results were rotavirus negative, the ﬁ rst admission to hospital for diarrhoea 
contributed to the control data.
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Role of the funding source
The funder had no role in the writing of the report or the 
decision to submit for publication. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
1974 children with acute diarrhoea aged from 18 weeks to 
23 months fulﬁ lled the study case deﬁ nition and had a 
stool sample and vaccination history available: 
540 rotavirus-positive cases and 1434 rotavirus-negative 
controls (ﬁ gure 2). 37 (6%) of 577 rotavirus cases and 
85 (6%) of 1522 rotavirus-negative controls did not have a 
vaccination history available and were therefore excluded 
from analyses. We recorded no signiﬁ cant diﬀ erences in 
characteristics between children with and without an 
available vaccination history (data not shown). In the 
subset of three hospitals with respiratory controls (Chris 
Hani Baragwanath Academic Hospital, Ngwelezane 
Hospital, and Red Cross War Memorial Children’s 
Hospital), 370 rotavirus-positive cases, 1024 rotavirus-
negative controls, and 1069 respiratory controls were 
included in the analysis (appendix pp 5–6). Table 1 shows 
comparisons of characteristics between cases and 
controls.
All hospitals Subset of hospitals*
Rotavirus-positive 
cases (n=540)
Rotavirus-negative 
controls (n=1434)
p value Rotavirus-positive 
cases (n=370)
Rotavirus-negative 
controls (n=1024)
p value Respiratory controls 
(n=1069)
p value
Hospital 0·029 0·279 <0·0001
Chris Hani Baragwanath Academic 101 (19%) 283 (20%) ·· 101 (27%) 283 (28%) 555 (52%)
Matikwane and Mapulaneng† 72 (13%) 167 (12%) ·· ·· ·· ·· ·· ··
Dr George Mukhari Academic 67 (12%) 200 (14%) ·· ·· ·· ·· ·· ··
Edendale 31 (6%) 43 (3%) ·· ·· ·· ·· ·· ··
Red Cross War Memorial Children’s 197 (36%) 504 (35%) ·· 197 (53%) 504 (49%) ·· 401 (38%) ··
Ngwelezana 72 (13%) 237 (17%) ·· 72 (20%) 237 (23%) ·· 113 (11%) ··
Age, months 9 (7–13) 10 (7–14) 0·004 9 (7–12) 10 (7–14) 0·002 8 (6–13) 0·601
Male sex 304 (56%) 810 (56%) 0·940 199 (54%) 575 (56%) 0·432 604/1068 (57%) 0·355
Black ethnic origin 499 (92%) 1327/1431 (93%) 0·805 329 (89%) 921 (90%) 0·580 960/1068 (90%) 0·598
Breastfeeding before age 4 months 0·218 0·562 0·807
Exclusive breastfeeding 303/539 (56%) 799/1432 (56%) ·· 202/369 (55%) 558 (55%) ·· 563/1066 (53%) ··
Mixed breast and formula 47/539 (9%) 95/1432 (7%) ·· 31/369 (8%) 70 (7%) ·· 91/1066 (9%) ··
Formula only 189/539 (35%) 538/1432 (38%) ·· 136/369 (37%) 396 (39%) ·· 412/1066 (39%) ··
House built of brick 341/537 (64%) 865/1431 (60%) 0·215 211/368 (57%) 558 (55%) 0·347 734/1062 (69%) <0·0001
Electricity available 475 (88%) 1221 (85%) 0·109 323 (87%) 874 (85%) 0·357 988 (92%) 0·003
Indoor water source 227 (42%) 571/1432 (40%) 0·383 141 (38%) 364 (36%) 0·380 431 (40%) 0·454
Flush toilet available 313/538 (58%) 791/1432 (55%) 0·241 249/368 (68%) 627/1023 (61%) 0·030 866/1066 (81%) <0·0001
Number of people sleeping in same 
room as the child
2 (2–3) 2 (2–3) 0·412 2 (2–4) 2 (2–4) 0·763 3 (2–4) 0·268
Daycare attendance 85/536 (16%) 296/1431 (21%) 0·016 70/366 (19%) 237/1023 (23%) 0·110 115/1064 (11%) <0·0001
Maternal education 0·170 0·410 0·770
None 5/524 (1%) 29/1422 (2%) ·· 4/366 (1%) 21/1020 (2%) ·· 11/1051 (1%) ··
Primary 44/524 (8%) 128/1422 (9%) ·· 29/366 (8%) 86/1020 (8%) ·· 69/1051 (7%) ··
Secondary 461/524 (88%) 1208/1422 (85%) ·· 322/366 (88%) 869/1020 (85%) ·· 932/1051 (89%) ··
Higher education 14/524 (3%) 57/1422 (4%) ·· 11/366 (3%) 44/1020 (4%) ·· 39/1051 (4%) ··
Low birthweight (<2·5 kg) 92/529 (17%) 226/1400 (16%) 0·510 61/363 (17%) 158/1002 (16%) 0·645 222/1045 (21%) 0·069
HIV infection status 0·267 0·163 <0·0001
Infected 45 (8%) 155 (11%) ·· 27 (7%) 83 (8%) ·· 36 (3%) ··
Uninfected 454 (84%) 1174 (82%) ·· 318 (86%) 897 (88%) ·· 1000 (94%) ··
Status unknown 41 (8%) 105 (7%) ·· 25 (7%) 44 (4%) ·· 33 (3%) ··
Days in hospital 2 (1–5) 2 (1–5) 0·097 2 (1–4) 2 (1–4) 0·118 1 (1–3) <0·0001
Died 7/533 (1%) 31/1412 (2%) 0·210 1/367 (<1%) 7/1017 (<1%) 0·689 2/1059 (<1%) >0·999
Data are n (%), median (IQR), or n/N (%). *Hospitals with respiratory controls: Chris Hani Baragwanath Academic Hospital, Ngwelezane Hospital, and Red Cross War Memorial Children’s Hospital. †Matikwane 
Hospital and Mapulaneng Hospital are two small hospitals that both serve the Bushbuckridge district; therefore, for the analysis these two hospitals were grouped together. All continuous variables were not 
normally distributed and were therefore assessed with the Wilcoxon rank-sum test; p<0·05 was judged to be signiﬁ cant. The χ2 test or Fisher’s exact test was used to assess dichotomous and categorical variables; 
p<0·05 was judged to be signiﬁ cant. Missing values: totals are given for each characteristic. Those with a missing value for any covariate were excluded for that particular bivariate analysis.  
Table 1: Baseline characteristics of rotavirus-positive cases, rotavirus-negative controls, and respiratory controls in children aged from 18 weeks to 23 months
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When we include all 3043 children who were available for 
analysis (540 rotavirus-positive cases, 1434 rotavirus-
negative controls, and 1069 respiratory controls), the 
median age at receipt of human rotavirus vaccine was 
6 weeks (IQR 6–8) for the ﬁ rst dose and 15 weeks (14–17) for 
the second dose. Of the 1868 children who received two 
doses of the vaccine, 1553 (83%)  completed vaccination by 
18 weeks and 1779 (95%) did so by age 24 weeks (appendix 
p 7). Oral polio vaccine was given concurrently with the ﬁ rst 
dose of rotavirus vaccine in 1869 (74%) of 2532 vaccinated 
children, with no signiﬁ cant diﬀ erences between cases and 
controls. Children who received only one dose of the 
human rotavirus vaccine received it at an older age (median 
8 weeks [IQR 6–14]) than the ﬁ rst dose in two-dose 
recipients (6 weeks [6–7]; p<0·0001), and this dose was less 
likely to have been given with oral polio vaccine than was 
the ﬁ rst dose in two-dose recipients (371/664 [56%] of 
one-dose recipients received concomitant oral polio vaccine 
vs 1498/1868 [80%] of two-dose recipients; p<0·0001).
In children aged from 18 weeks to 23 months, the 
overall adjusted vaccine eﬀ ectiveness was higher for two 
doses of human rotavirus vaccine than for one dose 
(table 2). In the age-stratiﬁ ed analyses, protection after 
two doses of the vaccine was similar in the two age 
groups (table 3). HIV exposure status was available for 
2570 (98%) of 2628 HIV-uninfected children (including 
all analysable rotavirus-positive cases, rotavirus-negative 
controls, and respiratory controls); 807 (31%) of 2570 were 
HIV-exposed-uninfected and 1763 (69%) were HIV-
unexposed-uninfected. In all HIV-uninfected children 
(including those both exposed and not exposed to the 
virus), protection after two doses was 57% (95% CI 39–70; 
table 4). The adjusted vaccine eﬀ ectiveness for two doses 
of human rotavirus vaccine was similar in HIV-exposed-
All hospitals Subset of hospitals*
Rotavirus-
positive cases 
(n=540)
Rotavirus-
negative 
controls 
(n=1434)
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
Rotavirus- 
positive cases 
(n=370)
Rotavirus-
negative 
controls 
(n=1024)
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
Respiratory 
controls 
(n=1069)
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
0 doses (reference) 136 (25%) 244 (17%) ·· 94 (25%) 181 (18%) ·· 140 (13%) ··
1 dose 126 (23%) 334 (23%) 40% (16–57) 87 (24%) 238 (23%) 35% (4–56) 232 (22%) 54% (31–69)
2 doses 278 (52%) 856 (60%) 57% (40–68) 189 (51%) 605 (59%) 52% (29–67) 697 (65%) 63% (45–75)
Data are n (%) unless otherwise shown.  A dose of human rotavirus vaccine was counted if it was administered ≥14 days before the date of hospital admission. *Hospitals with 
respiratory controls: Chris Hani Baragwanath Academic Hospital, Ngwelezane Hospital, and Red Cross War Memorial Children’s Hospital. †Unconditional logistic regression 
was used to calculate adjusted vaccine eﬀ ectiveness. Models that included sex, race, history of breastfeeding, maternal education, daycare attendance, birthweight, and 
variables of household characteristics did not change the adjusted odds ratio by >5% and were therefore not included in the ﬁ nal models. Hospital, birth month, birth year, 
month by year of birth (interaction term), quarter of hospital admission, year of hospital admission, and quarter by year of hospital admission (interaction term) were 
included in the models a priori.
Table 2: Eﬀ ectiveness of one and two doses of rotavirus vaccine in preventing hospital admission for acute rotavirus diarrhoea in children aged from 
18 weeks to 23 months
All hospitals Subset of hospitals*
Rotavirus- 
positive cases
Rotavirus-
negative 
controls
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
Rotavirus-
positive cases
Rotavirus-
negative 
controls
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
Respiratory 
controls
Adjusted vaccine 
eﬀ ectiveness, % 
(95% CI)†
Age 18 weeks–11 months
0 doses 
(reference)
90/389 (23%) 149/947 (16%) ·· 62/274 (23%) 107/671 (16%) ·· 80/749 (11%) ··
1 dose 92/389 (24%) 231/947 (24%) 39% (9 to 59) 65/274 (24%) 168/671 (25%) 35% (–4 to 60) 162/749 (22%) 60% (34 to 76)
2 doses 207/389 (53%) 567/947 (60%) 54% (32 to 68) 147/274 (54%) 396/671 (59%) 47% (18 to 66) 507/749 (68%) 66% (46 to 79)
Age 12–23 months
0 doses 
(reference)
46/151 (30%) 95/487 (20%) ·· 32/96 (33%) 74/353 (21%) ·· 60/320 (19%) ··
1 dose 34/151 (23%) 103/487 (21%) 40% (–7 to 66) 22/96 (23%) 70/353 (20%) 32% (–35 to 65) 70/320 (22%) 41% (–17 to 71)
2 doses 71/151 (47%) 289/487 (59%) 61% (35 to 77) 42/96 (44%) 209/353 (59%) 60% (26 to 79) 190/320 (59%) 60% (21 to 80)
A single logistic regression model was used, with introduction of an interaction term for age group by vaccination status. A dose of human rotavirus vaccine was counted if it 
was given ≥14 days before the date of admission to hospital. *Hospitals with respiratory controls: Chris Hani Baragwanath Academic Hospital, Ngwelezane Hospital, and Red 
Cross War Memorial Children’s Hospital. †Unconditional logistic regression was used to calculate adjusted vaccine eﬀ ectiveness. Models that included sex, ethnic origin, 
history of breastfeeding, maternal education, daycare attendance, birthweight, and variables of household characteristics did not change the adjusted odds ratio by >5% and 
were therefore not included in the ﬁ nal models. Hospital, birth month, birth year, month by year of birth (interaction term), quarter of hospital admission, year of hospital 
admission, and quarter by year of hospital admission (interaction term) were included in the models a priori.
Table 3: Eﬀ ectiveness of one and two doses of rotavirus vaccine in preventing admission to hospital for acute rotavirus-diarrhoea in children aged from 
18 weeks to 23 months, stratiﬁ ed by age group
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uninfected and HIV-unexposed-uninfected children 
(table 4). The study was not powered to assess 
eﬀ ectiveness in HIV-infected children (45 cases).
The most common rotavirus strains (data for which are 
available for 538 patients) during the study period were 
G12P[8] (n=230), G2P[4] (n=76), G1P[8] (n=64), G9P[8] 
(n=42), G8P[4] (n=38), and G2P[6] (n=28). Other strains 
were detected infrequently (n=45) or were mixed strains 
(n=15). Strain-speciﬁ c adjusted vaccine eﬀ ectiveness for 
two doses of human rotavirus vaccine was 71% (95% CI 
55–82) against the dominant G12P[8] strain; 62% (45–74) 
against any homo typic or partly heterotypic strains (in 
which G protein or P protein were of the same type as the 
vaccine strain [369 cases]); and 52% (20–72) against any 
fully heterotypic strains (in which both G and P proteins 
were diﬀ erent from those of the vaccine strain [155 cases]).
We did additional viral testing for 464 (86%) of 
540 rotavirus-positive cases and one or more viruses were 
detected in 140 (30%) of these children. The two-dose 
adjusted vaccine eﬀ ectiveness with use of only rotavirus 
cases without an additional virus detected in the stool 
(54%, 95% CI 31–69) was similar to that using rotavirus 
cases with an additional virus detected (62%, 36–77).
In the subset of three hospitals with respiratory controls, 
the two-dose adjusted vaccine eﬀ ectiveness estimates were 
similar when either rotavirus-negative controls or respi-
ratory controls were used as the control group (tables 2–4).
Discussion
This case-control study is the ﬁ rst to assess the 
eﬀ ectiveness of rotavirus vaccination under routine 
conditions of a national immunisation programme in an 
African country, which included a range of socio demo-
graphic and HIV prevalence settings (panel). Two doses 
of human rotavirus vaccine provided protection against 
admission to hospital for acute rotavirus diarrhoea in 
children younger than 2 years of age using rotavirus-
negative controls, with similar eﬀ ective ness recorded 
with use of respiratory controls in a subset of hospitals. 
Vaccine eﬀ ectiveness seemed to be sustained through 
the second year of life and was similar in children both 
exposed and unexposed to HIV.
The rationale for implementation of a 6-week and 
14-week human rotavirus vaccine schedule was to induce 
immunity from an early age, which was why the ﬁ rst 
dose was given at 6 rather than 10 weeks, and the 14-week 
dose logistically helped concurrent implementation of 
pneumococcal conjugate vaccine and human rotavirus 
vaccine into the immunisation programme (since the 
pneumococcal conjugate vaccine is also administered at 
6 and 14 weeks).18 Our present study showed an overall 
adjusted vaccine eﬀ ectiveness (54%) in the ﬁ rst year of 
life that seems to be lower than the eﬃ  cacy of two doses 
at 10 and 14 weeks shown in the clinical trial (72%).8 
Diﬀ erences in study methods might have contributed to 
All hospitals Subset of hospitals†
Rotavirus-
negative cases
Rotavirus-
negative 
controls
Adjusted 
vaccine 
eﬀ ectiveness, % 
(95% CI)‡
Rotavirus- 
positive cases
Rotavirus-
negative 
controls
Adjusted 
vaccine 
eﬀ ectiveness, % 
(95% CI)‡
Respiratory 
controls
Adjusted 
vaccine 
eﬀ ectiveness, % 
(95% CI)‡
All HIV-uninfected children*
0 doses 
(reference)
110/454 (24%) 191/1174 (16%) ·· 77/318 (24%) 152/897 (17%) ·· 133/1000 (13%) ··
1 dose 106/454 (23%) 265/1174 (23%) 37% (10 to 56) 75/318 (24%) 201/897 (22%) 32% (–4 to 56) 215/1000 (22%) 52% (27 to 69)
2 doses 238/454 (52%) 718/1174 (61%) 57% (39 to 70) 166/318 (52%) 544/897 (61%) 53% (30 to 69) 652/1000 (65%) 60% (39 to 74)
HIV-exposed, HIV-uninfected children§
0 doses 
(reference)
30/131 (23%) 50/396 (13%) ·· 21/94 (22%) 40/295 (14%) ·· 28/280 (10%) ··
1 dose 26/131 (20%) 90/396 (23%) 61% (22 to 81) 21/94 (22%) 67/295 (23%) 54% (–1 to 79) 69/280 (25%) 73 (38 to 88)
2 doses 75/131 (57%) 256/396 (65%) 64% (34 to 80) 52/94 (55%) 188/295 (64%) 58% (16 to 79) 183/280 (65%) 67 (31 to 84)
HIV-unexposed, HIV-uninfected children§
0 doses 
(reference)
79/320 (25%) 132/741 (18%) ·· 55/222 (25%) 107/584 (18%) ·· 100/702 (14%) ··
1 dose 79/320 (25%) 166/741 (22%) 24% (–17 to 51) 54/222 (24%) 133/584 (23%) 25 (–25 to 54) 144/702 (21%) 45 (9 to 67)
2 doses 162/320 (51%) 443/741 (60%) 54% (31 to 69) 113/222 (51%) 344/584 (59%) 52 (23 to 70) 458/702 (65%) 60 (36 to 75)
A single logistic regression model was used, with introduction of an interaction term for HIV exposure status by vaccination status. A dose of human rotavirus vaccine was counted 
if it was administered ≥14 days before the date of admission to hospital. *The total number of HIV-uninfected children was 2628 (454 rotavirus-positive cases, 1174 rotavirus-
negative controls, and 1000 respiratory controls). Children who tested positive for HIV and those with unknown HIV status were excluded. †Hospitals with respiratory controls: 
Chris Hani Baragwanath Academic Hospital, Ngwelezane Hospital, and Red Cross War Memorial Children’s Hospital. ‡Unconditional logistic regression was used to calculate 
adjusted vaccine eﬀ ectiveness. Models that included sex, ethnic origin, history of breastfeeding, maternal education, daycare attendance, birthweight, and variables of household 
characteristics did not change the adjusted odds ratio by >5% and were therefore not included in the ﬁ nal models. Hospital, birth month, birth year, month by year of birth 
(interaction term), quarter of hospital admission, year of hospital admission, and quarter by year of hospital admission (interaction term) were included in the models a priori. §HIV 
exposure status in HIV-uninfected children was not available for three rotavirus-positive cases, 37 rotavirus-negative controls, and 18 respiratory controls.
Table 4: Eﬀ ectiveness of one and two doses of rotavirus vaccine in preventing admission to hospital for acute rotavirus-diarrhoea in children aged from 
18 weeks to 23 months, stratiﬁ ed by HIV exposure in HIV-uninfected children only*
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this outcome. Furthermore, infants enrolled in the 
eﬃ  cacy study were vaccinated before the onset of the 
rotavirus season, whereas in our study we included 
children vaccinated throughout the year, which might 
aﬀ ect the amount of protection especially if infants were 
vaccinated soon after the peak rotavirus season. Vaccine 
eﬃ  cacy might diﬀ er depending on the season of birth 
and time of vaccination, and was greater when given 
immediately before the rotavirus season in an early 
rotavirus vaccine trial.23
Nevertheless, our ﬁ ndings suggest that the vaccine 
provides sustained protection through the second year of 
life, which is important because the eﬃ  cacy trial, although 
not powered to assess protection against severe rotavirus 
diarrhoea in the second year of life, showed a lower point 
estimate across two consecutive rotavirus seasons than 
the ﬁ rst rotavirus season in the group who had been 
randomly assigned to receive the two-dose schedule but 
not in those allocated to the three-dose schedule.15 A recent 
post-licensure assessment of the eﬀ ect of human rotavirus 
vaccine in South Africa that used data from a hospital-
based rotavirus surveillance programme estimated that 
the reduction in rotavirus diarrhoea hospital admissions 
was 45–50% greater than the reduction in rotavirus-
negative admissions to hospital for infants—but not for 
children aged 12–23 months—since vaccine introduction.24 
This ﬁ nding corroborates our results in children younger 
than 12 months, but we showed continued protection in 
the second year of life. Our results are similar to those 
from a study in Bolivia, which showed similar eﬀ ectiveness 
of the Rotarix human rotavirus vaccine in preventing 
admission to hospital for rotavirus between the younger 
(64%) and older age groups (72%).25 
Human rotavirus vaccine has been shown to be safe and 
immunogenic in HIV-infected children,26 but insuﬃ  cient 
numbers of these children were enrolled in the present 
study to assess eﬀ ectiveness in this group. Improvement 
in access to antiretroviral treatment and success of 
programmes for the prevention of mother-to-child 
transmission of HIV have reduced HIV prevalence in 
children in South Africa—between 2008 and 2011, the 
proportion of infants who were HIV infected decreased 
from 9·6% to 2·8%.27 However, the antenatal HIV 
prevalence in women of childbearing age remains high at 
30% in South Africa.19 Furthermore, HIV-exposed-un-
infected children have emerged as a high-risk group for 
morbidity and mortality, including from diarrhoeal 
disease.28,29 We showed that the two-dose eﬀ ectiveness of 
the rotavirus vaccine was similar in HIV-exposed-
uninfected and HIV-unexposed-uninfected children. 
However, one-dose adjusted vaccine eﬀ ectiveness point 
estimates were higher in HIV-exposed-uninfected than in 
HIV-un exposed-uninfected children, and could suggest 
lower trans placental transmission of rotavirus-speciﬁ c 
anti bodies in HIV-exposed-uninfected children, leading to 
a more robust immune response in these infants. 
Although some evidence exists to support this theory in 
HIV-exposed-uninfected children receiving pneu mococcal 
conjugated vaccine,30 further studies are needed to test 
this hypothesis.
One dose of human rotavirus vaccine provided 
protection against admission to hospital for rotavirus 
diarrhoea, which is an encouraging ﬁ nding because 
children in low-income countries might not return for the 
second dose and therefore can be protected early in life by 
a single dose. Infants receiving only one dose tended to be 
older and less likely to receive their dose with oral polio 
vaccine than were those who received two doses.
Studies have shown that the human rotavirus vaccine 
protects against several rotavirus strains;31 however, 
potential waning of immunity might be a concern against 
illness caused by strains that share neither the G nor 
P type with the vaccine strain.32 We showed protection 
against homotypic, partly heterotypic, and fully hetero-
typic strains, but our analyses were not powered to assess 
strain-speciﬁ c protection, except for G12P[8], or the 
durability of this protection into the second year of life.
Lower eﬀ ectiveness estimates in low-income countries 
could result from misattribution of rotavirus as the 
pathogen responsible for the illness necessitating 
admission to hospital, especially if vaccination reduced 
the severity of illness but not the actual rate of infection. 
Previous assessments have not directly addressed this 
possibility; we showed similar results using cases for 
which additional testing for viruses did not yield other 
pathogens and cases that did yield additional pathogens, 
suggesting that this possible misclassiﬁ cation of illness 
as rotavirus disease did not substantially bias our results. 
However, we did not uniformly assess for bacterial 
pathogens in our study.
The limitations of our study include the fact that we 
excluded children in whom vaccination cards were 
Panel: Research in context
Systematic review
A recent review of the present status of rotavirus vaccines was done by Catherine Yen and 
colleagues in 2014.22 This review lists all published rotavirus vaccine impact and 
eﬀ ectiveness studies (up to April, 2014) undertaken in countries that have introduced 
rotavirus vaccination into their national immunisation programmes.
Interpretation
Studies of the eﬀ ects of the rotavirus vaccine, mainly done in Australia and countries in 
Europe and the Americas, have shown reductions in diarrhoea-associated mortality, 
diarrhoea-associated hospital admissions, and rotavirus-speciﬁ c hospital admissions in 
children younger than 5 years. Rotavirus vaccine eﬀ ectiveness studies have been 
undertaken in high-income and upper-middle-income countries, and in low-income 
countries outside Africa, and good protection against rotavirus-associated hospital 
admission has been shown. One assessment of vaccine impact has been done in South 
Africa and showed a reduction in diarrhoea-associated and rotavirus-speciﬁ c admissions to 
hospital after rotavirus vaccine introduction, but until the present study there have been 
no published rotavirus vaccine eﬀ ectiveness studies from an African country. We present 
the ﬁ rst rotavirus vaccine eﬀ ectiveness data from Africa, showing sustained protection 
against admission to hospital for acute rotavirus diarrhoea during the ﬁ rst 2 years of life.
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unavailable, apart from those reporting no vaccination 
since the birth dose. However, the baseline characteristics 
of these children were similar to those included in the 
analysis. Study staﬀ  were also unaware of the child’s 
case or control status when their vaccination history was 
recorded. HIV status in the mother was ascertained by 
history alone, not by HIV testing, and might have led to 
misclassiﬁ cation of exposure status in the children. The 
proportion of children reported as having been exposed 
to HIV (31%) was, however, consistent with antenatal 
HIV prevalence data from South Africa. We included 
rural and urban communities from four of the nine 
provinces to best estimate the eﬀ ectiveness in our 
population but province-speciﬁ c variations exist (eg, 
diﬀ ering rotavirus strains in circulation),4 which we have 
not accounted for and could aﬀ ect the generalisability of 
our results. Cases and controls were not matched for age 
so we included only children in whom vaccine status 
was unlikely to change. Use of a cutoﬀ  of 18 weeks of age 
gave children an additional 4 weeks to be vaccinated with 
the second dose. A main reason for the unmatched 
design was a practical one, because rotavirus testing was 
batched every 2 weeks so results were not available 
immediately. An unmatched test-negative design has 
been used in published literature when assessing 
inﬂ uenza vaccine eﬀ ectiveness and, more recently, 
rotavirus vaccine eﬀ ectiveness.33 We adjusted for birth 
month and year, and admission quarter and year in the 
analyses to address residual confounding by age and 
rotavirus season. Eﬀ ectiveness estimates were similar 
when we restricted our analyses to children aged from 
24 weeks to 23 months (data not shown).
In summary, two doses of human rotavirus vaccine 
provided sustained protection against admission to 
hospital for acute rotavirus diarrhoea during the ﬁ rst and 
second years of life under conditions of routine use, in a 
setting with a high prevalence of maternal HIV infection. 
These ﬁ ndings are encouraging and establish the public 
health value of rotavirus vaccine in an African setting, 
especially as rotavirus vaccines are being introduced into 
an increasing number of African countries.
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Study population and study hospitals - Supplementary Information 
 
The study was conducted at seven hospitals in order to include a diversity of sites in South 
Africa, encompassing both urban and rural sites as well as differing HIV infection 
prevalence. The main criteria for selection included number of diarrhoeal admissions and 
ability and willingness of the site to accommodate the study. These included 5 sites which 
were currently involved in the rotavirus surveillance program in South Africa: Chris Hani 
Baragwanath Academic Hospital (Gauteng), Edendale Hospital (Kwazulu-Natal), 
Mapulaneng Hospital and Matikwana Hospital (Mpumalanga), and Dr George Mhukari 
Hospital (North West Province). Two additional sites Ngwelezane Hospital (Kwazulu-Natal) 
and the Red Cross War Memorial Children’s Hospital (Western Cape) were then included.  
The two Mpumalanga hospitals, Matikwana and Mapulaneng are small hospitals and were 
considered one site and referred to as the Agincourt site. The sites Chris Hani Baragwanath 
Academic Hospital, Ngwelezane and Red Cross War Memorial Children’s Hospital were 
recruiting patients for a concurrent study investigating the effectiveness of the PCV-7 
vaccine. At these sites patients already enrolled as part of the PCV-7 effectiveness study were 
included for the second group of controls in this rotavirus effectiveness study if eligible.  
 
Chris Hani Baragwanath Academic Hospital 
CHBH is located in an urban setting with a defined catchment population. It is the only 
public hospital which serves the population of Soweto and it is estimated that 90% of all 
hospitalisations in children from the area occur in this hospital. The population of Soweto 
includes an estimated 1.5 million people, including 120 000 children under five years of age.  
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Red Cross Children’s Hospital 
Red Cross hospital provides secondary-tertiary level care to the majority of children utilizing 
the public health-care sector in the Cape Town Metropolis. The birth cohort for the Cape 
Town Metropolis is approximately 22 000 per annum. 
 
 Ngwelezana Hospital 
This provincial hospital is the only regional referral centre for the eighteen district rural 
hospitals of the north eastern region of KwaZulu-Natal (KZN).The hospital has 150 
paediatric beds. The catchment population as a regional hospital is estimated at 2.3 million 
(including 295 000 under 5 years of age).  
 
Agincourt site 
The two hospitals Mapulaneng and Matikwana service the district of Bushbuckridge, 
Ehlanzeni and Mbombela with a combined population of more than 1 million. The Agincourt 
demographic and surveillance site (DSS) is situated between the hospitals and DSS activities 
have been ongoing in this area from 1994. The data collected by the DSS provides some 
population estimates. The population in the DSS is 58401, and reports under five mortality 
rates of 17 per 1000 live births. Total births in 2008 were 1389.   
 
Edendale hospital 
This regional and district hospital with 900 beds is situated near Pietermaritzburg, and serves 
a population of approximately 1.6 million, including urban and periurban populations.  
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Dr George Mukhari Academic Hospital 
DGMH is a tertiary care facility of 1600 beds that renders a service to about 6 million people 
and serves as a referral hospital to 43 communities and 4 provinces. The hospital serves 
catchment areas including Ga-Rankuwa, Soshanguve and Mabopane districts in the Gauteng 
province and parts of the Madibeng district in the North-West Province. In the catchment 
areas, there were 84 484 children under 5 years of age from the two provinces, divided as 
follows: 6 218 in Ga-Rankuwa, 19 318 in Mabopane, 28 882 in Soshanguve, and 30 066 in 
Madibeng, with approximately equal numbers of children in each 1-year age category. The 
areas include urban, rural and informal communities with moderate to low socio-economic 
status.  
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Supplementary information: genotyping methods 
For the RNA viruses, cDNA was synthesised using random primers and the Transcriptor First 
Strand cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany), according to 
the manufacturer’s instructions. The Lightcycler Taqman Master Kit (Roche Diagnostics 
GmbH) was used according to the manufacturer’s instructions and primers and probes from 
the following: norovirus genogroup I, norovirus, sapovirus, astrovirus and adenovirus.
1–7
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Supplementary Figure 1: Enrolment of children ≥18 weeks and <24 months of age, and age-eligible to have received rotavirus vaccine (born i.e. after 14 
June 2009) from the three hospitals where respiratory controls were enrolled (Chris Hani Baragwanath Academic Hospital, Ngwelezane Hospital, Red Cross 
War Memorial Children's Hospital). 
a
 Acute diarrhoea: ≥3 loose stools in a 24 hour period, diarrhoea duration ≤7 days at admission. 
Fulfilling case definition 
a
 
n=1550 
Rotavirus-positive cases 
 n=379 
Rotavirus-negative controls 
 n=1056 
Rotavirus-positive cases  
n=370 
Rotavirus-negative controls 
 n=1024 
No stool available/ 
insufficient sample 
n=115 
No vaccination 
history available
 d
 
n=9 
No vaccination 
history available
 d
 
n=32 
Respiratory controls 
fulfilling case definition 
b
 
 n=1100 
Previously a control 
c
 n=3 
No vaccination 
history available
 d
 n=28 
Respiratory controls 
 n=1069 
6 
 
b
 Enrolled into a concurrent study investigating the effectiveness of a pneumococcal conjugate vaccine. Age-eligible children hospitalised with physician-
diagnosed lower respiratory tract infection were assessed by C-reactive protein (CRP) and chest X-ray. Children who were presumed not to have bacterial 
pneumonia i.e. with CRP <40 mg/l and without radiological-confirmed pneumonia, were eligible for inclusion into the respiratory-control group. 
c
 A child enrolled more than once into the study for acute diarrhoea with any stool testing positive for rotavirus was defined as a case and the other 
hospitalisation excluded from the analysis. If all stool results were rotavirus-negative, the first diarrhoeal hospitalisation contributed to the control data. A 
rotavirus-negative control re-enrolled as a respiratory control could be included in the analysis, and vice versa, but a control re-enrolled into the same control 
group was excluded. 
d 
Vaccination history was ascertained by review of the vaccination card, a photocopy of which was obtained when possible. If the vaccination card was 
unavailable but the parent indicated that the child had not received any vaccines other than those given at birth, the child was included and considered not to 
have received any human rotavirus vaccine doses. Rotavirus-positive cases – 369/370 had a vaccination card available for review; rotavirus-negative controls 
– 1021/1024 had a vaccination card available for review; all respiratory controls had a vaccination card available for review. 
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Figure 2: Age at vaccination in weeks (up until 52 weeks) for the first and second HRV doses in children aged 18 weeks–23 months. 
Note: Total number of children available for the analysis (n=3043) included 540 rotavirus-positive cases, 1434 rotavirus-negative controls and 
1069 respiratory controls. Three children received their first HRV dose at 53, 78 and 102 weeks of age respectively, and were not included in the 
graph. HRV=human rotavirus vaccine. 
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Abstract  
Background: The public health impact of rotavirus vaccination in African settings with a high 
HIV infection prevalence is yet to be established. We evaluated trends in all-cause diarrhoeal 
hospitalisations in Soweto, Johannesburg before and after the introduction of rotavirus vaccine 
into South Africa’s national immunisation programme in August 2009. 
Methods: Hospitalisations in children <5 years of age with a diagnosis of diarrhoea, defined by 
one of the following ICD-10 codes A00-A05, A06.0-A06.3, A06.9, A07.0-A07.2, A07.9, A08-
A09, were identified at the Chris Hani Baragwanath Academic Hospital from 1 January 2006−31 
December 2014. The median annual pre-vaccine (2006−2008) hospitalisation incidence was 
compared to the vaccine-era (2010−2014), and stratified by age group and HIV infection status.  
Results: Incidence reductions (per 1000 population) were greatest in children aged <12 months: 
54.4 in the pre-vaccine era compared to 30.0, 23.6, 20.0, 18.8 and 18.9 in the post-vaccine years 
2010 to 2014 respectively; a 44.9% to 65.4% reduction. Lower incidence reductions (39.8% to 
49.4%) were observed among children aged 12−24 months from the second year post-vaccine 
introduction onward. Reductions were observed in both HIV-infected and HIV-uninfected 
children. There was a change in the seasonal pattern of diarrhoeal hospitalisations post-vaccine 
introduction, with flattening of the autumn-winter peaks seen in the pre-vaccine years.  
Discussion: An accelerated and sustained decline in all-cause diarrhoeal hospitalisations, 
temporally associated with rotavirus vaccine introduction, was observed in children <2 years of 
age. However, the impact of other interventions such as improved sanitation and changes in HIV 
management cannot be discounted. 
 
Key words: rotavirus vaccine, diarrhoea, HIV, children 
 
 
4 
 
Introduction 
Rotavirus is the leading cause of diarrhoea among children <5 years of age, accounting for 
approximately 27% of all severe diarrhoea episodes worldwide in 2011. Rotavirus vaccines have 
the potential to reduce diarrhoeal morbidity and mortality, especially in Africa where almost half 
of the global rotavirus deaths occur.1,2 Following demonstration of high vaccine efficacy of 
Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq® (Merck Vaccines, 
Whitehouse Station, NJ) in pre-licensure clinical trials in Latin America, Europe and the United 
States, introduction of rotavirus vaccines into national immunisation programmes resulted in a 
substantial decrease in diarrhoea-related hospitalisations and deaths in these countries.3-9 Lower 
vaccine efficacy was, however, observed in clinical trials in low-middle income countries in 
Africa, and there are limited data evaluating the impact of rotavirus vaccines on the burden of 
diarrhoeal hospitalisations in African settings.10,11  
The effectiveness of rotavirus vaccines in Malawi and South Africa has been evaluated by case-
control studies but these studies were not able to fully address the public health impact of this 
intervention.12,13 Sentinel surveillance in children <5 years in South Africa showed that 
diarrhoeal hospitalisations decreased by about a third in 2010 and 2011 compared to 2009, the 
year of vaccine introduction.14 A study from Ghana reported a 52-59% reduction in all-cause 
diarrhoea hospitalisations in children <5 years in the year following rotavirus vaccine 
introduction compared to the immediate pre-vaccination year.15 These studies were, however, 
limited to the first two years post-introduction and did not specifically assess reductions in 
diarrhoea hospitalisations in HIV-infected children, who are at fivefold greater risk of diarrheal 
hospitalisation compared to HIV-uninfected children.16 
We investigated the impact of routine infant rotavirus vaccination on all-cause diarrhoeal 
hospitalisations by comparing the incidence before (2006−2008) and after (2010−2014) vaccine 
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introduction among HIV-infected and HIV-uninfected children <5 years of age in Soweto, South 
Africa.  
Methods 
Study setting 
The Chris Hani Baragwanath Academic Hospital (CHBAH) was the only public hospital serving 
the urban community of Soweto, Johannesburg, South Africa, among whom <10% had private 
medical insurance. As a result the majority of children who required hospitalisation were 
admitted to this hospital, where care was provided free of charge to children <5 years. The 
prevalence of HIV infection among mothers attending antenatal clinics in the Gauteng province 
remained steady at 30% since 2006, however, due to improvement in the prevention of  mother-
to-child transmission of HIV, the HIV prevalence among children <5 years decreased from 5.0% 
in 2006 to 3.8% by 2013.17,18 Access to antiretroviral therapy (ART) improved since its 
introduction into the public sector in 2004, with the estimated coverage in HIV-infected children 
requiring treatment being 54% in 2009 and 63% in 2012.19,20 Rotarix® was introduced into the 
national immunisation programme on 1 August 2009, and is provided at no cost at primary 
healthcare facilities. Two doses are recommended at 6 and 14 weeks of age and children 
received trivalent oral polio vaccine (OPV-Merieux; Sanofi Pasteur, Lyon, France) concurrent 
with rotavirus vaccine at the 6-week immunisation visit. District Health Information Systems 
estimates of coverage rates for the second dose of rotavirus vaccine increased from 67% in 2010 
to 96% in 2011.21 
Study participants  
Children presenting with diarrhoea either came directly from the community or were referred 
from community clinics. Decisions regarding hospitalisation, investigations and treatment were 
at the discretion of the attending physicians. Patient discharge diagnoses were obtained from a 
discharge summary completed by the attending physician on discharge/death of the child or the 
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ward admission registry.  A study physician coded the discharge diagnoses using the 10th 
revision of the International Classification of Diseases (ICD-10). HIV infection status was 
obtained from HIV test results recorded in the discharge summary, ward registry or from the 
hospital laboratory. Children ≥9 months were considered to be HIV-infected if either HIV 
ELISA or HIV PCR test was positive; and HIV-uninfected if HIV ELISA or HIV PCR test was 
negative. Children <9 months were considered to be HIV-infected if HIV PCR test was positive 
and HIV-uninfected if HIV ELISA or HIV PCR test was negative. If a child was hospitalised 
more than once, results of any HIV test performed during these hospitalisations were used to 
assign HIV status to that child. 
Data analysis 
All-cause diarrhoeal hospitalisations were defined by the following ICD-10 diagnosis codes: 
A00-A05, A06.0-A06.3, A06.9, A07.0-A07.2, A07.9, A08-A09. Children <5 years of age 
hospitalised with a primary or secondary diagnosis of diarrhoea from 1 January 2006−31 
December 2014 were included in this study. Any hospitalisations with a co-diagnosis of 
nosocomial infection (ICD-10 code Y95) or occurring within 14 days of the discharge date of a 
previous admission in the same child were excluded. All data were anonymised for personal 
identifiers of patients. 
Monthly counts of all-cause diarrhoeal hospitalisations were plotted against time for age groups 
0−11, 12−23 and 24−59 months for the period 2006−2014. A general strike of hospital staff 
occurred during a three-week period in June 2007, resulting in only one paediatric ward 
remaining functional during this time. We adjusted for the resulting decrease in hospitalisations 
by calculating the ratio of hospitalisations, by age group, in June compared to May in 2006 and 
2008, and multiplying the number of hospitalisations in May 2007 by this factor. Annual 
incidence of all-cause diarrhoeal hospitalisation (per 1000 population) was estimated using the 
annual number of children hospitalised for diarrhoea in the numerator and the mid-year 
population estimate in the denominator. Population denominators for Soweto (sub-district D and 
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G, Johannesburg) were obtained from Statistics South Africa and HIV prevalence was estimated 
from projections of the Actuarial Society of South Africa’s (ASSA) 2008 AIDS and 
Demographical model.17 The median annual incidence during the pre-vaccine years 2006-2008 
was compared to the incidence in the vaccine-era (2010-2014), and stratified by age group and 
HIV status. Children who were not tested for HIV infection were assumed to be HIV-uninfected, 
on the assumption that physicians were less inclined to test for HIV in the absence of clinical 
stigmata. We assessed the incidence of hospitalisation for bronchiolitis (ICD-10 codes J21.0, 
J21.1, J21.8, J21.9), for which there were no preventative intervention strategies implemented 
over the same period, to determine whether there were any changes in hospital admission 
practices. Confidence intervals for incidence estimates were calculated using the Poisson 
distribution.  
Ethics statement 
Approval for the study was obtained from Human Research Ethics Committee (HREC approval 
number: M110528) of the University of the Witwatersrand. There was a waiver of consent for 
this observational study. 
Results 
Trends in diarrhoeal hospitalisations 
A total of 16 800 diarrhoeal hospitalisations occurred in children <5 years from 1 January 
2006−31 December 2014. There was a downward trend in the number of diarrhoeal 
hospitalisations after rotavirus vaccine introduction, especially in children aged 0−11 months 
(Figure 1). Before rotavirus vaccine introduction, 68.6% of diarrhoeal hospitalisations occurred 
in children 0−11 months, 20.9% in those 12−23 months and 10.5% in those 24−59 months of 
age, compared to the vaccine-era where 58.8%, 24.3% and 16.9% of hospitalisations occurred in 
the respective age groups (p<0.001). During the pre-vaccine period there were distinct annual 
peaks in the number of diarrhoeal hospitalisations during the autumn and early winter months of 
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March−May in children <24 months, albeit this varied in magnitude and timing from year to 
year. In contrast, the peaks in diarrhoeal hospitalisations during the vaccine-era were less 
pronounced and had a bimodal pattern.  
Annual diarrhoeal hospitalisation rates 
The estimated annual incidence (per 1000 population) of diarrhoeal hospitalisations among 
children <5 years decreased from 14.7 (median 2006−2008) to 9.7 in 2010; a 33.8% reduction 
(Table 1). Significant incidence reductions of 47.6% to 56.6% (7.0 to 8.3 per 1000) were 
maintained through the following four years (2011−2014). Reductions were most pronounced in 
children 0−11 months and were evident from the first year post-vaccine introduction (incidence 
reduction 24.4 per 1000; 44.9% in 2010 compared to the pre-vaccine era; Table 1). Further 
reduction was seen in 2011, the second post-vaccine year (30.8 per 1000, 55.6%), compared to 
pre-vaccine years and reductions of 63.2% to 65.2% (34.4 to 35.5 per 1000) were maintained 
during 2012−2014 in this age group. Among children 12−23 months, there was a marginal 
reduction in hospitalisation incidence in the first year post-vaccine introduction, and reductions 
of 39.8% to 49.4% were observed during the subsequent four years. Hospitalisation incidence 
among children 24−59 months remained relatively constant with minimal reductions in the 
vaccine-era compared to pre-vaccine years (Table1). In contrast to the vaccine-era declines in 
diarrhoeal hospitalisations, the incidence of bronchiolitis hospitalisations remained relatively 
constant throughout the observation period (Supplementary Figure). 
HIV-infected and HIV-uninfected children 
Of the total diarrhoeal hospitalisations, 1743 (10.4%) occurred in children diagnosed with HIV-
infection. The prevalence of HIV infection among children <5 years hospitalised for diarrhoea 
decreased from 14.1% in 2006 to 5.3% in 2014. Overall only 50% of children were tested for 
HIV infection, which varied by age group (older children were less likely to be tested) and year 
of hospitalisation (increased testing in the latter years; data not shown).  
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Among children assumed to be HIV-uninfected, significant declines in diarrhoeal hospitalisation 
incidence in the vaccine-era compared to pre-vaccine years, ranging from 23.2 to 32.8 per 1000 
(45.8% to 64.9%), were observed in those 0−11 months (Figure 2; Supplementary Table 1). In 
children 12−23 months, reductions of 36.5% to 49.5% were observed from the second year post-
vaccine introduction onward. There were minimal or no incidence reductions in children 24−59 
months.  
The hospitalisation incidence among HIV-infected children 0−11 months decreased by 102.0 per 
1000 (77%) in 2014 compared to the pre-vaccine years, with reductions ranging from 21.8% to 
70.8% during 2010−2013 (Figure 3; Supplementary Table 2). In children 12-23 months, 
reductions in diarrhoeal hospitalisations in the vaccine-era ranged from 45.0% to 64.8% (16.9 to 
24.4 per 1000). There were significant reductions (41.6% to 56.7%) in incidence in HIV-infected 
children 24-59 months in most post-vaccine years.  
Discussion 
The introduction of an oral live-attenuated rotavirus vaccine into the South African national 
immunisation programme was temporally associated  with a 34% to 57% decrease in the overall 
incidence of all-cause diarrhoeal hospitalisations in children <5 years in the urban setting of 
Soweto, Johannesburg. Reductions were greatest among children <12 months and maintained 
over a 5-year period post-vaccine introduction. A decrease of 45% in incidence was observed in 
the first year post-vaccine introduction in this age group, with further reductions of 57% to 65% 
maintained through the subsequent four years. Among children 12−24 months, reductions of 
40% to 49% were observed from the second year post-vaccine introduction and were also 
maintained over time. These trends were observed among both HIV-infected and HIV-
uninfected children. The incidence of all-cause diarrhoeal hospitalisations in the post-vaccine 
years remained relatively unchanged or changed minimally among children >24 months.  
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Rotavirus testing was not conducted, either routinely or as part of a surveillance program until 
diarrhoeal surveillance was established at CHBAH in May 2009. We could, therefore, not access 
the impact of rotavirus vaccine introduction on rotavirus-specific diarrhoeal hospitalisations and 
used all-cause diarrhoeal hospitalisations as a proxy. Our findings do, however, support the 
hypothesis that the observed decline in all-cause diarrhoeal hospitalisations can be attributed 
partly to the introduction of rotavirus vaccination into the routine immunisation program. The 
reductions in incidence that we observed occurred specifically in the age groups that received the 
vaccine and were consistent with increasing vaccine coverage. Children <12 months would have 
been eligible to receive rotavirus vaccine from August 2009 and a 45% reduction was observed 
in the first post-vaccination year (2010). As coverage increased to >90% at the end of 2010, 
consistent reductions of ~65% were observed from 2011 to 2014. Some of the children aged 12-
23 months and hospitalised in the latter half of 2010 may have received rotavirus vaccine, and 
there is a small incidence reduction observed in the first post-vaccination year with greater 
reductions observed from the second post-vaccination year in this age group. Previous South 
African studies showed that rotavirus disease occurred early in life, with 90-95% of children 
hospitalised for severe rotavirus diarrhoea being <18 months of age, hence we would expect that 
the major public health impact of vaccination would be in children <24 months.22,23 We did not 
see any clear evidence of indirect protection i.e. protection in older unvaccinated children, as has 
been observed in some high-income settings.24,25 In our setting very little rotavirus-associated 
hospitalisation occurred in children >2 years of age prior to vaccine introduction, so any indirect 
protection in this age group would likely be minimal. Encouragingly, we did not see a shift 
toward increased incidence of diarrhoeal hospitalisations in these older children either. 
There was a change in the epidemiology of diarrhoeal disease after rotavirus vaccine 
introduction. The pre-vaccine years were characterised by peaks in diarrhoeal hospitalisations 
among children <24 months during the autumn-winter months of March to May. This seasonal 
pattern is consistent with what was known about rotavirus epidemiology in South Africa prior to 
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vaccine introduction. Although rotavirus disease occurred year round, increases in rotavirus 
shedding had been observed during the cool, drier months resulting in autumn-winter peaks in 
rotavirus-associated hospitalisations.23 We observed a diminished peak in all-cause diarrhoeal 
hospitalisations during 2010 and these peaks were less pronounced during 2011−2014, where a 
bimodal pattern was observed.  
The Phase III clinical trial, which included both HIV-infected and HIV-uninfected children, 
demonstrated efficacy of the rotavirus vaccine against all-cause severe gastroenteritis of 44% 
(95% CI 19-61) during the first year of life, whereas our trend analysis showed reductions of 57-
65% in children <12 months.10 Although the confidence intervals do overlap, the point estimates 
we observed were higher. A decrease in transmission due to an overall decrease in circulation of 
rotavirus in the population could not be accounted for in the efficacy study design, and may 
account for the greater reductions which we observed in children <12 months. Our observed 
reductions are also greater than estimates of the reductions in all-cause diarrhoeal 
hospitalisations in children <12 months obtained from sentinel surveillance conducted in South 
Africa: 38% in the first and 43% in the second year post vaccine introduction.14 However, these 
data were based on comparison with pre-vaccine estimates from 2009, the year of vaccine 
introduction, with no data available prior to vaccine introduction and analyses were also limited 
to the months of May-December.  
The oral rotavirus vaccine has been shown to be safe and immunogenic in HIV-infected children, 
but vaccine efficacy against diarrhoea has never been specifically assessed in this sub-group.26 
The rotavirus vaccine effectiveness study conducted in South Africa observed similar 
effectiveness in HIV-exposed uninfected and HIV-unexposed children but was not able to assess 
effectiveness specifically among HIV-infected children.12 To our knowledge, this is the first 
study to show the impact of rotavirus vaccine introduction on diarrhoeal hospitalisations in HIV-
infected children. The reductions we observed may have been confounded by interventions other 
than rotavirus vaccine introduction, most notably the expanded use of ART. During the study 
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period there was increased uptake of ART among HIV-infected children as well as several 
changes in the South African guidelines for ART use. In 2010 and 2013 the HIV management 
guidelines were revised to include initiation of ART in all children <12 months and <5 years of 
age, respectively, irrespective of immunological status.27,28 The monitoring of ART access and 
usage in South Africa is challenging, with changes in reporting practices, lack of data on age of 
patients, changes in treatment guidelines leading to changes in the denominator for estimation of 
treatment coverage and debate over the best measures to use to access coverage. It is thus 
difficult to tease out the specific impact of ART versus rotavirus vaccine among these children, 
and it is likely that both interventions contributed to the reduced diarrhoeal hospitalisations 
observed in HIV-infected children.  
An ecological study such as this has inherent limitations, including the ability to attribute 
causality. We used all-cause diarrhoeal hospitalisations as a proxy for rotavirus-associated 
hospitalisations but without pathogen-specific testing it is difficult to definitively conclude on a 
causal relationship between rotavirus vaccine introduction and reductions in diarrhoeal 
hospitalisations. We cannot exclude other possible reasons for the decline in diarrhoeal 
hospitalisations such as changes in the socioeconomic factors in the population or variability in 
the natural occurrence of rotavirus or other enteric pathogens, most notably norovirus and 
bacteria. Furthermore, vaccine coverage data were not available specifically for the Soweto 
population, only on a national level. Comparing census data from 2001 and 2011 respectively, 
there were improvements in the proportion of households with access to tapped water (84.5%  to 
91.6%) and flush toilets (86.5% to. 90.5%) as well as a decrease in the average household size 
(3.1 to 2.9) in the Johannesburg region, although no sub-district level or year-on-year data were 
available.29 One would assume that changes in sanitation would improve consistently over the 
years leading to a steadier decline in annual diarrhoeal hospitalisations rather than the more 
accelerated decline that we observed in the vaccine-era.  
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Our incidence calculations relied on population estimates that are based on census data (2001 
and 2011) with extrapolation to other years and this may have led to under- or over-estimation of 
the incidence. HIV prevalence was determined using the ASSA model with extrapolation of 
provincial estimates to the Soweto population, which may also have influenced our incidence 
calculations. Our assumption that children without a documented HIV status were HIV-
uninfected may have underestimated the disease burden among HIV-infected children. We 
believe, however, that this assumption likely approximates the true prevalence of HIV among 
diarrhoeal hospitalisations in that clinicians generally only tested children they suspected of 
being HIV-infected. An HIV-infected child would most likely have had more than one 
hospitalisation, prompting HIV testing and if a child tested positive on a subsequent admission, 
we assumed that the child would have been positive on all admissions. Lastly, our study was 
restricted to one urban community in South Africa and may not be generalizable to other African 
settings.  
While the impact of other interventions such as improvement in socio-economic conditions and 
changes in HIV management cannot be discounted, the accelerated decline in all-cause 
diarrhoeal hospitalisations after rotavirus vaccine introduction and the observed changes in 
diarrhoeal epidemiology are suggestive of a significant public health impact of rotavirus vaccine 
introduction in an African setting with a high prevalence of HIV infection.  
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Figure legends 
 
Figure 1: Monthly count of all-cause diarrhoeal hospitalisations in children <5 years of age at 
Chris Hani Baragwanath Academic Hospital, Soweto, South Africa: 2006−2014.  
Note: vertical line represents introduction of rotavirus vaccine into the national immunisation 
program in August 2009. 
 
Figure 2: Annual incidence (per 1000 population, 95% confidence interval) of diarrhoeal 
hospitalisations among HIV-uninfected children <5 years of age in Soweto, 2006-2014. 
Values are incidence difference = incidence in vaccine-era years 2010, 2011, 2012, 2013 and 
2014 respectively minus median incidence in the pre-vaccine years 2006-2008 (percent change). 
A negative value indicates a reduction in incidence; a positive value indicates an increase in 
incidence. 
* p<0.05 
Note: 95% confidence intervals and p-values are provided in Supplementary Table 1. 
 
Figure 3: Annual incidence (per 1000 population, 95% confidence interval) of diarrhoeal 
hospitalisations among HIV-infected children <5 years of age in Soweto, 2006-2014. 
Values are incidence difference = incidence in vaccine-era years 2010, 2011, 2012, 2013 and 
2014 respectively minus median incidence in the pre-vaccine years 2006-2008 (percent change). 
A negative value indicates a reduction in incidence; a positive value indicates an increase in 
incidence. 
* p<0.05 
Note: 95% confidence intervals and p-values are provided in Supplementary Table 2. 
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Table 1: Incidence of all-cause diarrhoeal hospitalisations (per 1000 population) pre-vaccine introduction 
(2006−2008) compared to vaccine-era (2010−2014) among children <5 years of age in Soweto, South 
Africa 
Year 
Hospitalisation 
incidence 
(per 1000 population) 
Incidence 
differencea 
(95% CIb) 
Percent change 
in incidencec  
(95% CIb) 
P value 
0−59 months     
2006−2008d 14.7 (14.1, 15.3)    
2010 9.7 (9.3, 10.2) -5.0 (-5.7, -4.2) -33.8 (-37.8, -29.7) <0.001 
2011 7.7 (7.3, 8.1) -7.0 (-7.7, -6.3) -47.6 (-51.0, -44.1) <0.001 
2012 6.7 (6.3, 7.1) -8.0 (-8.7, -7.3) -54.5 (-57.6, -51.3) <0.001 
2013 6.4 (6.0, 6.8) -8.3 (-9.0, -7.6) -56.6 (-59.5, -53.4) <0.001 
2014 6.9 (6.6, 7.3) -7.8 (-8.5-7.1) -52.9 (-56.0, -49.6) <0.001 
0−11 months     
2006−2008d 54.4 (51.9, 57.0)    
2010 30.0 (28.2, 31.9) -24.4 (-27.6, -21.3) -44.9 (-49.0, -40.4,) <0.001 
2011 23.6 (22.1, 25.3) -30.8 (-33.8, -27.8) -56.6 (-60.0, -52.8) <0.001 
2012 20.0 (18.6, 21.5) -34.4 (-37.3, -31.5) -63.2 (-66.3, -59.8) <0.001 
2013 18.8 (17.4, 20.3) -35.6 (-38.5, -32.7) -65.4 (-68.4, -62.2) <0.001 
2014 18.9 (17.6, 20.4) -35.5 (-38.4, -32.6) -65.2 (-68.2, -62.0) <0.001 
12−23 months     
2006-2008d 14.9 (13.6, 16.2)    
2010 13.0 (11.8, 14.2) -1.9 (-3.6, -0.1) -12.7 (-23.2, -0.8) 0.035 
2011 8.7 (7.7., 9.7) -6.2 (-7.8, -4.6) -41.6 (-49.4, -32.6) <0.001 
2012 7.6 (6.7, 8.5) -7.3 (-8.9, -5.7) -49.0 (-56.2, -40.9) <0.001 
2013 7.5 (6.7, 8.5) -7.3 (-8.9, -5.8) -49.4 (-56.4, -41.2) <0.001 
2014 8.9 (8.0, 10.0) -5.9 (-7.5, -4.3) -39.8 (-47.7, -30.7) <0.001 
24−59 months     
2006-2008d 2.5 (2.2, 2.8)    
2010 2.3 (2.1, 2.7) -0.2 (-0.6, 0.3) -6.2 (-21.2, 11.6) 0.461 
2011 2.2 (1.9, 2.5) -0.3 (-0.7, 0.1) -13.0 (-27.1, 3.9) 0.116 
2012 2.0 (1.7, 2.2) -0.5 (-0.9, -0.1) -21.7 (-34.9, -6.1) 0.007 
2013 1.8 (1.6, 2.1) -0.7 (-1.1, -0.3) -26.5 (-39.0, -11.5) <0.001 
2014 2.2 (1.9, 2.5) -0.3 (-0.7, 0.1) -12.9 (-27.1, 4.0) 0.118 
a Incidence in vaccine-era years 2010, 2011, 2012, 2013 and 2014 respectively compared to median 
incidence in the pre-vaccine years 2006-2008. A negative value indicates a reduction in incidence; a 
positive value indicates an increase in incidence 
b Confidence interval 
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c A negative percent change indicates a reduction in incidence; a positive percent change indicates an 
increase in incidence 
d Median hospitalisation incidence 2006-2008  
 
 Figure 1: Monthly count of all-cause diarrhoeal hospitalisations in children <5 years of age at Chris Hani Baragwanath Academic Hospital, Soweto, 
South Africa: 2006−2014.  
Note: vertical line represents introduction of rotavirus vaccine into the national immunisation program in August 2009. 
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-28.9 (-21.8%)* 
Pre-rotavirus vaccine-era 
Rotavirus vaccine-era  
1 
 
Supplementary Table 1: Incidence of all-cause diarrhoeal hospitalisations (per 1000 population) pre-
vaccine introduction (2006−2008) compared to vaccine-era (2010−2014) among HIV-uninfected children 
<5 years of age in Soweto, South Africa 
Year 
Hospitalisation 
incidence  
(per 1000 population) 
Incidence 
differencea  
(95% CIb) 
Percent change in 
incidencec 
(95% CIb) 
P value 
0−11 months     
2006−2008d 50.6 (48.1, 53.2)    
2010 27.5 (25.7, 29.3) -23.2 (-26.3, -20.1) -45.8 (-50.1, -41.1) <0.001 
2011 22.5 (20.9, 24.1) -28.1 (-31.1, -25.2) -55.6 (-59.3, -51.6) <0.001 
2012 19.4 (18.0, 20.9) -31.2 (-34.1, -28.3) -61.6 (-65.0, -58.0) <0.001 
2013 17.8 (16.4, 19.2) -32.8 (-35.7, -30.0) -64.9 (-68.0, -61.4) <0.001 
2014 18.6 (17.2, 20.0) -32.1 (-34.9, -29.2) -63.3 (-66.6, -59.8) <0.001 
12−23 months     
2006-2008d 13.8 (12.6, 15.2)    
2010 12.0 (10.9, 13.2) -1.8 (-3.5, -0.1) -13.1 (-24.2, -0.4) 0.041 
2011 8.2 (7.3, 9.2) -5.6 (-7.2, -4.0) -40.8 (-49.1, -31.1) <0.001 
2012 7.3 (6.4, 8.2) -6.5 (-8.1, -5.0) -47.3 (-55.0, -38.4)  <0.001 
2013 7.0 (6.1, 7.9) -6.8 (-8.4, -5.3) -49.5 (-57.0, -40.9) <0.001 
2014 8.8 (7.8, 9.8) -5.0 (-6.7, -3.4) -36.5 (-45.3, -26.5) <0.001 
24−59 months     
2006-2008d 2.1 (1.8, 2.4)    
2010 2.3 (2.0, 2.6) 0.2 (-0.2, 0.6) 6.9 (-12.2, 22.9) 0.443 
2011 2.1 (1.8, 2.4) -0.0 (-0.4, 0.4) -1.1 (-18.3, 19.8) 0.910 
2012 1.9 (1.6, 2.1) -0.2 (-0.6, 0.1) -11.8 (-27.6, 7.4) 0.201 
2013 1.7 (1.5, 2.0) -0.4 (-0.8, -0.0) -17.9 (-32.9, 0.3) 0.048 
2014 2.1 (1.9, 2.4) 0.0 (-0.4, 0.4) 1.2 (-19.5, 18.3) 0.902 
 
a Incidence in vaccine-era years 2010, 2011, 2012, 2013 and 2014 respectively compared to median 
incidence in the pre-vaccine years 2006-2008. A negative value indicates a reduction in incidence; a 
positive value indicates an increase in incidence 
b Confidence interval 
c A negative percent change indicates a reduction in incidence; a positive percent change indicates an 
increase in incidence 
d Median hospitalisation incidence 2006-2008  
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Supplementary Table 2: Incidence of all-cause diarrhoeal hospitalisations (per 1000 population) pre-
vaccine introduction (2006−2008) compared to vaccine-era (2010−2014) among known HIV-infected 
children <5 years of age in Soweto, South Africa 
Year 
Hopsitalisation 
incidence  
(per 1000 population) 
Incidence difference a  
(95% CIb) 
Percent change in 
incidencec  
(95% CIb) 
P value 
0−11 months     
2006−2008d 132.5 (114.7, 152.3)    
2010 103.6 (85.8, 124.1) -28.9 (-55.2, -2.7) -21.8 (-38.3, -1.3) 0.033 
2011 58.4 (45.4, 74.1) -74.1 (-97.2, -51.0) -55.9 (-67.0, -41.7) <0.001 
2012 38.8 (28.3, 51.9) -93.8 (-115.4, -72.1) -70.8 (-79.3, -59.4) <0.001 
2013 50.3 (38.2, 65.0) -82.3 (-104.8, -59.7) -62.1 (-72.2, -48.9) <0.001 
2014 30.5 (21.2, 42.4) -102.0 (-123.1, -81.0) -77.0 (-84.4, -66.9) <0.001 
12−23 months     
2006-2008d 37.6 (29.4, 47.4)    
2010 31.8 (23.9, 41.5) -5.8 (-18.0, 6.3) -15.5 (-41.7, 22.0) 0.352 
2011 20.2 (13.6, 28.8) -17.5 (-28.8, -6.2) -46.4 (-66.2, -16.9) 0.003 
2012 14.4 (8.9, 22.0) -23.3 (-33.9, -12.6) -61.8 (-77.7, -37.2) <0.001 
2013 20.7 (14.0, 29.6) -16.9 (-28.3, -5.5) -45.0 (-65.3, -14.6) 0.005 
2014 13.2 (8.0, 20.7) -24.4 (-34.9, -13.9) -64.8 (-80.0, -41.0) <0.001 
24−59 months     
2006-2008d 7.5 (5.4, 10.3)    
2010 3.9 (2.4, 6.0) -3.6 (-6.5, -0.8) -48.4 (-71.4, -9.6) 0.014 
2011 4.0 (2.5, 6.2) -3.5 (-6.4, -0.6) -46.7 (-70.5, -6.6) 0.020 
2012 4.1 (2.5, 6.4) -3.4 (-6.4, -0.5) -45.8 (-70.3, -4.1) 0.025 
2013 4.4 (2.6, 6.9) -3.1 (-6.2, -0.1) -41.6 (-68.0, 3.3) 0.051 
2014 3.3 (1.7, 5.6) -4.3 (-7.2, -1.3) -56.7 (-78.8, -17.4) 0.006 
 
a Incidence in vaccine-era years 2010, 2011, 2012, 2013 and 2014 respectively compared to median 
incidence in the pre-vaccine years 2006-2008. A negative value indicates a reduction in incidence; a 
positive value indicates an increase in incidence 
b Confidence interval 
c A negative percent change indicates a reduction in incidence; a positive percent change indicates an 
increase in incidence 
d Median hospitalisation incidence 2006-2008  
 
 
 
Supplementary Figure: Annual incidence (per 1000 population) of diarrhoeal hospitalisations 
(A) compared to bronchiolitis hospitalisations (B) among children <5 years of age in Soweto, 
2006-2014. 
 
  
Supplementary Figure: Annual incidence (per 1000 population) of diarrhoeal hospitalisations 
(A) compared to bronchiolitis hospitalisations (B) among children <5 years of age in Soweto, 
2006-2014. 
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Effect of breastfeeding on immunogenicity of oral live-attenuated 
human rotavirus vaccine: a randomized trial in HIV-uninfected infants 
in Soweto, South Africa
Michelle J Groome,a Sung-Sil Moon,b Daniel Velasquez,b Stephanie Jones,a Anthonet Koen,a Nadia van Niekerk,a 
Baoming Jiang,b Umesh D Parasharb & Shabir A Madhia
Introduction
Rotavirus is the leading cause of severe gastroenteritis in young 
children.1 It was estimated that 453 000 of the deaths – or 37% 
of all of the diarrhoea-related deaths – that occurred globally 
in 2008 were attributable to rotavirus infection.1 In South Af-
rica in 2009, diarrhoea was the leading cause of death among 
children younger than 5 years and accounted for 18% of the 
deaths in this age group.2 In a review of relevant published 
studies, the median rate of rotavirus detection reported among 
children hospitalized for diarrhoea in South Africa was found 
to be 24% (range: 13–55%).3,4
Two live oral vaccines against rotavirus – Rotarix® 
(GlaxoSmithKline Biologicals, Rixensart, Belgium) and 
RotaTeq® (Merck Vaccines, Whitehouse Station, United States 
of America) – have been licensed for international use. Both 
are being introduced into national immunization programmes, 
in accordance with World Health Organization recommenda-
tions.5 Clinical trials have demonstrated that the two vaccines 
are highly effective against severe rotavirus gastroenteritis 
in middle- and high-income countries in Europe and Latin 
America.6,7 However, the vaccines appear to show relatively 
lower efficacy and immunogenicity in some low- to middle-
income countries in Africa and Asia.8–11 In an African study, 
two or three doses of Rotarix® were found to reduce the inci-
dence of severe rotavirus gastroenteritis during the first year 
of life by 77% in South Africa and 49% in Malawi.8 RotaTeq® 
was found to have vaccine efficacies – again measured against 
severe rotavirus disease in the first year of life – of 64% in a 
multicentre trial in Ghana, Kenya and Mali9 and of 51% in a 
separate study based in Bangladesh and Viet Nam.10 Other 
live oral vaccines, such as those against polio and cholera and 
earlier potential rotavirus vaccines, have also shown relatively 
lower efficacies when tested in low-income countries.12
There are several possible reasons why rotavirus vac-
cines might show relatively lower efficacies in low- and 
middle-income countries in Africa and Asia. These include 
interference from high levels of rotavirus-specific antibodies 
that infants may acquire – either transplacentally or via breast-
feeding – from their mothers; the co-administration of oral 
polio vaccine; micronutrient deficiency; enteric co-infections 
and other concurrent diseases, such as infection with human 
immunodeficiency virus (HIV).11 In trials of earlier vaccine 
candidates for the control of rotavirus infection, seroconver-
sion was sometimes found to be less common among breastfed 
infants than among non-breastfed infants who had been given 
the same number of doses of the vaccine.13–15 Although there 
appears to be no evidence to indicate that, during the first 
year of life, Rotarix® or RotaTeq® shows lower efficacy among 
breastfed infants than among infants given only formula milk, 
there has been no detailed attempt to explore this possibil-
ity.16,17 Titres of anti-rotavirus IgA in sera of infants and levels 
of lactoferrin and rotavirus-specific neutralizing activity in 
the breast milk of mothers have been shown to vary by set-
ting. For example, breast milk samples from Indian and South 
African women with low socioeconomic status tend to have 
Objective To investigate the effect of abstention from breastfeeding, for an hour before and after each vaccination, on the immune responses 
of infants to two doses of rotavirus vaccine.
Methods In Soweto, South Africa, mother–infant pairs who were uninfected with human immunodeficiency virus (HIV) were enrolled as 
they presented for the “6-week” immunizations of the infants. Each infant was randomly assigned to Group 1 – in which breastfeeding was 
deferred for at least 1 h before and after each dose of rotavirus vaccine – or Group 2 – in which unrestricted breastfeeding was encouraged. 
Enzyme-linked immunosorbent assays were used to evaluate the titres of rotavirus-specific IgA in samples of serum collected from each 
infant immediately before each vaccine dose and 1 month after the second dose. Among the infants, a fourfold or greater increase in titres 
of rotavirus-specific IgA following vaccination was considered indicative of seroconversion.
Findings The evaluable infants in Group 1 (n = 98) were similar to those in Group 2 (n = 106) in their baseline demographic characteristics 
and their pre-vaccination titres of anti-rotavirus IgA. After the second vaccine doses, geometric mean titres of anti-rotavirus IgA in the sera 
of Group-1 infants were similar to those in the sera of Group-2 infants (P = 0.685) and the frequency of seroconversion in the Group-1 infants 
was similar to that in the Group-2 infants (P = 0.485).
Conclusion Among HIV-uninfected South African infants, abstention from breastfeeding for at least 1 h before and after each vaccination 
dose had no significant effect on the infants’ immune response to a rotavirus vaccine.
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higher titres of anti-rotavirus IgA and 
neutralizing activity than those collected 
from women in the United States.18–20 
Such differences may partially explain 
why current rotavirus vaccines have 
relatively poor efficacy in low-income 
settings. Among infants, the efficacies 
of both Rotarix® and RotaTeq® appear 
to be positively correlated with serum 
titres of rotavirus-specific IgA.20
The main objectives of the present 
study were to determine the titres of 
rotavirus-specific IgA in infant serum, 
maternal serum and maternal breast 
milk in a cohort of HIV-uninfected 
South African mother–infant pairs, and 
to investigate the effect of abstention 
from breastfeeding at the time of vac-
cination on the immunogenicity of the 
Rotarix® vaccine.
Methods
Participants and specimen 
collection
We conducted a prospective, ran-
domized, longitudinal cohort study of 
consenting, healthy, HIV-uninfected 
mother–infant pairs. The mothers 
and infants were enrolled – between 2 
December 2009 and 9 April 2010 – as 
they presented for their “6-week” rou-
tine immunization visits at Diepkloof 
Primary Health Clinic, Soweto, South 
Africa. Follow-up continued until Au-
gust 2010. Infants were considered for 
enrolment if they were aged 5 to 8 weeks, 
were being breastfed, had received no 
vaccines except oral polio vaccine and 
bacille Calmette–Guérin (BCG) at birth 
and had mothers who had been found 
seronegative for HIV after week 24 of 
gestation. Infants with known underly-
ing immunosuppressive conditions and 
infants showing failure to thrive – that is, 
infants who fell below the third centile for 
weight-for-age or had dropped more than 
two weight-for-age centiles since birth 
– were excluded. Enrolled infants were 
randomized into two groups, known 
simply as Group 1 and Group 2. Mothers 
of Group 1 infants were instructed not 
to breastfeed their infants for at least 1 h 
before and after administration of each 
dose of rotavirus vaccine. Unrestricted 
breastfeeding was encouraged among the 
mothers of Group 2 infants. Breastfeed-
ing of the enrolled infants was monitored 
at the study clinic as the mother–infant 
pairs presented for vaccination. The 
laboratory personnel who tested sera 
and breast-milk samples were blind to 
the group allocation.
All vaccines were provided ac-
cording to the standard schedule of the 
expanded programme on immunization 
in South Africa. According to this sched-
ule, each South African infant should 
be given trivalent oral polio vaccine 
(OPV-Merieux; Sanofi Pasteur, Lyon, 
France) at 6 weeks of age, a combina-
tion diphtheria and tetanus toxoids and 
acellular pertussis adsorbed, inactivated 
poliovirus and Haemophilus influenzae 
type b conjugate vaccine (Pentaxim; 
Sanofi Pasteur) and a hepatitis B vac-
cine (Heberbiovac HB; Heber Biotec, 
Havana, Cuba) at 6, 10 and 14 weeks, 
and rotavirus vaccine (Rotarix®) and 
a heptavalent pneumococcal conjugate 
vaccine (Prevenar; Wyeth, Madison, 
USA) at 6 and 14 weeks.
Serum samples were collected from 
the infants immediately before the 
first and second doses of Rotarix® and 
1 month after the second dose. Samples 
of serum and breast milk were collected 
from the mothers shortly before their 
infants received each dose of Rotarix®. 
All of the sera and breast-milk samples 
were given code numbers to hide the 
identities of their donors. The samples 
were kept frozen at −70 °C until they 
were shipped – on solid carbon dioxide 
– to the Division of Viral Diseases of the 
United States Centers for Disease Con-
trol and Prevention, in Atlanta, United 
States, where they were investigated. 
Titres of anti-rotavirus IgA in all of the 
sera and breast milk samples, titres of 
anti-rotavirus IgG in the sera collected 
from the infants before the first dose of 
Rotarix®, and levels of rotavirus-specific 
neutralizing antibodies in the breast-
milk samples were evaluated.
The protocol was reviewed and ap-
proved by the Human Research Ethics 
Committee (Medical) of the University 
of the Witwatersrand (M090824). Writ-
ten informed consent was obtained 
from a parent of each enrolled infant. 
The trial was registered on the South 
African National Clinical Trial Register 
(DOH-27–0511–2991).
Specimen testing
Titres of rotavirus-specific IgA were 
determined in enzyme-linked immu-
nosorbent assays.18 For these assays, 
microplate wells were coated with 
rabbit hyperimmune serum to rhesus 
rotavirus and incubated either with 
diluted Rotarix® strain or 5% (v/v) 
skim milk in phosphate-buffered saline 
(PBS). After washing, breast milk di-
luted 1:5–1:5120 in diluent buffer – PBS 
supplemented with 1% (v/v) skim milk 
and 0.5% (v/v) of a 10% solution of 
polyoxyethylene ether W1 – or serum 
diluted 1:20–1:10 240 in the same buffer 
– was added to each well, followed by 
biotin-conjugated goat anti-human IgA 
antibodies (KPL, Gaithersburg, USA). 
After incubation and washing, Extravi-
din (Sigma-Aldrich, St Louis, USA) was 
added to the wells and incubated, and 
then the reactions were developed with 
3,3ʹ,5,5ʹ-tetramethylbenzidine (Sigma-
Aldrich) and stopped with 1 M HCl. 
The optical density of the contents of 
each well was determined, at 450 nm, in 
a plate reader (MRX Revelation; Dynex 
Technologies, Chantilly, USA).
Anti-rotavirus IgA titres were cal-
culated as the reciprocals of the highest 
dilutions that gave mean optical densi-
ties that were greater than the cut-off 
value. The cut-off value was set three 
standard deviations above the mean 
optical density for the negative-control 
wells. Rotavirus-specific IgG was tested 
and analysed in the same manner as IgA 
except that biotin-conjugated goat anti-
human IgG antibodies (KPL) were used 
and 0.5% (v/v) normal rabbit serum was 
added to the biotin-conjugate solution.
The level of rotavirus-specific neu-
tralizing activity in each breast-milk 
sample was evaluated in a microneutral-
ization assay.18 For this, a twofold serial 
dilution of each breast-milk sample was 
prepared and 50 μl of each dilution were 
mixed with an equal volume of trypsin-
activated Rotarix® vaccine virus in the 
well of a microtitre plate – to yield a 
concentration of 4000 focus-forming 
units per well – and incubated at 37 °C 
for 1 h. The contents of each well were 
then placed on a PBS-washed monolayer 
of MA104 cells that had been grown in a 
96-well plate. After another incubation 
at 37 °C for 1 h, the plate was washed 
with PBS and 100 µl of Iscove’s modi-
fied Dulbecco’s medium (Invitrogen, 
Carlsbad, USA) containing 5 μg trypsin 
per ml were added to each well. After 
incubation at 37 °C for 20 hours, 15 μl 
of 37% (w/v) formaldehyde were added 
to each well and left at 4 °C for 30 min-
utes. Rotavirus antigen in the MA104 
cells was detected by incubating plates 
with a rabbit anti-rhesus-rotavirus hy-
perimmune serum, then anti-rabbit IgG 
labelled with horseradish peroxidase, 
and finally with 3,3ʹ,5,5ʹ-tetramethyl-
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benzidine. The neutralizing titre in a 
breast milk sample was determined as 
the reciprocal of the highest dilution that 
showed a reduction in the absorbance 
value – relative to that in the virus-only 
controls – of more than 70%.
Sample size
The study was powered to detect at least a 
20% higher frequency of seroconversion 
among the Group 1 infants than among 
the Group 2 infants. It was assumed 
that about 55% of the Group-2 infants 
would seroconvert in terms of their anti-
rotavirus IgA, since 57% of infants given 
two doses of the vaccine had previously 
shown such seroconversion in a trial of 
the efficacy of Rotarix® in South Africa.8 
After setting a 5% significance level and 
80% power and allowing for 20% loss to 
follow-up, our aim was to enrol at least 123 
infants into each of the two study groups.
Statistical analysis
For the allocation of infants to each 
study group, a randomization list was 
generated using the SAS software pack-
age (SAS Institute, Cary, USA). Data 
analysis was performed using version 
12.1 of the STATA package (StataCorp. 
LP, College Station, USA). A P-value of 
0.05 or lower was considered statistically 
significant. Titres were log-transformed 
to give a better approximation to a nor-
mal distribution. Geometric mean titres 
were calculated. Continuous variables 
were compared using two-sample Stu-
dent’s t-tests – if the data were normally 
distributed – or Wilcoxon rank-sum 
tests. Temporal changes in the log-
transformed titres within a single study 
group were investigated in t-tests for 
matched pairs. Categorical variables 
were compared using χ2 tests. For the 
calculation of geometric mean titres, 
titres of anti-rotavirus IgA in serum that 
fell below 20 and titres of anti-rotavirus 
IgA in breast milk that fell below 5 were 
each assigned a value of 1. Even the data 
for infants who had pre-vaccination ti-
tres of anti-rotavirus IgA in serum that 
exceeded 20 were included in the final 
analyses. Seroconversion was defined 
as a fourfold or greater increase in anti-
rotavirus IgA titre compared with the 
titre recorded before the first dose of 
Rotarix®.
Results
In total, 250 infants were enrolled at a 
median age of 6.1 weeks. At enrolment, 
each of these infants received a first 
dose of Rotarix®, oral polio vaccine and 
other, scheduled, childhood vaccines. 
Although 125 infants were allocated to 
each study group, only 98 (78%) of those 
allocated to Group 1 and 106 (85%) of 
those allocated to Group 2 were fully 
adherent to the study protocol and in-
cluded in the final analysis (Fig. 1). No 
significant differences were observed 
– in infant age at enrolment, sex or 
birth weight or baseline titres of anti-
rotavirus IgA and IgG in the infants and 
their mothers – between the “evaluable” 
infants who were included in the final 
analysis and the other enrolled infants 
(data not shown).
In terms of sex, birth weight and 
age at vaccination, the evaluable infants 
in Group 1 were similar to those in 
Group 2 (Table 1). The second Rotarix® 
dose was administered at a median of 
9.1 weeks (range: 5.4–16.9) after the first 
dose and subsequent immunogenicity 
was measured a median of 4.5 weeks 
(range: 3.9–8.3) later. The timing of 
these events was similar in the two study 
groups. When measured before the first 
vaccine dose, the geometric mean titres 
of anti-rotavirus IgG and IgA in infant 
sera and anti-rotavirus IgA in maternal 
sera and breast milk samples and the 
geometric mean neutralizing titres in 
breast milk were also similar in the two 
study groups (Table 1).
There were no significant between-
group differences in the geometric mean 
titres of anti-rotavirus IgA in infant 
sera measured after the first (P = 0.612) 
or second doses (P = 0.685) of Rotarix® 
(Table 1). However, in both the Group 1 
infants and the Group 2 infants, such 
mean titres were higher after both the 
first dose of Rotarix® (53.4 and 46.0, 
respectively) and the second (137.7 
and 122.7, respectively) than the titres 
recorded before the first dose (14.2 and 
14.6, respectively). These within-group 
temporal changes were all statistically 
significant (P < 0.001).
Compared with the values recorded 
at baseline, the maternal sera and breast 
milk samples collected after the infants 
had received their first dose of Rotarix® 
also showed significantly higher geo-
metric mean titres – of anti-rotavirus 
Fig. 1. Flowchart of mother–infant pair enrolment and follow-up in study of the effect 
of breastfeeding on the immunogenicity of rotavirus vaccine, South Africa, 
2009–2010
Allocated to interrupted breastfeeding 
(n = 125)
• Received allocated intervention (n = 118)
• Did not receive allocated intervention: 
breastfed < 60 min pre- or post- vaccina-
tion (n = 7)
Allocated to unrestricted breastfeeding 
(n = 125)
• Received allocated intervention (n = 124)
• Did not receive allocated intervention: 
incorrect intervention received (n = 1)
Lost to follow-up (n = 5)
• Relocated (n = 4)
• Withdrew consent (n = 1)
Discontinued intervention: no longer being 
breastfed (n = 8)
Analysed (n = 98)
• Excluded from analysis because of missing 
data (n = 7)
Analysed (n = 106)
• Excluded from analysis because of missing 
data (n = 2)
Lost to follow-up (n = 9)
• Relocated (n = 4)
• Withdrew consent (n = 5)
Discontinued intervention: no longer being 
breastfed (n = 7)
Excluded (n = 16)
• Not meeting inclusion criteria (n = 8)
• Declined to participate (n = 1)
• Other reasons: parent < 18 years of age, 
planned relocation (n = 7)
Assessed for eligibility (n = 266)
Randomized (n = 250)
Enrolment
Allocation
Follow-up
Analysis
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IgA, neutralizing activity or both – in 
both Group 1 and Group 2 (Table 1). At 
each time point that we investigated, the 
distribution of titres among Group 1 in-
fants was similar to that seen in Group 2 
(data not shown). There were also no 
significant between-group differences 
in the frequency of seroconversion after 
either one dose (P = 0.859) or two doses 
(P = 0.485) of Rotarix® (Fig. 2). The fre-
quency of seroconversion in the whole 
study cohort was 35% (95% confidence 
interval, CI: 28–42) after one dose of 
Rotarix® and 61% (95% CI: 54–68) after 
two doses.
Discussion
There has been much speculation about 
the reasons for the relatively low effi-
cacy and immunogenicity of rotavirus 
vaccines in low- and middle-income 
countries in Africa and Asia. One 
hypothesis is that rotavirus-specific an-
tibodies and other neutralizing factors 
present in breast milk may diminish a 
breastfed infant’s immune responses 
to a rotavirus vaccine – by lowering 
the effective titre of vaccine delivered 
to the infant’s gut. This hypothesis was 
supported by the results of two recent in 
vitro studies in which levels of lactofer-
rin, anti-rotavirus IgA and neutralizing 
activity in breast milk samples from 
mothers who were breastfeeding their 
infants were evaluated. Breast milk with 
low titres of rotavirus-specific neutral-
izing activity did not seem to affect the 
vaccine virus but milk with high titres 
could neutralize the vaccine virus, even 
when diluted.18,19 These observations 
indicated that a short abstention from 
breastfeeding at the time of each vac-
cination could potentially improve the 
immunogenicity of a rotavirus vaccine. 
However, the results of the present study 
indicate that abstaining from breastfeed-
ing for at least an hour before and after 
each of two doses of Rotarix® had no 
significant effect on the frequency of 
seroconversion among the vaccinated 
infants or the titres of anti-rotavirus IgA 
in the sera of the same infants.
The results of earlier, related in 
vivo studies – in which the effects of 
breast milk on immunogenicity and 
seroconversion after the administration 
of candidate vaccines against rotavirus 
were investigated – were equivocal.21–23 
Although each of two meta-analyses 
led to the conclusion that breastfeeding 
did significantly reduce the immune 
response to a single dose of rhesus ro-
tavirus vaccine, the data analysed came 
from studies that differed markedly in 
terms of the number of vaccine doses, 
Table 1. Comparison of mother–infant pairs assigned to two arms of a study on the effect of breastfeeding on the immunogenicity of 
rotavirus vaccine, South Africa, 2009–2010
Infants/mothers Groupa P
1 2
Infants
No. evaluated in full 98 106 –
Males, no. (%) 55 (56.1) 57 (53.8) 0.736
Mean birth weight, kg (SD) 3.0 (0.5) 3.1 (0.5) 0.641
Median age, weeks (range)
    On enrolment 6.3 (5.7–7.7) 6.1 (5.9–7.3) 0.200
    When investigated after first vaccine dose 15.7 (11.6–23.4) 15.3 (13.9–19.9) 0.418
    When investigated after second vaccine dose 20.6 (17.4–27.4) 20.1 (18.0–24.1) 0.408
Serum anti-rotavirus IgG, GMT (95% CI)
    On enrolmentb 1508.6 (1194.8–1904.9) 1524.7 (1220.4–1904.9) 0.948
Serum anti-rotavirus IgA, GMT (95% CI)
    On enrolment 14.2 (9.8–20.6) 14.6 (10.0–21.5) 0.910
    After first dose of vaccinec 53.4 (36.7–77.7) 46.0 (29.7–71.3) 0.612
    After second dose of vaccine 137.7 (90.2–210.2) 122.7 (84.6–177.9) 0.685
Mothers
Serum anti-rotavirus IgA, GMT (95% CI)
    On enrolmentd 26.2 (15.6–44.0) 27.4 (16.5–45.5) 0.908
    After infant received first dose of vaccinee 164.0 (103.8–259.1) 186.8 (125.4–278.1) 0.670
Breast-milk anti-rotavirus IgA, GMT (95% CI)
    On enrolmente 39.3 (28.5–51.6) 42.4 (32.2–55.7) 0.624
    After infant received first dose of vaccinee 52.2 (39.3–69.2) 56.4 (41.4–76.8) 0.715
Breast-milk neutralizing activity, GMT (95% CI)
    On enrolment 8.8 (6.0–13.0) 8.3 (6.0–11.5) 0.813
    After infant received first dose of vaccinef 19.1 (12.9–28.3) 21.5 (14.9–31.1) 0.662
CI , confidence interval; GMT, geometric mean titre; SD, standard deviation.
a  Each infant was randomly assigned to either Group 1 – in which there was an abstention from breastfeeding for at least 1 h before and after each dose of rotavirus 
vaccine – or Group 2 – in which unrestricted breastfeeding was encouraged.
b  No data available for four infants (one in Group 1).
c  No data available for 21 infants (11 in Group 1).
d  No data available for one mother of an infant in Group 1.
e  No data available for one mother of an infant in Group 2.
f  No data available for two mothers (one of an infant in Group 1).
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the antibody assays and the criteria for 
seroconversion and breastfeeding that 
were used.13,14 It appears that the effect 
of breast milk interference on the immu-
nogenicity of rotavirus vaccines can be 
overcome by administering more than 
one dose of vaccine.15
Our results are consistent with 
those of a study on the effects of breast-
feeding on antibody response to oral 
polio vaccine in infants. In this polio 
study, the frequency of post-vaccination 
seroconversion among infants on 
unrestricted breastfeeds was found to 
be similar to that seen among infants 
abstaining from breastfeeding for a 
period of time.24
The mothers of both groups of 
infants enrolled in the present study 
showed higher titres of anti-rotavirus 
IgA and rotavirus-specific neutralizing 
activity after their infants had received 
one dose of Rotarix® than before this 
dose. These increases may partly reflect 
the mothers’ natural infection with 
rotavirus during the peak rotavirus 
season in South Africa, which gener-
ally runs from April to September each 
year.4 However, the majority (71%) of 
the maternal samples collected after 
the corresponding infants had received 
one dose of Rotarix® were collected 
after the rotavirus season of 2009 and 
before the onset of the rotavirus season 
of 2010. No attempt was made to check 
the mothers of the enrolled infants for 
the signs or symptoms of rotavirus 
disease. An alternative explanation 
for the increasing immunogenicity of 
the mothers to the Rotarix® vaccine 
strain is that maternal antibodies were 
boosted by the vaccination of the in-
fants of these women. The conferring 
of immunity to people in close contact 
with vaccinated children has been ob-
served in studies on oral polio vaccine25 
and may also occur with rotavirus vac-
cine. The horizontal transmission of a 
human rotavirus vaccine strain – from 
vaccinated children to their unvac-
cinated twins – was demonstrated in a 
placebo-controlled study of twins who 
lived in close contact with each other 
in the Dominican Republic.26
The overall frequency of serocon-
version observed in the present study 
following the second dose of Rotarix® 
– 61% – is reassuring, bearing in mind 
that the rotavirus vaccination schedule 
currently followed in South Africa, of 
doses at 6 and 14 weeks of age, has not 
yet been studied in clinical trials. This 
frequency of seroconversion is similar to 
the values observed in the South African 
trial of the clinical efficacy of Rotarix®, 
which were 57.1% (95% CI: 44.7–68.9) 
after two doses and 66.7% (95% CI: 
54.0–77.8) after three doses.8 However, 
comparisons between the efficacy trial 
and the present study must be made 
with caution since different assays to 
assess immunogenicity were used in 
the two investigations. In the efficacy 
trial, a commercial enzyme-linked im-
munosorbent assay with a cut-off point 
for seroconversion of 20 “units” per ml 
was used, whereas we used another im-
munosorbent assay and defined serocon-
version as a fourfold or greater increase 
in an infant’s titres of anti-rotavirus IgA. 
The dosing schedule used in the two 
investigations also differed: the two-dose 
group in the efficacy trial received Ro-
tarix® at 6 and 10 weeks of age, while in 
the present study the same vaccine was 
given at approximately 6 and 14 weeks 
of age. The identification of a correlate 
of protection after rotavirus vaccination 
has proven difficult, mainly because of 
differences between the relevant studies 
in terms of vaccine type, dose schedule, 
regional pre-immunization titres, labo-
ratory assays and the impact of natural 
exposure. However, serum titres of anti-
rotavirus IgA have been identified as 
one important predictor of protection.20
There were some limitations to our 
study. The second dose of Rotarix® could 
only be given to some of the infants 
one month later than scheduled because 
the vaccine stocks became exhausted 
between April and May of 2010. This 
meant that not all infants received two 
doses before the onset of the rotavirus 
season in 2010. Towards the end of our 
study, therefore, there may have been 
natural rotavirus in circulation and 
this could have affected the titres of the 
antibodies that we investigated, in both 
the infants and the mothers. However, 
the level of natural exposure to rotavirus 
would have been similar in the two study 
groups and not likely to have affected 
our conclusions.
Fig. 2. Frequency of seroconversion in infants assigned to two arms of a study on the 
effect of breastfeeding on the immunogenicity of rotavirus vaccine, South Africa, 
2009–2010
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Note: Each enrolled infant was randomly assigned to either Group 1 – in which there was an abstention 
from breastfeeding for at least 1 h before and after each dose of rotavirus vaccine – or Group 2 – in which 
unrestricted breastfeeding was encouraged. The bars indicate the median frequencies of seroconversion 
observed after one and two doses of rotavirus vaccine. 
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صخلم
 لىع ةيئاوشع ةبرتج :يومفلا يلحا نهولما يشربلا ليجعلا سويرفلا حاقلل ةعانلما باستكا ةيلباق لىع ةيعيبطلا ةعاضرلا رثأ
ايقيرفأ بونجب ،وتيوس في يشربلا يعانلما زوعلا سويرف ىودعب ينباصلما يرغ عضرلا
 لبق ،ةعاس ةدلم ةيعيبطلا  ةعاضرلا  نع عانتملاا رثأ  يرتح ضرغلا
 حاقل  يتعرلج  ةيعانلما  عضرلا  تاباجتسا  لىع  ،هدعبو  ميعطت  لك
.ليجعلا سويرفلا
 تاهملأا  جاوزأ  ليجست  مت  ،ايقيرفأ  بونجب  ،وتيوس  في  ةقيرطلا
 روضلحا دنع يشربلا يعانلما زوعلا سويرفب ينباصلما يرغ عضرلاو
 لك  صيصتخ  متو  .“عيباسأ  6”  نس  في  عضرلا  تمايعطت  يقلتل
 ةعاضرلا ليجأت مت يتلا - 1 ةعومجملل يئاوشع وحن لىع عيضر
 ةعرج لك دعب  وأ  لبق  لقلأا  لىع ةدحاو  ةعاس ةدلم  اهيف  ةيعيبطلا
 عيجشت  مت  يتلا  -  2  ةعومجلما  وأ  -  ليجعلا  سويرفلا  حاقل  نم
 زتملما تاسياقم مادختسا متو .اهيف ةديقلما يرغ ةيعيبطلا ةعاضرلا
 A  يعانلما  ينلوبولغلا  تارايع  مييقتل  تمايزنلإاب  طبترلما  يعانلما
 نم اهعجم مت متلا مدلا لصم تانيع في ليجعلا سويرفلاب صالخا
 ةيناثلا  ةعرلجا  دعبو  ةشرابم  حاقللا  نم ةعرج لك لبق  عيضر لك
 في  رثكأ  وأ  فاعضأ  ةعبرأ  ةبسنب  ةدايزلا  رابتعا  متو  .دحاو  رهشب
 دعب  ليجعلا  سويرفلاب  صالخا  A  يعانلما  ينلوبولغلا  تارايع
.لصلما ةيلعافت بلاقنا لىع ًاشرؤم عضرلا ينب ميعطتلا
 ) 98=ددعلا( 1 ةعومجلما في مييقتلل نولباقلا عضرلا هباشت جئاتنلا
 ةيفارغميدلا صئاصلخا في )106=ددعلا( 2 ةعومجلما في عضرلا عم
 ليجعلا سويرفلل داضلما A يعانلما ينلوبولغلا تارايعو ةيساسلأا
 تارايع تبهاشت ،ةيناثلا حاقللا تاعرج دعبو .مهميعطتل ةقباسلا
 ليجعلا  سويرفلل  داضلما  A  يعانلما  ينلوبولغلل  سيدنلها  طسوتلما
 عضر مد لاصمأ في تارايعلا عم 1 ةعومجلما عضر مد لاصمأ في
 بلاقنا  رتاوت  لدعم  هباشتو  )0.685=-لماتحلاا(  2  ةعومجلما
 ةعومجلما عضر في لدعلما عم 1 ةعومجلما عضر في لصلما ةيلعافت
.)0.485 = لماتحلاا( 2
 ةدحاو ةعاس ةدلم ةيعيبطلا ةعاضرلا نع عانتملال نكي لم جاتنتسلاا
 سويرفب ينباصلما يرغ عضرلا ينب ،اهدعبو ميعطت ةعرج لك لبق
 حاقلل  ةيعانلما  عضرلا  ةباجتسا  لىع  يربك  رثأ  ،شربلا  يعانلما  زوعلا
.ليجعلا سويرفلا
摘要
母乳喂养对人轮状病毒口服减毒活疫苗免疫原性的影响：南非索韦托艾滋病病毒未感染婴儿随机试验
目的 调查在每次疫苗接种之前和之后一个小时避免母
乳喂养对婴儿对两剂量轮状病毒疫苗的免疫反应的影
响。
方法 在南非索韦托，在提出“6 周”婴儿免疫接种的
母婴对中招募未受艾滋病毒（HIV）感染的母婴对。
将每个婴儿随机指定到第 1 组（该组在每剂轮状病毒
之前和之后至少隔开 1 小时母乳哺育）或者第 2 组（该
组鼓励不受限制的母乳喂养）。使用酶联免疫吸附试
验评估在每剂疫苗即将接种时和接种第二剂之后 1 个
月所收集每个婴儿血清样本中的轮状病毒特异性 IgA
滴度。在这些婴儿当中，如果疫苗接种之后轮状病毒
特异性 IgA 的滴度出现四倍或更多的增加，则表示出
现血清转换。
结果 在基线人口特征和疫苗接种前抗轮状病毒 IgA 滴
We only assessed whether absten-
tion from breastfeeding for about 1 h 
before and after each vaccination had an 
effect on immunogenicity. Although it 
remains possible that a more prolonged 
abstention may have had a greater im-
pact, leaving an infant unfed for more 
than 2 h may not be programmatically 
possible or acceptable. Although the 
mothers of Group 2 infants were en-
couraged to breastfeed their infants soon 
after the vaccines were given, the length 
of each first feed after the vaccination 
was not recorded. As suckling is often 
used as a comfort, a full feed may not 
have been given at this time. The interac-
tion between vaccine and breast milk in 
the Group 2 infants may therefore have 
been less than the maximum possible.
The present study was designed to 
detect a 20% difference in the frequency 
of seroconversion between the two 
groups of infants. A larger sample size 
may have allowed detection of a signifi-
cant difference of smaller magnitude. 
However, policy-makers are unlikely to 
promote changes in national breastfeed-
ing habits if such changes only lead to 
small increases in the immunogenicity 
of rotavirus vaccines given to infants.
Abstention from breast-feeding for 
1 h before and after vaccination does not 
appear to have any significant effect on 
the immune response to Rotarix® in a 
low- to middle-income African setting. 
The reason or reasons that oral rotavirus 
vaccines appear to have relatively low 
efficacy in low-income settings – which 
may include enteric co-infections and 
concurrent medical conditions – require 
further investigation. The potential for 
boosting the efficacy of such vaccines – 
for example, by zinc supplementation 
or the co-administration or probiotics 
– and other approaches to rotavirus 
vaccination – such as vaccines derived 
from neonatal strains or parenteral vac-
cines – should also be investigated. ■
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度方面，第 1 组（n = 98）和第 2 组（n = 106）可评估
婴儿的结果相似。在第二剂疫苗接种之后，第 1 组婴
儿血清抗轮状病毒 IgA 的几何平均滴度与第 2 组婴儿
血清中的滴度相似（P = 0.685），第 1 组婴儿血清转化
率和第 2 组第 2 组婴儿相似（P = 0.485）。
结论 在南非未受艾滋病毒感染的婴儿中，在每剂疫苗
接种之前和之后一个小时避免母乳喂养对婴儿对轮状
病毒疫苗的免疫反应没有显著影响。
Résumé
Effet de l’allaitement sur l’immunogénicité du vaccin oral vivant atténué contre le rotavirus humain: un essai randomisé parmi 
les nourrissons séronégatifs à Soweto, en Afrique du Sud
Objectif Étudier l’effet de l’abstention d’allaitement, une heure avant et 
après chaque vaccination, sur les réactions immunitaires des nourrissons 
à deux doses de vaccin contre le rotavirus.
Méthodes À Soweto, en Afrique du Sud, des couples mère-enfant 
non infectés par le virus de l’immunodéficience humaine (VIH) ont été 
inscrits à cette étude, alors qu’ils se présentaient pour les vaccinations 
des nourrissons de 6 semaines. Chaque enfant a été placé au hasard 
dans le groupe 1 – au sein duquel l’allaitement était reporté au moins 
d’une heure avant et après chaque dose de vaccin contre le rotavirus - 
ou dans le groupe 2 - au sein duquel l’allaitement sans restriction a été 
encouragé. Des dosages immuno-enzymatiques ont été utilisés pour 
évaluer les titres d’IgA spécifiques du rotavirus dans des échantillons 
de sérum prélevés chez chaque enfant immédiatement avant chaque 
dose de vaccin et un mois après la deuxième dose. Chez les nourrissons, 
une augmentation par 4 ou plus des titres d’IgA spécifiques du 
rotavirus après la vaccination a été considérée comme une indication 
de séroconversion.
Résultats Les nourrissons évaluables du groupe 1 (n = 98) étaient 
similaires à ceux du groupe 2 (n = 106) en ce qui concernaient leurs 
caractéristiques démographiques de base et leurs titres d’IgA anti-
rotavirus avant la vaccination. Après les deuxièmes doses de vaccin, 
les titres moyens géométriques d’IgA anti-rotavirus du sérum des 
nourrissons du groupe 1 étaient semblables à ceux du sérum des 
nourrissons du groupe 2 (P = 0,685), et la fréquence de séroconversion 
des nourrissons du groupe 1 était semblable à celle des nourrissons du 
groupe 2 (P = 0,485).
Conclusion Chez les nourrissons non infectés par le VIH en Afrique du 
Sud, l’abstention d’allaitement pendant au moins une heure avant et 
après chaque dose de vaccination n’a eu aucun effet significatif sur la 
réaction immunitaire des nourrissons à un vaccin contre le rotavirus.
Резюме
Влияние грудного вскармливания на иммуногенность пероральной живой вакцины ослабленного 
ротавируса человека: рандомизированное исследование среди ВИЧ-неинфицированных младенцев в 
Соуэто (Южная Африка)
Цель Исследовать эффект воздержания от грудного 
вскармливания в течение часа до и после каждой вакцинации 
двумя дозами ротавирусной вакцины на иммунные реакции 
младенцев.
Методы В исследовании, проводимом в Соуэто (Южная Африка), 
принимали участие пары мать-ребенок, не зараженные вирусом 
иммунодефицита человека (ВИЧ) и проходящие «6-недельную» 
иммунизацию младенцев. Каждый ребенок был случайным 
образом распределен в одну из групп: группу 1, в которой 
грудное вскармливание не проводилось, по крайней мере, в 
течение 1 часа до и после введения каждой дозы ротавирусной 
вакцины, или группу 2, в которой матерям было предложено 
неограниченное грудное вскармливание. Для оценки титра 
антител IgA к ротавирусу в образцах сыворотки использовался 
иммуноферментный анализ сыворотки, отбираемой у каждого 
младенца непосредственно перед введением каждой дозы 
вакцины и через один месяц после введения второй дозы. 
Увеличение в титрах ротавирусных антител IgA в четыре и более 
раз после вакцинации считалось показателем сероконверсии у 
младенцев.
Результаты Дети в группе 1 (n = 98) были похожи на детей в группе 
2 (n = 106) по своим базовым демографическим характеристикам 
и титрам антиротавирусных антител класса IgA, полученным 
в ходе предварительной вакцинации. После введения второй 
дозы вакцины средние геометрические величины титров 
анти-ротавирусных IgA в сыворотке детей из группы 1 были 
аналогичны данным величинам у детей из группы 2 (Р = 0,685), 
а частота сероконверсии среди детей в группе 1 была такой же, 
как и у детей в группе 2 (P = 0,485).
Вывод Среди ВИЧ-неинфицированных южноафриканских 
младенцев воздержание от грудного вскармливания, по крайней 
мере, в течение 1 часа до и после каждой дозы вакцины не 
оказало существенного влияния на иммунный ответ младенцев 
на вакцину против ротавируса.
Resumen
Efecto de la lactancia materna en la inmunogenicidad de la vacuna oral contra el rotavirus humano vivo atenuado: un estudio 
aleatorizado en lactantes infectados por el VIH en Soweto, Sudáfrica
Objetivo Investigar el efecto de la abstención de la lactancia materna, 
una hora antes y después de cada vacuna, en las respuestas inmunes 
de los lactantes a dos dosis de la vacuna contra el rotavirus.
Métodos En Soweto, Sudáfrica, se inscribieron parejas de madres-
bebés que no estaban infectados por el virus de la inmunodeficiencia 
humana (VIH), ya que se sometieron a las inmunizaciones de «seis 
semanas» de los lactantes. Se asignó al azar a cada niño al Grupo 
1 – en el cual se aplazó la lactancia materna al menos 1 hora antes y 
después de cada dosis de la vacuna contra el rotavirus – o al Grupo 
2 – en el cual se fomentó la lactancia sin restricciones. Se utilizaron 
ensayos de inmunoadsorción enzimática para evaluar los títulos de IgA 
específica de rotavirus en muestras de suero recogidas de cada lactante 
inmediatamente antes de cada dosis de vacuna y 1 mes después de la 
segunda dosis. Entre los lactantes, un incremento cuádruple o mayor en 
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los títulos de IgA específica de rotavirus tras la vacunación se consideró 
indicativo de seroconversión.
Resultados Las características demográficas de base y los títulos de 
vacunación previa de la IgA antirrotavirus de los lactantes evaluables 
del Grupo 1 (n = 98) fueron similares a los del Grupo 2 (n = 106). Tras la 
segunda dosis de la vacuna, los títulos de la media geométrica de la IgA 
antirrotavirus en los sueros de los lactantes del Grupo-1 eran similares a 
los de los sueros de los lactantes del Grupo-2 (P = 0,685) y la frecuencia 
de la seroconversión en los lactantes del Grupo-1 fue similar a la de los 
lactantes del Grupo-2 (P = 0,485).
Conclusión Entre los lactantes sudafricanos infectados por el VIH, la 
abstención a la lactancia materna durante al menos 1 hora antes y 
después de cada dosis de la vacuna no tuvo efectos importantes en 
la respuesta inmune de los lactantes a la vacuna contra el rotavirus. 
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Prevaccination Rotavirus Serum IgG and IgA Are
Associated With Lower Immunogenicity of Live,
Oral Human Rotavirus Vaccine in South African Infants
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(See the Major Article by Emperador et al on pages 150–6.)
Background. Live oral rotavirus (RV) vaccines have shown modest efﬁcacy among children in African countries for reasons that
are not completely understood. We examined the possible inhibitory effect of preexisting antirotavirus antibodies on immunogenic-
ity of monovalent RV vaccine (RV1).
Methods. Mother–infant pairs were enrolled at presentation for their routine immunization visit in Soweto, South Africa, when
infants were aged 5–8 weeks. Infant serum samples were obtained before the ﬁrst and second doses of RV1 and 1 month after the
second dose. Maternal serum and breast milk samples were obtained prior to administration of each dose of RV1 to infants. RV-
speciﬁc immunoglobulin G (IgG), IgA, and neutralizing activity in sera of infants and serum or breast milk samples of mothers were
measured using enzyme-linked immunosorbent assays or a microneutralization test.
Results. Of the 107 serum pairs from infants who were seronegative for RV IgA at enrollment, we observed a strong positive
association between IgG titers in pre-dose 1 sera of infants and mothers and signiﬁcant negative associations between IgG titers in
pre-dose 1 sera of infants and seroconversion to RV1 post-dose 1. Similarly, mothers whose infants’ IgA seroconverted after RV1 had
signiﬁcantly lower pre-dose 1 IgG titers in sera than those whose infants did not seroconvert.
Conclusions. High levels of preexisting serum IgG, including transplacentally acquired maternal IgG, appeared to have an in-
hibitory effect on the immunogenicity of RV1 among infants and may, in part, contribute to lower efﬁcacy of RV vaccines in this and
other low-income settings.
Keywords. rotavirus; Rotarix; breast milk; transplacental antibody.
Rotavirus (RV) is the leading cause of severe gastroenteritis in
young children and is responsible for 275 000–450 000 deaths,
approximately 85% of which occur in low-income countries of
Africa and Asia [1]. In South Africa, diarrhea accounts for ap-
proximately 18% of deaths among children aged <5 years [2],
and RV infection is estimated to cause 17 644 to 25 630 hospi-
talizations annually among children aged <2 years [3]. Two
live oral vaccines (Rotarix [RV1], GlaxoSmithKline Biologi-
cals, and RotaTeq [RV5], Merck) are commercially available
and recommended by the World Health Organization for all
children worldwide and, to date, have been used for routine
immunization programs in more than 60 countries [4]. Clini-
cal trials of both vaccines showed that efﬁcacy in middle- and
high-income countries of North America, Europe, and Latin
America ranged from 85% to 98% [5, 6]. However, the 2 vac-
cines are considerably less efﬁcacious in low- to middle-
income countries of Africa, Asia, and Latin America, with
an efﬁcacy ranging from approximately 40% to approximately
70% [7–11]. The reasons for this lower efﬁcacy have not been
fully explained but mimic the lower efﬁcacy of other live oral
vaccines such as oral polio vaccine (OPV) and typhoid and
cholera vaccines in similar settings [8].
It has been reported that levels of RV immunoglobulin A
(IgA), secretory IgA (sIgA), lactoferrin, and neutralizing activ-
ity in mothers’ breast milk vary by setting, with higher titers
found among women in low-income countries compared
with those in high-income countries [12–14].These high levels
of neutralizing activity in breast milk, together with maternal
antibody transferred to the infant through the placenta, may
have an inhibitory effect on the infectivity of live-attenuated
vaccine viruses in the gut and thus the ability of vaccines to
induce robust immune response among infants [7, 9, 11, 15].
To test this hypothesis, we recently investigated the effect of
a transient delay of breastfeeding before and after the ﬁrst
and second vaccination with RV1 on the immune response
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among human immunodeﬁciency virus (HIV)–unexposed in-
fants in Soweto, South Africa [16]. We found that infants with
delayed and unrestricted breastfeeding had similar RV IgA re-
sponse, suggesting that a transient delay of breastfeeding at the
time of vaccination did not appear to improve the immune re-
sponse to RV1. In the present study, we performed more de-
tailed analyses to examine associations between maternal
antibodies, particularly preexisting RV IgG, and the immuno-
genicity of 1 or 2 doses of RV1 among infants in South Africa.
We also assessed the potential impact of IgA from natural in-
fection prior to vaccination on subsequent immune response
to RV1.
METHODS
Participants and Specimen Collection
A previously described mother–infant pair population from a
prospective, randomized, longitudinal cohort study was used
in this analysis [16]. These healthy HIV-unexposed infants
were enrolled at presentation for their routine immunization
visit at Diepkloof Primary Health Clinic, Soweto, South Africa,
between 2 December 2009 and 9 April 2010. Infants who were
aged 5–8 weeks at enrollment, breast fed, and did not receive
any previous vaccines except for OPV and bacille Calmette-
Guérin at birth were included in the study. Mothers who tested
seronegative for HIV at beyond 24 weeks gestational age were
also enrolled. Infants with known underlying immunosuppres-
sive conditions and failure to thrive (<3rd percentile weight-
for-age or decrease of more than 2 major centiles since birth)
were excluded.
All vaccines were provided according to the standard sched-
ule of the expanded program on immunization in South Africa.
RV vaccine RV1 was administered at 6 and 14 weeks of age,
concurrently with heptavalent pneumococcal conjugate vaccine
(Prevenar; Wyeth, Madison, Wisconsin). All infants received
trivalent OPV (Merieux, Sanoﬁ Pasteur, Lyon, France) at 6
weeks and Pentaxim (diphtheria toxoid, tetanus toxoid, acellu-
lar pertussis adsorbed–inactivated poliovirus–Haemophilus in-
ﬂuenzae type b conjugate vaccine [DTap-IPV-Hib]; Sanoﬁ
Pasteur) and Heberbiovac-HB (hepatitis B vaccine; Heber Bio-
tec, Havana, Cuba) at 6, 10, and 14 weeks. Serum samples were
obtained from the infants before the ﬁrst and second doses of
RV vaccine and 1 month after the second RV dose. Maternal
serum and breast milk samples were obtained prior to admin-
istration of each dose of RV in their infants. All specimens were
kept frozen at −70°C until shipment on dry ice for analysis at
the US Centers for Disease Control and Prevention (CDC). The
Human Research Ethics Committee (Medical) of the University
of the Witwatersrand (M090824) reviewed and approved the
protocol. Written informed consent was obtained from the par-
ent or guardian on behalf of the infant. Because the CDC tested
only anonymized specimens, this research did not require re-
view by the CDC Institutional Review Board. The trial was
registered on the South African National Clinical Trial Register
(DOH-27-0511-2991).
Specimen Testing
RV-speciﬁc IgA in breast milk and serum samples was deter-
mined using enzyme-linked immunosorbent assay as previous-
ly described [12]. Brieﬂy, microplate wells were coated with
rabbit hyperimmune serum to rhesus rotavirus (RRV) and in-
cubated with diluted RV1 strain or blotto (5% skim milk in
phosphate-buffered saline [PBS]). After washing, breast milk
samples (1:5–1:5120) and serum samples (1:10–1:10 240) that
were serially diluted in diluent buffer (1% skim milk and
0.5% [v/v] of 10% polyoxyethylene ether W1 in PBS) were
added to the wells, followed by biotin-conjugated goat anti-
human IgA antibodies (KPL, Gaithersburg, Maryland). After
incubation and washing, extravidin (Sigma, St. Louis, Missouri)
was added to the wells and incubated, and then the reactions
were developed with 3,3′,5,5′-tetramethylbenzidine (TMB;
Sigma) and stopped with 1N hydrogen chloride. Optical density
(OD) was determined at 450 nm with an enzyme immunoassay
reader (MRX Revelation; Dynex Technologies, Chantilly, Virginia).
IgA titers in breast milk and serumwere calculated as the reciprocal
of the highest dilution that gave a mean OD greater than the cutoff
value (3 standard deviations above the mean OD of the negative-
control serum wells). RV-speciﬁc IgG in serum samples was tested
and analyzed in the same manner as IgA except that 0.5% normal
rabbit serum was added to the biotin-conjugate solution.
RV-speciﬁc neutralizing activity in breast milk was measured
using a microneutralization assay as previously described [12].
Brieﬂy, breast milk samples (50 µL) in 2-fold dilutions were
mixed with an equal volume of trypsin-activated RV1 vaccine
virus to yield a concentration of 4000 FFU/well and incubated
at 37°C for 1 hour. Monolayers of MA104 cells grown in 96-well
plates were washed with PBS and incubated with diluted breast
milk and virus mixture. Following incubation at 37°C for
1 hour, the plates were washed with PBS and incubated with
100 µL of Iscove’s modiﬁed Dulbecco’s medium (Invitrogen,
Carlsbad, California) containing 5 μg/mL trypsin. After 20
hours of incubation at 37°C, the plates were ﬁxed with 15 μL
of 37% formaldehyde at 4°C for 30 minutes. RV antigen in
MA104 cells was detected by incubating plates with a rabbit
anti-RRV hyperimmune serum, horseradish peroxidase-labeled
anti-rabbit IgG, and then TMB. Neutralizing titer in a breast
milk specimen was determined as the reciprocal of the highest
dilution that showed a >70% reduction in the absorbance value
compared with that in virus-only controls.
Statistical Analyses
Data analyses were performed using SPSS Statistics, version 20
(IBM Corp., Armonk, New York). The Wilcoxon signed-rank
test was used to compare titers within or between groups.
Comparisons between categorical variables were done using
the χ2 and relative risk tests. IgA titers ≥40 in serum were
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Table 1. Comparison of Mother–Infant Pairs (n = 181) Assigned to Analysis of Rotavirus (RV) Antibodies in Sera and RV Antibodies and Neutralizing Activity in Breast Milk by Infant Immunoglobulin A
Seroconversion Post-Dose 1 and Post-Dose 2 of Rotarix
Subjects
Seroconversion Post-Dose 1 Status Seroconversion Post-Dose 2 Status
Total (N = 181) Yes (n = 64) No (n = 117) P Valuea Yes (n = 108) No (n = 73) P Valuea
Infants
Percentage (95% CI), n/N 35 (28–42), 64/181 60 (52–67), 108/181 <.001b
Age, in weeks, at dose 1 median (range) 6 (6–8) 6 (6–7) 6 (6–8) .233 6 (6–8) 6.1 (6–7) .799
Age, in weeks, at dose 2 median (range) 16 (12–24) 16 (14–23) 16 (12–20) .981 16 (14–24) 15 (12–19) .006
IgG pre-dose 1, median (range) 1280 (20–20 480) 1280 (20–10 240) 1280 (80–20 480) .010 1280 (20–10 240) 1280 (80–20 480) .072
IgA pre-dose 1, Positivity, % (95% CI), n/N 41 (34–48), 74/181 34 (22–46), 22/64 44 (35–54), 52/117 .188 32 (23–41), 35/108 53 (42–65), 39/73 .005
IgA pre-dose 1, median (range) 20 (1–1280) 20 (1–320) 20 (1–1280) .151 20 (1–320) 40 (1–1280) .005
IgA post-dose 1, median (range) 40 (1–10 240) 160 (40–10 240) 40 (1–1280) <.001 80 (1–10 240) 40 (1–1280) .001
IgA post-dose 2, median (range) 160 (1–20 480) 320 (40–20 480) 80 (1–5120) <.001 320 (40–20 480) 40 (1–640) <.001
Mothers
IgG sera pre-dose 1, median (range) 10 240 (80–163, 840) 5120 (80–81 920) 10 240 (640–163 840) .031 10 240 (80–163 840) 10 240 (640–163 840) .235
IgA sera pre-dose 1, median (range) 40 (1–10, 240) 20 (1–5120) 40 (1–10 240) .053 40 (1–10 240) 40 (1–5120) .123
IgA sera post-dose 1, median (range) 160 (1–10 240) 160 (1–10 240) 160 (1–10 240) .395 160 (1–10, 240) 320 (1–10 240) .331
IgA BM, pre-dose 1, median (range) 40 (1–2560) 30 (1–1280) 40 (1–2560) .499 20 (1–1280) 40 (1–2560) .615
IgA BM post-dose 1, median (range) 40 (1–10 240) 40 (1–2560) 40 (1–10 240) .520 40 (5–2560) 40 (1–10, 240) .781
NA BM pre-dose 1, median (range) 8 (1–2048) 8 (1–2048) 8 (1–2048) .445 8 (1–2048) 8 (1–2048) .848
NA BM post-dose 1, median (range) 16 (1–2048) 16 (1–2048) 16 (1–2048) .629 16 (1–2048) 16 (1–2048) .737
Serum and breast milk specimens from 181 infant–mother pairs were analyzed as described in the text. Seroconversion was defined as a ≥4-fold rise in IgA titer from baseline to post-dose 2. Seropositivity of IgA was defined as titer ≥1:40.
Significant P values are highlighted in bold (P < .05).
Abbreviations: BM, breast milk; CI, confidence interval; Ig, immunoglobulin; NA, neutralizing activity.
a Statistical difference was established by Wilcoxon rank-sum test.
b Statistical difference was established by χ2 test.
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Table 2. Comparison of Mother and Rotavirus (RV)-Unexposed Infant Pairs (n = 107) Assigned to Analysis of RV Antibodies in Sera and RV Antibodies and Neutralizing Activity in Breast Milk, by Infant
Immunoglobulin A Seroconversion Post-Dose 1 and Post-Dose 2 of Rotarix
Subjects
Seroconversion 1 Status Seroconversion 2 Status
Total (N = 107) Yes (n = 42) No (n = 65) P Valuea Yes (n = 73) No (n = 34) P Valuea
Infants
Percentage % (n/N) 39 (42/107) 68 (73/107) <.001b
Age, in weeks, at dose 1 median (range) 6 (6–8) 6 (6–7) 6 (6–8) .219 6 (6–8) 6 (6–7) .756
Age, in weeks, at dose 2 median (range) 16 (14–23) 16 (14–23) 16 (14–19) .767 16 (14–23) 15 (14–19) .053
IgG pre-dose 1, median (range) 1280 (20–20 480) 1280 (20–10 240) 2560 (160–20 480) .004 1280 (20–10 240) 2560 (320–20 480) .051
IgA post-dose 1, median (range) 40 (1–10 240) 80 (40–10 240) 20 (1–60) <.001 40 (1–10 240) 20 (1–60) <.001
IgA post dose 2, median (range) 80 (1–20 480) 160 (40–20 480) 40 (1–2560) <.001 160 (40–20 480) 20 (1–40) <.001
Mother
IgG sera pre-dose 1, median (range) 10 240 (80–163 840) 5120 (80–81 920) 10 240 (640–163 840) .040 10 240 (80–163 840) 20 480 (640–163 840) .166
IgA sera pre-dose 1, median (range) 40 (1–5120) 20 (1–5120) 40 (1–5120) .203 40 (1–5120) 80 (1–2560) .102
IgA sera post-dose 1, median (range) 160 (1–10 240) 160 (1–10 240) 160 (1–10 240) .632 160 (1–10 240) 320 (1–10 240) .255
IgA BM, pre-dose 1, median (range) 40 (1–2560) 40 (1–1280) 40 (1–2560) .420 40 (1–1280) 40 (1–2560) .534
IgA BM post-dose 1, median (range) 40 (5–10 240) 40 (10–2560) 40 (5–10 240) .620 40 (5–2560) 40 (5–10 240) .801
NA BM pre-dose 1, median (range) 8 (1–2048) 4 (1–2048) 8 (1–2048) .849 8 (1–2048) 8 (1–2048) .606
NA BM post-dose 1, median (range) 16 (1–2048) 16 (1–2048) 16 (1–2048) .817 16 (1–2048) 12 (1–2048) .616
Serum and breast milk specimens from 107 infant–mother pairs were analyzed as described in the text. Seroconversion was defined as a ≥4-fold rise in IgA titer from baseline to post-dose 2. Seropositivity of IgA was defined as titer ≥1:40.
Significant P values are highlighted in bold (P < .05).
Abbreviations: BM, breast milk; Ig, immunoglobulin; NA, neutralizing activity.
a Statistical difference was established by Wilcoxon rank-sum test.
b Statistical difference was established by χ2 test.
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considered positive. Seroconversion was deﬁned as greater
than 4-fold increase in RV-speciﬁc IgA titers following the
ﬁrst or second RV vaccine doses compared with titers prior
to the ﬁrst dose.
Univariate linear regression analyses were performed to ex-
amine the relationships between infants’ IgG and mothers’
IgG pre-dose 1 in sera and between neutralizing activity and
IgA pre-dose 1 and 2 in breast milk specimens. Log transformed
(log2) titers of IgG, IgA, and neutralizing activity were used in
the linear regression models. Linear regression models were
assessed for violations of assumptions. Spearman rank correla-
tions were used in univariate analyses to examine relationships
between continuous variables when the assumptions of the
regression model were not met. Univariate and multivariate lo-
gistic regression analyses were performed to examine the rela-
tionships between continuous variables and seroconversion
post-dose 1 and 2. Finally, log2 titers of IgA, IgG, and neutral-
izing activity were used in the logistic regression models. An
alpha level of 0.05 (P < .05) was considered signiﬁcant for all
tests.
RESULTS
We enrolled 250 infants with a median age of 6.1 weeks (range
6–8) at the time of their ﬁrst RV1 immunization, given concom-
itantly with OPV and other scheduled pediatric vaccines [16].
Because some infants were not fully adherent to the protocol
and were excluded from the study, or some specimens were
not collected, we analyzed available matched serum and breast
milk samples from 181 mother–infant pairs. RV IgA serocon-
version rate at post-dose 1 was 35% (64/181) and increased sig-
niﬁcantly to 60% (108/181) at post-dose 2 (P < .001). Then, we
generated 2 groups based on the status of IgA seroconversion,
that is, infants who did or did not seroconvert at post-dose 1 or
post-dose 2, and evaluated biological predictors of the IgA sero-
conversion (Table 1). Infant pre-dose 1 serum RV IgG titers
were signiﬁcantly higher in the group of infants who did not se-
roconvert than those of infants who seroconverted at post-dose
1 (P = .010). While seroconverted and nonseroconverted post-
dose 1 infants had similar pre-dose 1 serum IgA titers, we
found that infants who did not seroconvert at post-dose 2
were more likely to be IgA positive at pre-dose 1 than those
who seroconverted (53% vs 32%, P = .005).
To examine whether maternal antibodies inﬂuenced immune
response to RV1 in infants, we compared titers of IgG, IgA in
serum, and IgA and neutralizing activity in breast milk speci-
mens of mothers with infants who seroconverted or did not
seroconvert (Table 1). Mothers whose infants seroconverted
post-dose 1 had signiﬁcantly lower titers of IgG (P = .031)
and IgA (P = .053) in pre-dose 1 sera than those whose infants
did not seroconvert, but these differences were not signiﬁcant in
mothers at post-dose 2. There were no differences observed for
titers of post-dose 1 IgA in serum and pre-dose 1 and post-dose
1 IgA and neutralizing activity in breast milk. For mothers
whose infants seroconverted or did not seroconvert post-dose
2, none of the IgG, IgA, and neutralizing activity titers in
serum or breast milk specimens were signiﬁcantly different.
We then performed a second analyses by excluding 74 infants
who might have had an early neonatal RV infection, as evi-
denced by a pre-dose 1 RV IgA titer of ≥40 in serum (Table 2
and Figure 1). In this new subset of mother–infant pairs
(n = 107), 39% of infants seroconverted post-dose 1 and 68% se-
roconverted post-dose 2. Infants who failed to seroconvert post-
dose 1 had signiﬁcantly higher pre-dose 1 RV IgG titers than
those who seroconverted (P = .004). This trend continued
Figure 1. Cumulative frequency profiles of rotavirus immunoglobulin G (RV IgG) titers in pre-dose 1 sera of 107 RV-unexposed infants (A) and their mothers (B), by infant IgA
seroconversion post-dose 1 of RV vaccine. Seroconversion was defined as a 4-fold increase in RV-specific IgA titers in post-dose 1 sera when compared with the corresponding
preimmunization sera. Pre-dose 1 sera of infants and their mothers were tested for RV-specific IgG as described in the text.
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Table 3. Predictors for Serum Immunoglobulin A Seroconversion to Rotarix in Rotavirus-Unexposed Infants (n = 107), South Africa, 2009–2010
Explanatory
Variables
IgA Seroconversion Post-Dose 1 IgA Seroconversion Post-Dose 2
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
Coefficient OR (95% CI) P Value Coefficient
Adjusted
OR (95% CI) P Value Coefficient OR (95% CI) P Value Coefficient
Adjusted
OR (95% CI) P Value
Infants
IgG pre-dose 1 −0.38 0.69 (.53–.88) .004 −0.30 0.74 (0.55–.99) .044 −0.28 0.76 (.59–.98) .034 −0.19 0.83 (0.63–1.08) .166
IgA post-dose 1 0.36 1.43 (1.19–1.71) <.001 0.34 1.40 (1.17–1.68) <.001
Age at dose 1 −1.0188 0.36 (.10–1.36) .133 0.15 1.16 (.33–4.05) .817
Age at dose 2 0.1043 1.11 (.85–1.44) .436 0.32 1.38 (.99–1.91) .055
Gender (male) −0.16 0.85 (.39–1.86) .686 −0.14 0.87 (.39–1.97) .741
Weight at birth, kg 0.26 1.29 (.56–2.98) .547 0.41 1.51 (.63–3.60) .357
Mothers
IgG sera pre-dose 1 −0.23 0.80 (.66–.96) .015 −0.11 0.90 (.72–1.11) .311 −0.14 0.87 (.72–1.05) .138
IgA sera pre-dose 1 −0.1 0.90 (.81–1.01) .066 −0.08 0.93 (.83–1.04) .177
IgA sera pre-dose 2 −0.09 0.91 (.80–1.05) .19
IgA BM, pre-dose 1 −0.07 0.93 (.78–1.11) .411 −0.10 0.90 (.75–1.08) .275
IgA BM pre-dose 2 0.00 1.00 (.83–1.20) .998
NA BM pre-dose 1 −0.02 0.98 (.85–1.13) .774 0.03 1.03 (.89–1.20) .672
NA BM pre-dose 2 0.04 1.04 (.90–1.20) .559
Log-2 transformed antirotavirus titers were used in the analysis as described in the text.
Significant P values are highlighted in bold (P < .05).
Abbreviations: BM, breast milk; CI, confidence interval; Ig, immunoglobulin; NA, neutralizing activity; OR, odds ratio.
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until post-dose 2 (P = .051). Mothers whose infants serocon-
verted post-dose 1 had signiﬁcantly lower median titers of
IgG in pre-dose 1 sera than those whose infants did not sero-
convert post-dose 1, but this difference was not seen post-
dose 2. Similarly, infants who did not seroconvert and their
mothers had higher cumulative IgG titers in pre-dose 1 sera
than those who seroconverted at post-dose 1 (Figure 1). None
of the titers for IgA or neutralizing activity in serum or breast
milk specimens of mothers were signiﬁcantly different regard-
less of seroconversion status post-dose 1 and post-dose 2 in
infants.
We also performed univariate and multivariate analysis to
identify variables that might inﬂuence IgA seroconversion
(Table 3). The levels of pre-dose 1 IgG in infant sera were neg-
atively associated with seroconversion post-dose 1 by both
univariate and multivariate analyses and seroconversion
post-dose 2 by univariate analysis. IgG titers in mothers’
sera were negatively associated with seroconversion post-
dose 1 in the univariate analysis only. We also analyzed the re-
lationship between the pre-dose 1 IgG titers in infants and IgA
titers in response to RV1 at post-dose 1 and post-dose 2. We
found a relatively strong negative association between preexist-
ing IgG titers in pre-dose 1 sera and IgA titers in post-dose 1
sera (r = − 0.28, P = .003). Similarly, we found a weaker but
signiﬁcant negative association between preexisting IgG titers
in pre-dose 1 sera and IgA titers in post-dose 2 sera (r = − 0.23,
P = .016; data not shown).
We further observed a strong signiﬁcant association between
IgG titers in pre-dose 1 sera of paired infants and mothers using
univariate regression analyses (r = 0.56, P < .001; Figure 2A).
We also found a weak but signiﬁcant correlation between IgA
titers in breast milk and sera from mothers at pre-dose 1
(r = 0.27, P = .005; Figure 2B). In addition, we found signiﬁcant
positive associations between RV IgA and neutralizing activity
in breast milk at pre-dose 1 (r = 0.41, P < .001) and post-dose 1
(r = .40, P < .001; data not shown).
DISCUSSION
In this cohort of mothers and their HIV-unexposed infants
in Soweto, South Africa, we demonstrated a strong association
between levels of IgG in sera of mother–infant pairs at the time
of ﬁrst RV immunization, suggesting direct transplacental
transmission of this antibody from mothers to infants. Infants
who failed to seroconvert to RV1 had signiﬁcantly higher RV
IgG titers in pre-dose 1 sera than those who seroconverted.
The second dose of RV1 somewhat overcame the interference
of preexisting RV IgG since levels of this antibody in infants
with a median age of 16 weeks (range 12–24) had waned.
These ﬁndings indicate that maternal IgG may have interfered
with the immune response to RV1 in infants.
Maternal IgG is transported across the placenta by an active,
receptor-mediated process during pregnancy, thereby protect-
ing term infants against infection [17]. In newborns and
young infants, RV IgG comes primarily from the mother in
the ﬁrst or second month of life, depending on settings. Since
the median age of this infant cohort was 6.1 weeks at the ﬁrst
dose of vaccination, levels of RV IgG were expected to be
high, as reported in Indian, Mexican, and Nicaraguan infants
of similar age [18–20]. Our observations of high IgG levels in
sera of these South African infants at age 6.1 weeks may explain
higher seroconversion rates to RV1 when administered at a 3-
dose (6, 10, and 14 weeks) or a 2-dose (10 and 14 weeks) sched-
ule than at the 6- and 10-week schedule recommended by the
manufacturer in the same setting [21]. Since transplacental RV
Figure 2. Association of rotavirus immunoglobulin G (RV IgG) titers in pre-dose 1 sera of 107 RV-unexposed infants and their mothers (A) and association of RV IgA titers in
pre-dose 1 sera and breast milk from mothers (B). Log-transformed (log2) IgG titers in paired mother and infant sera were analyzed by univariate linear regression analysis. The
log2 IgA titers were analyzed using Spearman correlation analysis. Regression models were assessed for violations of assumptions. Color intensity and circle size at each point
were proportional to the number of samples.
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IgG decreases with a half-life of 3–4 weeks, this 4-week delay in
vaccine administration might explain the improved immunoge-
nicity of the vaccine. Of note, since RV immunity is believed to
be polygenic and cross-reactive, we think the preexisting serum
IgG is a mixture of nonneutralizing RV antibody directed pri-
marily against VP6 group antigen and, to a lesser degree, VP4
and VP7 serotype antigens. Thus, this inhibitory effect would
apply for both RV1 and RV5 vaccines. Maternal antibody inter-
ference has also been reported in children who received polio
and measles vaccines [22, 23].
We previously reported positive associations between levels
of IgA and neutralizing activity against RV1, RV5, and 116E
strains in breast milk of mothers in India and South Africa,
but not in specimens from mothers in the United States [13].
In the present study, we again found signiﬁcant correlations be-
tween RV IgA titers and neutralizing titers against RV1 strain in
breast milk collected at the time of the ﬁrst and second RV vac-
cinations from South African mothers. We also observed a sig-
niﬁcant association between IgA titers in pre-dose 1 sera and
breast milk from mothers, suggesting some transmission of
IgA between systemic and mucosal systems [24]. This associa-
tion could also be explained by dual natural infection with RV
in both mother and infant. Additionally, a correlation between
IgA in sera and sIgA in breast milk has been reported [14, 25].
Of note, we observed similar levels of IgA and neutralizing activ-
ity in breast milk of mothers whose infants seroconverted or did
not seroconvert, supporting the recent report of no effect from a
short abstention of breastfeeding before and after each vaccina-
tion on immune response to RV1 in South African infants. How-
ever, we could not evaluate the effect of long-term breastfeeding
on vaccine immunogenicity since all infants were breastfed.
Long-term breastfeeding practices have been reported to be asso-
ciated with lower immune response to RV1 or RV5 among in-
fants in both high- and low-income countries [26–28].
The apparent inhibitory effect of maternal antibody could
represent one of the complicated mechanisms to explain why
live oral RV vaccines have been less immunogenic and effective
in low-income settings such as Africa [11, 15] where infants typ-
ically acquire high titer RV IgG transplacentally from their
mothers. In addition, preexisting serum IgA appeared to have
some damping effect on vaccine immunogenicity as well. Future
studies should investigate other potential confounders such as
malnutrition, coinfections, comorbidities, and gut microbiota.
Given that multiple factors are likely involved in gut enteropa-
thy and reduced efﬁcacy of oral vaccines and that intervention
strategies to date have not shown any major improvements,
alternative approaches, such as parenteral immunization with
inactivated RV or subunit vaccine, should be assessed.
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